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ABSTRACT 
The robust glycolytic metabolism of glioblastoma multiforme (GBM) has proven 
them susceptible to increases in oxidative metabolism induced by the pyruvate mimetic 
dichloroacetate (DCA). Recent reports demonstrate that the anti-diabetic drug 
metformin enhances the damaging oxidative stress associated with DCA treatment in 
cancer cells. We sought to elucidate the role of metformin’s reported activity as a 
mitochondrial complex I inhibitor in the enhancement of DCA cytotoxicity in the VM-M3 
model of GBM. We demonstrated that metformin potentiated DCA-induced superoxide 
production and that this was required for enhanced cytotoxicity towards VM-M3 cells 
with the combination. Similarly, rotenone enhanced oxidative stress resultant from DCA 
treatment and this too was required for the noted augmentation of cytotoxicity. 
Adenosine monophosphate kinase (AMPK) activation was not observed with the 
concentration of metformin required to enhance DCA activity. Moreover, addition of an 
activator of AMPK did not enhance DCA cytotoxicity, whereas an inhibitor of AMPK 
heightened the cytotoxicity of the combination. We also show that DCA and metformin 
reduce tumor burden and prolong survival in VM-M3 tumor-burdened mice as individual 
therapies. In contrast to our in vitro work, we did not observe synergy between DCA and 
metformin in vivo. Our data indicate that metformin enhancement of DCA cytotoxicity is 
dependent on complex I inhibition. Particularly, that complex I inhibition cooperates with 
DCA-induction of glucose oxidation to enhance cytotoxic oxidative stress in VM-M3 
  xii 
GBM cells. This work supports further investigation and optimization of a 
DCA/metformin combination as a potential pro-oxidant combinatorial therapy for GBM.
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CHAPTER 1: CANCER METABOLISM 
 
1.1 Chapter Synopsis 
Herein we provide a review of the metabolic programs employed by tumors to 
meet the biosynthetic requirements of tumorigenesis. The metabolism of tumors is 
intricately linked to the hallmarks of the disease and provides cancer cells with a 
survival advantage in response to the stresses imposed by the tumor microenvironment. 
An understanding of the metabolic characteristics of tumors provides a basis for rational 
targeting of these metabolic dependencies as a therapeutic strategy. Current 
approaches in targeting cancer metabolism are also discussed in this chapter.  
 
1.2 Altered Energy Metabolism 
 Cancer is traditionally considered a genetic disease, characterized by genomic 
instability and frequent mutation that cooperate to promote a distinct cellular 
environment that permits unbridled proliferation (1). Genomic sequencing of tumors has 
identified a multitude of drug targetable mutations that have driven research and 
pharmaceutical development. Unfortunately, the promise of encouraging pre-clinical 
findings has not often translated to clinical efficacy. This has driven the field to consider 
additional hallmarks of tumor development and disease progression and devise 
alternative strategies for cancer management (1).  
  2 
Resultant from this initiative was a renewed appreciation for the distinct 
metabolic activity of tumors (2). Beyond the dysregulation of the cell cycle and loss of 
deoxyribonucleic acid (DNA) quality control that accompany cancer cell proliferation is a 
fundamental demand for biomass. An intricate network of metabolic pathways 
converges to generate the molecular building blocks required for biosynthesis (3). 
Cancer cell metabolism is wired in such a manner that allows for the continuous 
production of the nucleotides, proteins and lipid membranes necessary for proliferation 
whilst also generating the energy and reduction potential required for cell survival (4). 
The past decade of research on cancer metabolism has encompassed a 
methodological renaissance for characterizing the metabolic dependencies of cancer 
cells and the intersection between metabolism and tumor biology (5-8). Most 
importantly, this work has demonstrated that targeting cancer metabolism may be a 
sustainable therapeutic alternative for the management of the devastating disease. 
 
1.2.1 Aerobic Fermentation 
 The notion of peculiar metabolism in cancer is not a recent phenomenon. Otto 
Warburg first observed a distinct difference in the metabolism of tumors compared to 
normal tissue in the early 20th century (9). Warburg reported that tumors took up 
significantly more circulating glucose than normal tissue, and whereas very little lactate 
was generated by the normal tissue, Warburg calculated that 66% of the consumed 
glucose was converted to lactate by the tumor. This suggests that the tumors were 
predominantly fermenting glucose rather than respiring on the sugar.  
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 Glucose is the predominant energy metabolite in the body, and is preferentially 
metabolized by most tissues. Upon entering the cell, glucose is metabolized to pyruvate 
through the Embden-Meyerhof, or glycolytic pathway. Typically, pyruvate is then 
imported into the mitochondria where it is fully oxidized to carbon dioxide (CO2) as long 
as oxygen, the final electron acceptor of the electron transport chain is not limiting. 
Tissues are adequately perfused under normal physiological conditions, which 
facilitates the delivery of oxygen and permits mitochondrial respiration of glucose. In the 
context of limiting oxygen, such as in muscle during vigorous exercise, pyruvate is 
fermented to lactate by lactate dehydrogenase (LDH).   
 What is remarkable about Warburg’s findings is that the tumors were reported to 
be well perfused and thus oxygen was not limiting (9). Hence, the tumors were 
preferentially fermenting pyruvate to lactate in an aerobic environment. This aerobic 
fermentation of glucose is now widely recognized as a hallmark phenotype of most 
cancers and is now termed the Warburg effect (10). In fact, the robust uptake of glucose 
by tumors is the basis for diagnostic fluorodeoxyglucose positron emission tomography 
(FDG-PET) scanning (11).  
 A reliance on glycolytic metabolism seems counterintuitive for robust proliferation 
from a bioenergetics perspective. Generating the biomass required for cell division 
depends in part on the potential energy stored in adenosine triphosphate (ATP), a 
byproduct of certain catabolic reactions. Glycolysis is rather energy inefficient, 
generating only 2 moles (mol) of ATP per mol of glucose, whereas the complete 
oxidation of glucose yields ~36 mol ATP/mol glucose.  Yet, cancer cells that exhibit this 
Warburg metabolism do not suffer from an ATP deficit (12). The conversion of pyruvate 
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to lactate by LDH is coupled to the oxidation of reduced nicotinamide adenine 
dinucleotide (NADH) to its oxidized form, NAD+. The regeneration of NAD+ maintains a 
high cytosolic NAD+/NADH ratio that permits rapid glycolytic flux, as the glycolytic 
enzyme glyceraldehyde phosphate dehydrogenase (GAPDH) requires NAD+ as a 
cofactor. 
 
1.2.2 Mitochondrial Metabolism 
 Based on his original observation, Warburg hypothesized that aerobic 
fermentation in tumors was a result of an irreversible insult to oxidative capacity that 
prevented cancer cells from deriving sufficient energy from oxidative metabolism (13). 
Evidence suggests that ATP production is not a necessary function of cancer 
mitochondria, however mitochondrial metabolism is critical for cancer cell proliferation 
(14). In principle, the abundant generation of lactate as a result of the Warburg effect 
could restrict the flux of pyruvate into the mitochondria, where it is readily metabolized 
to acetyl coenzyme A (acetyl-CoA) and CO2 via the pyruvate dehydrogenase (PDH) 
complex.  
Acetyl-CoA is a critical carbon carrier that is utilized extensively in central carbon 
metabolism. Acetyl-CoA is required for continuous flux of the Citric Acid (TCA) cycle, 
which generates the reducing equivalents NADH and reduced Flavin adenine 
dinucleotide (FADH2). These reducing equivalents are oxidized by protein complexes in 
or associated with the inner mitochondrial membrane (IMM) in reactions that couple the 
release of electrons with the movement of protons (H+) from the mitochondrial matrix 
into the intermembrane space. The movement of these electrons through subsequent 
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protein complexes, that collectively make up the electron transport chain (ETC), is also 
coupled to the movement of H+ across the IMM. The translocation of these H+ 
generates a proton motive force and membrane potential across the IMM. ATP 
synthase harnesses this proton motive force to couple the movement of H+ back into 
the matrix with the generation of ATP from adenine diphosphate (ADP) and inorganic 
phosphate (Pi). 
In addition to providing the reducing equivalents for oxidative phosphorylation, 
the TCA cycle intermediates are important for the biosynthesis of critical 
macromolecules. Reduced flux of glucose carbon through the PDH complex would thus 
restrict TCA cycling and decrease the levels of TCA cycle intermediates. Cancer cells, 
especially in culture, have upregulated glutamine metabolism to compensate for deficits 
in glucose carbon flux through the TCA cycle (15). Glutamine is an anaplerotic amino 
acid that is converted to glutamate in the mitochondria by glutaminase (GS). Glutamate 
can then be deaminated to ⍺-ketoglutarate (⍺-KG), a TCA cycle intermediate. ⍺-KG can 
then contribute to the replenishment of subsequent intermediates through traditional flux 
through the cycle or be converted to the upstream metabolite, isocitrate, through 
isocitrate dehydrogenase 2 (IDH2)-mediated reductive carboxylation.  
In certain tumor species, the branched-chain amino acids (BCAAs) leucine and 
valine can be used as anaplerotic substrates (5). Moreover, glucose carbon can enter 
the TCA cycle in a PDH-independent manner through pyruvate carboxylase (PC), which 
converts cytosolic pyruvate to oxaloacetate. This oxaloacetate is then converted to 
malate via malate dehydrogenase (MDH). Malate can be taken up into the mitochondria 
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through the malate-aspartate shuttle and incorporate into the TCA cycle. Together, 
these pathways provide alternative means for maintaining TCA function. 
The advent of isotope-labeled metabolite tracing has demonstrated that aerobic 
fermentation does not fully restrict glucose oxidation, rather the tracing of 13C-glucose 
metabolic flux shows concurrent fermentation and oxidation of glucose carbon in certain 
cancers (16). Cellular energy metabolism is dependent on the regulated movement of 
electrons between metabolic intermediates and enzymatic cofactors through a series of 
oxidative-reduction (redox) reactions. Recent evidence suggests that mitochondrial 
oxidation is critical for the cell proliferation independent of the generation of ATP. 
  Stimulation of ETC activity through oxidation of reducing equivalents promotes 
redox balance through regeneration of NAD+ and oxidized Flavin adenine dinucleotide 
(FAD+), which are critical electron acceptors. Electron acceptors are necessary for 
continuous metabolic flux, especially in the context of meeting the biosynthetic demands 
of rapid proliferation (17). Oxygen serves as the terminal electron acceptor in oxidative 
metabolism and this reduction of oxygen is considered the most vital aspect of 
mitochondrial oxidative metabolism for proliferating cells (18). The amino acid aspartate 
is also shown to serve as an essential electron acceptor for proliferation (17, 18).  
Maintenance of the mitochondrial membrane potential (ΔΨm) is generally 
dependent on the continual regulated flux of electrons through the ETC resultant from 
oxidative metabolism. The preservation of ΔΨm is critical to the proliferative capacity of 
cells independent of its coupling to ATP production (19). In fact, cancer mitochondria 
are often hyperpolarized, suggesting inefficient flux of H+ back into the matrix for the 
purposes of ATP generation (20).  
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In addition to glucose, fatty acids can serve as a substrate for mitochondrial 
oxidative metabolism. The beta-oxidation of fatty acids (FAO) yields acetyl-CoA, which 
is incorporated into the TCA cycle, and NADH and FADH2 for electron transport and the 
potential generation of ATP.  FAO is shown to be essential for survival and growth 
under conditions of metabolic stress (21). Certain haematopoietic malignancies exhibit 
increased FAO (22, 23). Diffuse large B cell lymphoma (DLBCL) appear to rely on FAO 
largely to maintain cellular ATP levels. Whereas leukemia cells often display enhanced 
FAO that is associated with preventing the toxic buildup of fatty acids (21). Additionally, 
some leukemia cells require FAO for maintenance of cytosolic redox balance in the form 
of citrate-dependent reduced nicotinamide adenine dinucleotide phosphate (NADPH) 
generation.  
 
1.2.3 Maintenance of Redox Balance 
 As mentioned above, cellular metabolism is dependent on the coordinated 
movement of electrons through intermediate metabolites and the oxidation state of 
important electron carriers. Cells harness the reducing power of NADH and NAPDH for 
the catabolic and biosynthetic reactions necessary for growth and viability. The ratios of 
NAD+/NADH and oxidized nicotinamide adenine dinucleotide phosphate 
(NADP+)/NADPH are indicators of the redox state of the cell. Metabolic flux and the 
activity of bidirectional metabolic enzymes are dependent on the status of these ratios. 
The redox state of the cell is compartmentalized within organelles, as there are distinct 
metabolic mechanisms for regulating NAD+/NADH and NADP+/NADPH in the cytosol 
and mitochondrial matrix for example. Yet, these are not completely independent of 
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each other as there are mechanisms for the exchange of metabolites between 
compartments that facilitate alterations to these ratios. 
 Maintenance of the NAD+/NADH ratio is predominantly mediated in the cytosol 
through glycolysis and through the TCA cycle in the mitochondrial matrix. As previously 
mentioned, cancer cells exhibit enhanced LDH activity, which recycles the NADH 
generated through glycolysis to NAD+, facilitating the rapid glycolytic flux associated 
with Warburg metabolism (4). The shuttling of pyruvate between the cytosol and matrix 
links the NAD+/NADH pools of the two compartments and is tightly regulated in cancer 
(24).  
 NADPH provides the reducing power for biosynthesis and is a critical component 
of cellular antioxidant capacity, both of which will be thoroughly discussed later in this 
review. Cytosolic NADPH is generated through two enzymatic reactions in the pentose 
phosphate pathway (PPP), via the conversion of malate to pyruvate by malic enzyme 
(ME) and oxidation of isocitrate to ⍺-KG by IDH1. The exchange of citrate between the 
matrix and cytosol links the NADPH pools of the two compartments. Reductive 
carboxylation of glutamine is shown to contribute to the cytosolic pools of NADPH 
through citrate, which can be metabolized to oxaloacetate by citrate lyase and 
subsequently to malate via MDH. Ultimately, this citrate-derived malate is converted to 
pyruvate by ME, generating NADPH (25, 26). 13C-glutamine tracing demonstrated that a 
significant fraction of mitochondrial NADPH is derived from folate metabolism (27, 28). 
Additional contributing factors to the matrix NADPH pool are IDH2 and the IMM-
associated enzyme nicotinamide nucleotide transhydrogenase (NNT), which harnesses 
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the proton motive force across the IMM and the reducing power of NADH to generate 
NADPH. 
 Cellular redox state is also affected by oxidative stress, a natural byproduct of 
metabolism. Oxidative stress is caused by the generation of highly reactive free radical 
oxygen- or nitrogen-containing species (ROS, RNS) that exhibit an array of biological 
functions, both cell-sustaining and cytotoxic. For instance, electron transport is not a 
totally efficient process. Electrons can be prematurely released from the ETC to reduce 
molecular oxygen to superoxide anion (·O2-). This occurs on the matrix side of the IMM 
at complex I (NADH dehydrogenase) and complex II (succinate dehydrogenase) of the 
ETC. Additionally, ·O2- can be generated on both the matrix- and intermembrane space 
(IMS)-facing sides of the IMM at complex III (coenzyme Q: cytochrome c 
oxidoreductase). ·O2- can also be generated in the cytosol and matrix through an 
NADPH-dependent process catalyzed by NADPH oxidases (NOXs).  
 In the presence of nitric oxide (NO), a byproduct of arginine metabolism, 
superoxide contributes to the formation of the very reactive peroxynitrite ion (ONOO-). 
Additionally, this ·O2- can be dismutated to hydrogen peroxide (H2O2) by superoxide 
dismutases (SODs). H2O2 can subsequently be detoxified to water through a number of 
enzymatic systems. Peroxiredoxins (PRXs) undergo H2O2-mediated oxidation that 
initiates a catalytic cycle in which thioredoxin (TRX), thioredoxin reductase (TrxR) and 
NADPH cooperate to regenerate reduced PRXs. Glutathione peroxidases (GPXs) utilize 
reduced glutathione (GSH) to detoxify H2O2. Glutathione reductase then utilizes NADPH 
to convert the oxidized glutathione (GSSG) to GSH. Finally, catalase can also convert to 
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H2O2 to water. Alternatively, in the presence of ferrous (Fe2+) or cupric (Cu+) ions, H2O2 
can generate hydroxyl radical (·OH) through Fenton reactions.  
 Collectively, these detoxifying enzymes contribute to the antioxidant capacity of 
the cell, which prevents the accumulation of the free radicals that potentiate oxidative 
stress. Transcriptional regulation of these enzymes is controlled by the master regulator 
of cellular antioxidant machinery, nuclear factor-like 2 (Nrf2). Nrf2 activity is stimulated 
by oxidative stress, resulting in the upregulation of a host of detoxifying enzymes and a 
metabolic program that boosts antioxidant capacity. The balance between ROS and 
RNS generation and antioxidant detoxification greatly influences cell function and 
viability and is a critical component of tumorigenesis (29).  
 
1.3 Consequences of Cancer Metabolism 
 Tumors exist as a heterogeneous population of cells that are under severe 
selection pressures that drive an evolutionary response. The mutations acquired during 
tumorigenesis must either confer a survival advantage or passively permit unbridled 
proliferation (1, 2). Tumors are subject to the constraints of natural selection and those 
mutations that reduce cancer cell fitness are ultimately selected against (30). Given that 
altered cellular metabolism is a consistent hallmark of cancer, there must be a survival 
benefit associated with the metabolism of neoplastic cells. Herein, I describe the 
consequences of cancer metabolism that provide a survival benefit to cancer cells and 
contribute to disease progression. 
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1.3.1 Proliferative Advantage 
 Robust glycolytic metabolism is not supremely unique to cancer cells. Rapidly 
proliferating cells such as lymphocytes and fibroblasts also exhibit aerobic fermentation 
of glucose under normal physiological conditions (31, 32). As noted previously, 
glycolysis is a rather energy inefficient pathway, however many glycolytic intermediates 
are critical biosynthetic precursors. It is proposed that increased flux of glucose through 
glycolysis facilitates the generation of abundant intermediates for the shunting of these 
metabolites into biosynthetic pathways. Moreover, the enhanced metabolism of other 
metabolites seen in cancer cells further contributes to the generation of amino acids, 
nucleotides and lipid species that are required for generating the macromolecular 
constituents of the cellular architecture (5-9, 15).  
 
1.3.1.1 Amino Acid Biosynthesis and Metabolism 
 The accumulation of glycolytic intermediates provides cancer cells with abundant 
3-phosphoglycerate, the substrate for serine and glycine biosynthesis. Serine and 
glycine metabolism is shown to be upregulated in many cancers and this is often 
associated with an overexpression of the first enzyme in the biosynthetic pathway, 3-
phosphoglycerate dehydrogenase (PGHDH) (33, 34). Upon de novo synthesis, serine is 
taken up into the mitochondrial matrix where it is cleaved to glycine by serine 
hydroxymethyltransferase 2 (SHMT2). Concurrently, SHMT2 transfers the methyl side 
chain of serine to tetrahydrofolate (THF) generating methyl-THF, promoting the folate 
cycle and one-carbon metabolism. As such, serine and glycine are the predominant 
sources of one-carbon units, which are required for a series of biosynthetic reactions 
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including the generation of methionine and cysteine (35). Methionine is further 
metabolized to S-adenosylmethionine (SAM), the principle substrate for histone and 
DNA methylation, one of several links between metabolism and genetic regulation. 
Cysteine synthesis results from an intersection between the folate and transsulfuration 
cycles. Cysteine and glycine are two of the amino acid components of the tripeptide 
antioxidant GSH. 
 The third amino acid component of GSH, glutamate, can promote the uptake of 
cysteine in the absence of sufficient de novo synthesis. Glutamate is exchanged for 
cysteine via the cysteine/glutamate antiporter (xCT), which is upregulated in lymphoma, 
gliomas and prostate cancer (36). The increased uptake of glutamine in cancer provides 
abundant substrate for GS-dependent generation of glutamate. Glutamate is a critical 
substrate for transamination reactions, serving as a nitrogen donor for non-essential 
amino acid synthesis. Alternatively, glutamine serves as a direct nitrogen donor for the 
synthesis of asparagine. This enhanced synthesis of amino acids contributes to the 
robust protein synthesis required for proliferation.  
To supplement amino acid pools in the face of deficiency, such as in the event of 
energetic stress, tumor cells upregulate autophagy (37). Autophagy permits cancer cell 
resilience but does not allow for proliferation as no new biomass is generated from the 
degradation of cellular protein. In contrast, recent evidence suggests that cancer can 
employ macropinocytosis, the endocytic uptake of extracellular fluid and its substituent 
contents, to satisfy the amino acid demand for proliferation (38). 
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1.3.1.2 Nucleotide Biosynthesis 
 The upregulation of glutamine metabolism in cancer not only contributes to TCA 
cycle anaplerosis and the subsequent generation of non-essential amino acids but also 
to the production of nucleotides. In fact, glutamine is the principle nitrogen donor for 
nucleotide synthesis; synthesis of uracil and thymine require a single glutamine 
molecule, cytosine and adenine require two, and guanine synthesis demands 3 
molecules of glutamine. The transaminaton of oxaloacetate and glutamine-derived 
glutamate produces aspartate, which is incorporated into both purine and pyrimidine 
rings. 
 Glucose metabolism also contributes to nucleotide synthesis. The glycolytic 
intermediate glucose-6-phosphate (G6P) is shunted into the oxidative branch of the 
PPP. Increased flux through the PPP promotes the abundant generation of ribose-5-
phosphate, which serves as a precursor for the pentose sugar backbone of nucleic 
acids. The folate cycle, which as previously noted is stimulated by enhanced serine 
metabolism in cancer, contributes one-carbon units to the generation of purine 
nucleotides. Additionally, purine ring synthesis requires the incorporation of glycine, 
signifying the intersection of glucose and glutamine metabolism. 
 
1.3.1.3 Lipid Biosynthesis 
 In addition to protein and nucleic acids, cells require various lipid species that 
make up the membranous superstructure of the cell. The synthesis of fatty acids occurs 
in the cytosol and is typically dependent on glucose-derived acetyl-CoA. Citrate 
generated in the TCA cycle is exported from the mitochondria and metabolized to 
  14 
oxaloacetate by ACL, releasing acetyl-CoA in the process. This acetyl-CoA is 
carboxylated to malonyl-CoA by acetyl-CoA carboxylase (ACC), stimulating the 
synthesis of the fatty acid palmitate. In the absence of sufficient glucose-derived acetyl-
CoA, cancer cells have shown the ability to utilize glutamine and acetate as alternative 
sources of citrate for fatty acid synthesis (39-41). Fatty acids are essential components 
of phospholipids, which make up the lipid bilayer of the plasma membrane and cellular 
organelles. 
 Phospholipid synthesis further intersects with glucose metabolism in the 
metabolism of dihydroxyacetone phosphate (DHAP). DHAP, a glycolytic intermediate, is 
siphoned for the generation of phosphatidic acid, a critical phospholipid precursor. 
Moreover, serine is a direct substrate for the generation of the phospholipid, 
phosphatidylserine. Together, these subsidiary biosynthetic pathways of glycolysis help 
to generate the phospholipids required for lipid membrane assembly.  
 The stimulation of the oxidative PPP upon G6P accumulation not only facilitates 
nucleotide synthesis, but also generates 2 molecules of NADPH per G6P. Lipid 
synthesis is a very energy-intensive process that demands reduction potential and 
NADPH provides the majority of this reducing power. Synthesis of the 14-carbon fatty 
acid palmitiate requires 14 equivalents of NADPH. Moreover, cholesterol synthesis, 
which also utilizes citrate-derived acetyl-CoA, requires 26 equivalents of NADPH. Thus 
the enhanced glucose metabolism of cancer cells provides not only carbon, but the 
reducing potential required to generate the essential lipid species for proliferation. 
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1.3.2 Enhanced Antioxidant Capacity 
 As discussed previously, a natural byproduct of metabolism is the generation of 
ROS and RNS which contribute to a cellular state of oxidative stress. Cells must 
balance the generation of these reactive species with detoxification to maintain redox 
balance. It is well established that cancer cells generate more reactive species, 
especially ROS, than normal cells; both from inefficient oxidative metabolism and 
through enzymatic production (29). Consequently, cancer cells exhibit an extraordinary 
antioxidant capacity mediated by Nrf2 stimulation (42). Accumulation of H2O2 promotes 
the cysteine oxidation of the negative regulator of Nrf2, Kelch-like ECH-associated 
protein 1 (KEAP1). This ROS mediated oxidation of KEAP1 causes its dissociation from 
Nrf2, releasing KEAP1 inhibition of Nrf2 and promoting its transcriptional regulation of 
antioxidant machinery. 
 Upregulation of antioxidant enzymes does not wholly negate the induction of 
oxidative stress. These enzyme systems employ redox cycles that require reducing 
potential to drive functional cycling. This reducing potential is derived from NADPH. As 
previously described, the enhanced metabolism of glucose and glutamine exhibited by 
cancer cells promotes NADPH production and is thus critical to the antioxidant capacity 
of tumors (43). Furthermore, glycolytic stimulation of serine metabolism and the 
generation of glutamate from glutamine provide the precursors for GSH synthesis, 
sustaining availability of the vital antioxidant. The maintenance of redox balance in 
cancer cells through enhanced antioxidant capacity contributes to tumorigenesis and 
disease progression. 
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1.3.2.1 Prevention of Cytotoxic Oxidative Damage 
  The accumulation of ROS and RNS is detrimental to cellular viability. Though 
the reactivity of these species varies, their robust production nonetheless increases the 
probability of macromolecular oxidation. Oxidation of proteins, nucleic acid and lipid 
species can alter their function and fidelity. Protein degradation can result from the 
initiation of peptide bond cleavage by ·OH oxidation. Moreover, certain amino acid side 
chains are subject to radical oxidation. These oxidation events can result in the loss of 
structural conformation or enzymatic activity (44). Antioxidant quenching of ROS 
prevents the formation and accumulation of toxic products of protein oxidation such as 
protein carbonyls.  
 H2O2 is less reactive than other ROS and is membrane diffusible, this allows for 
nuclear association where it can be converted to ·OH through Fenton chemistry. ·OH is 
highly reactive and is known to cause DNA damage (45). Oxidation of DNA can result in 
crosslinking, single- or double-stranded breaks as well as less severe structural 
modifications to nitrogenous base, such as the formation of 8-hydroxydeoxy guanosine 
(8-OHdG). 8-OHdG contributes to the genomic instability and mutability of the cancer 
genome and is intrinsically linked to carcinogenesis (46, 47). The upregulation of 
antioxidant defenses in cancer permit the mutagenicity of the cancer genome, while 
preventing the initiation of cell death pathways associated with substantial DNA damage 
(48). 
  ·OH also promotes lipid peroxidation and the generation of radical lipid species. 
These result in lipid fragmentation, which reduces the structural integrity of various 
cellular components. This is particularly detrimental to cellular membranes. The 
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peroxidation of phospholipids alters membrane permeability and fluidity and reduces the 
integrity of their associated membranes. Abundant mitochondrial ROS production is 
associated with the induction of apoptosis (49, 50). Temporal production of ROS at the 
ETC increases the probability that subsequently generated ·OH will react with the 
phospholipid constituents of the IMM. In the presence of profound oxidative stress, IMM 
integrity is lost, which disrupts the proton gradient and causes the loss of ΔΨm. 
Disruption of mitochondrial integrity also promotes the release of cytochrome c into the 
cytosol, where it can initiate the apoptotic cascade. The increase in antioxidant capacity, 
coupled with mitochondrial hyperpolarization prevents the induction of cell death in 
cancer cells despite robust mitochondrial ROS production (20). 
   
1.3.2.2 Equilibration of ROS signaling  
 ROS and RNS generation is fundamentally associated with the induction of a 
stressful cellular environment that promotes macromolecular damage. However, there is 
accumulating evidence that ROS have alternative signaling functions when present at 
tightly regulated concentrations (51). This signaling function is shown to be prevalent in 
cancer and has profound effects on tumorigenesis (29). 
 Similar to its stimulation of Nrf2 activity, H2O2 can reversibly oxidize cysteine 
residues of several signaling proteins relevant to cancer. H2O2 potentiates aberrant 
signaling through the phosphoinositide 3-kinase (PI3K) pathway in cancer (52). The 
negative regulator of PI3K signaling, phosphatase and tensin homolog (PTEN), is a 
target for inhibitory H2O2 oxidation, which contributes to constitutive activation of PI3K. 
PI3K signaling promotes growth and proliferation and is hyperactivated in many tumors 
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(52, 53). The mitogen-activated protein kinase (MAPK) signaling axis is also regulated 
at the post-translational level by ROS (54). Oxidation of MAPK-associated 
phosphatases prevents the inactivating dephosphorylation of MAPKs, leading to 
unregulated MAPK signaling. MAPK signaling stimulates a transcriptional response that 
drives growth and proliferation. Though typically a response to growth factor signaling, 
MAPK activation often occurs independent of an extracellular stimulus in cancer and 
this is in part mediated by this ROS-mediated protein oxidation (55). 
 Furthermore, ROS production has been implicated in the stabilization of hypoxia 
inducible factor alpha (HIF1-⍺) through multiple proposed mechanisms. HIF-1⍺ is a 
component of the hypoxia inducible factor (HIF) transcription factor, and whose 
regulation and transcriptional program as it relates to cancer will be more thoroughly 
discussed later in this review. Sequestration of Fe2+ for ·OH production via the Fenton 
reaction is shown to promote HIF-1⍺ accumulation (56). Moreover, ROS mediates the 
transcription of HIF-1⍺ in a nuclear factor κB (NF-κB)-dependent manner (57). HIF 
activity has profound effects on cancer metabolism and this ROS-based regulation of 
HIF likely potentiates tumor metabolism in a feed-forward manner. 
  
1.3.2.3 Therapeutic Resistance  
 In addition to debulking surgery when appropriate, traditional therapeutic 
management of cancer often employs chemotherapy and radiation. Many 
chemotherapies elicit cytotoxicity through mechanisms that depend on the generation of 
ROS. For instance, the topoisomerase inhibitor doxorubicin also promotes free radical 
production through the chelation of Fe2+, which induces ·OH production. Doxorubicin 
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induction of ROS likely cooperates with its interruption of DNA synthesis to promote 
cancer cell death through catastrophic DNA damage (58). Moreover, the platinum 
based alkylating agent, cisplatin, displays ROS mediated toxicity that independent of its 
interaction with DNA (59).  Additionally, arsenic trioxide inhibits mitochondrial respiratory 
capacity, which potentiates superoxide production and leads to cancer cell death (60).  
 Radiotherapy involves the directed administration of high-energy waves or 
particles for the purpose of eradicating cancer cells. Irradiation promotes cytotoxic DNA 
damage that is mediated through two mechanisms, direct and indirect ionization. Direct 
ionization involves immediate DNA damage, often in the form of single-strand breaks, 
caused by the radiation. Indirect ionization involves the radiolysis of water, which yields 
·OH, leading to DNA oxidation (61). Moreover, radiation is shown to activate NOX and 
potentiate continual ROS production (62). 
 The clinical failure of cancer therapy is often a function of chemoresistance that 
leads to disease recurrence. It is now widely appreciated that chemoresistance results 
in large part due to the robust antioxidant capacity of tumors (63). As many 
chemotherapies and radiotherapy are mechanistically dependent on ROS production, 
the upregulation of antioxidant systems in cancer cells restricts prolonged efficacy of 
these therapies. This is particularly true of cancer stem cells (CSCs), a distinct cellular 
subpopulation of tumors that have even greater antioxidant capacity than the bulk of the 
tumor (64). These CSCs have long been suggested to facilitate disease recurrence 
(65). Even if a therapy is initially successful, CSC resilience in response to therapy 
allows for repopulation of the tumor mass with cells resistant to treatment. 
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 1.3.3 Alteration of the Tumor Microenvironment 
 Tumors are not a homogenous entity, rather they exist as a diverse population 
consisting not only of cancer cells but also immune and stromal constituents. 
Collectively these cells along with a cocktail of signaling molecules and extracellular 
matrix (ECM) constitute the tumor microenvironment. The confluence of these diverse 
cell types and signaling factors ultimately promotes tumor (66). There is also 
accumulating evidence that the metabolism of cancer cells has a profound effect on the 
tumor microenvironment and contributes to tumor aggressiveness and disease 
progression (15). 
 As previously described, a consequence of the increased glycolytic metabolism 
employed by tumors is the abundant generation of lactate. Intracellular accumulation of 
lactate is a negative regulator of glycolysis through feedback inhibition. To prevent this 
negative regulation, cancer cells rapidly export lactate. Lactate export is mediated by 
monocarboxylate transporters (MCTs). Accordingly, MCT expression is upregulated in 
cancer, and is essential for cancer cell proliferation (67, 68).   
 MCT-mediated lactate export is coupled to the movement of H+ into the 
extracellular space. The rapid rate of tumor cell lactate export facilitates acidification of 
the tumor microenvironment. Whereas the intracellular pH of tumor cells is maintained 
between 7.2 – 7.3, the pH of the extracellular space of solid tumors can range from 6.5 
– 6.8 (69). The concurrent mitochondrial metabolism of glucose and glutamine carbon 
yields excess CO2, which freely diffuses into the extracellular space. Signals transduced 
from the tumor microenvironment drive the expression of carbonic anhydrase IX (CAIX), 
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which facilitates the conversion of CO2 to bicarbonate (HCO3-) and H+ (70). This activity 
exacerbates the acidification of the tumor microenvironment.  
 The accumulation of lactate has substantial effects on tumor-associated immune 
cells. As mentioned above, many immune cells exhibit a metabolism that is similar to 
that of cancer cells. This is particularly evident in effector T cells, which upon activation 
are highly glycolytic (71). Lactate transport via MCTs is dependent on a concentration 
gradient. Therefore, the robust export of lactate from cancer cells disrupts the export of 
lactate from neighboring effector T cells. The cytosolic accumulation of lactate in T cells 
promotes a shift towards oxidation that corresponds with cellular differentiation to a 
regulatory phenotype (Treg) (71). Moreover, high levels of extracellular lactate inhibit 
dendritic cell activation and monocyte migration (72, 73). The confluence of immune cell 
inhibition yields an immuno-permissive environment that prevents host detection of the 
growing tumor. 
 Increased lactate in the tumor microenvironment can promote hyaluronic acid 
(HA) production by tumor-associated fibroblasts (74). HA promotes cell motility and is 
shown to stimulate the epithelial-mesenchymal transition (EMT) that is believed to 
facilitate cancer metastasis (75). Moreover, the acidification of the tumor 
microenvironment promotes the activation of matrix metalloproteinases (MMPs), which 
degrade extracellular matrix and facilitate tumor cell migration and cancer metastasis 
(76). Thus, the metabolism of cancer cells enhances the metastatic potential of the 
tumor through modulation of the microenvironment.  
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1.4 Regulation of Cancer Metabolism  
 Though there are characteristics that are present across all tumor species, 
different tumors exhibit distinct metabolic phenotypes that differentially utilize the 
metabolic pathways described above. There are several inputs, both extrinsic and 
intrinsic, that impose particular selective pressures that dictate metabolic pathway utility 
in cancer. The aberrant signaling that is hallmark of the disease not only promotes rapid 
cell cycling and apoptotic resistance, but also greatly affects the metabolism of cancer 
cells. Moreover, whole body health and physiology as well as the specific tumor niche 
influence tumor metabolism. 
 
1.4.1 Aberrant Signaling 
 The need for paracrine stimulation of growth factor signaling in cancer cells is 
often dispensable as very often these neoplastic cells have acquired the ability to 
sustain proliferative signaling in an unregulated fashion (15).  This is often achieved 
through constitutive activation of growth factor signaling pathways irrespective of 
external stimuli (77). The accumulation of mutations in these pathways contribute to this 
aberrant signaling and not surprisingly are implicated in the metabolic phenotypes 
present in cancer. Some of the most commonly affected proteins have well 
characterized effects on energy metabolism and biosynthesis, which will be discussed 
below.  
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1.4.1.1 PI3K/Akt/mTOR Signaling Axis 
 The PI3K/Akt/mammalian target of rapamycin complex 1 (mTORC1) signaling 
axis frequently harbors mutations in cancer (ref). Typically, growth factor stimulation of 
associated receptor tyrosine kinases (RTKs) stimulates PI3K generation of activated 
lipid species that promote the plasma membrane association and subsequent activation 
of the serine/threonine kinase, Akt. Akt has many phosphorylation targets that are 
involved in the cell cycle, angiogenesis and anti-apoptotic signaling. Perhaps most 
critically to cancer, Akt is a potent driver of glycolytic metabolism (78). Akt mediates the 
translocation of glucose transporters (GLUTs) to the plasma membrane, where they 
facilitate the enhanced glucose uptake associated with many tumors (79). Constitutive 
activation of Akt promotes inhibition of the forkhead box O3 (FOXO3) transcription 
factor. Inactivation of FOXO3 promotes a transcriptional program that stimulates 
glycolytic metabolism as well as an increase in oxidative stress (80). Moreover, Akt 
directly activates the glycolytic enzymes, phosphofructokinase (PFK) and hexokinase 
(HK). Activated HK2 associates with the outer mitochondrial membrane (OMM) and the 
membrane spanning mitochondrial voltage-gated anion channel (VDAC). The VDAC 
facilitates the export of ATP generated through oxidative metabolism. Thus, HK2 
association with the VDAC couples mitochondrial ATP production to glycolysis and 
facilitates the rapid entry of glucose into the glycolytic pathway upon GLUT-mediated 
import (81). 
 An additional target of Akt activation is mTORC1. mTORC1 activity is stimulated 
directly through Akt-phosphorylation as well as through the inhibitory phosphorylation of 
its negative regulator, tuberous sclerosis complex 2 (TSC2). mTORC1 is a master 
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regulator of anabolic metabolism as it stimulated protein and lipid biosynthesis in 
nutrient replete conditions (82). Enhanced mTORC1 activity promotes glutamine uptake 
and GS activity, which facilitates glutamate production and TCA cycle anaplerosis (83). 
Coupled to this stimulation of glutamine metabolism is mTORC1-dependent activation 
of the pyrimidine synthesis initiator carbomyl phosphate synthase (CAD), this ensures 
that nucleotide synthesis is occurs under conditions of sufficient glutamine-derived 
nitrogen (84, 85). 
 
1.4.1.2 c-Myc 
 The proto-oncogene, c-Myc, codes for a transcription factor that is involved in the 
regulation of the cell cycle and apoptosis. A chromosomal translocation event involving 
c-Myc is associated with the development of Burkitt lymphoma (86). c-Myc is also an 
important regulator of glutamine and glucose metabolism in cancer. Glutamine uptake is 
enhanced by c-Myc through transcriptional activation of the glutamine/neutral amino 
acid transporter (ASCT2) and the system N 2 transporter (SN2) (87). Furthermore, c-
Myc enhances the expression of GS, CAD and phosphoribosyl pyrophosphate 
synthetase (PRPS2), which cooperate to stimulate nucleotide synthesis (88-90). This 
enhanced glutamine metabolism also contributes to the antioxidant capacity of cancer 
cells through increasing glutamate levels for GSH synthesis (7). 
 Glycolytic metabolism is also enhanced by c-Myc induction of GLUT and 
glycolytic enzyme transcription. Moreover, c-Myc facilitates aerobic fermentation 
through activation of LDH and pyruvate dehydrogenase kinase 1 (PDK1), the negative 
regulator of PDH, which promotes cytosolic accumulation of pyruvate (91). Additionally, 
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c-Myc activity is associated with increased mitochondrial biogenesis, which along with 
the increase in glutamine metabolism enhances mitochondrial function (92). 
 
1.4.1.3 Ras 
 Ras is a cellular guanosine triphosphatase (GTPase) that is an intermediary 
mediator of cell signaling that propagates many extracellular stimuli (93). The Kirsten rat 
sarcoma oncogene homolog (KRAS) member of the ras family of GTPases is implicated 
the tumorgenesis of non-small cell lung cancer (NSCLC) and prostate cancers (94, 95). 
KRAS is a driver of metabolism in these cells through stimulation of glucose uptake and 
the shunting of glycolytic intermediates into the PPP and hexosamine pathways. 
Davidson et al. recently demonstrated that KRAS-driven NSCLC tumors exhibit 
increased fermentation and oxidation of glucose compared to normal adjacent lung 
tissue (96). Moreover, KRAS is shown to direct glutamine-dependent aspartate 
synthesis. This increase in aspartate facilitates cytosolic accumulation, where it is 
metabolized to pyruvate to enhance the cytosolic NADPH pool (97). KRAS also appears 
to regulate protein and amino acid levels in NSCLC and pancreatic ductal 
adenocarcinoma (PDAC). Guo et al. showed that KRAS stimulates autophagy to 
maintain intracellular glutamine stores in NSCLC (94). Whereas, KRAS promotes 
uptake of extracellular protein through macropinocytosis in PDAC (98). 
 
1.4.1.4 p53 
  The canonical tumor suppressor, p53, is traditionally associated with its 
regulation of the cell cycle and apoptosis in cancer. However, p53 has a profound 
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impact on tumor metabolism. p53 is mutated or deleted in ~50% of all human cancers 
and its mutant status dictates its effect on cancer metabolism. Wild-type p53 supports 
mitochondrial oxidation and suppresses glycolytic metabolism (99). p53 upregulates 
TP53 induced glycolysis regulatory phosphatase (TIGAR), which decreases the level of 
fructose-2,6-bisphosphate, an intermediate metabolite that stimulates glycolytic flux 
(100).  Additionally, p53 enhances oxidative capacity through induction of SCO2, which 
codes for the cytochrome c oxidase assembly protein, a critical component of complex 
IV of the ETC (101). Wild-type p53 also promotes stabilization of Nrf2 and enhanced 
antioxidant capacity through activation of p21, which disrupts the KEAP1-Nrf2 
interaction (102).  The loss of p53 is thought to contribute to tumorigenesis through 
activation of glycolytic metabolism and entry of glycolytic intermediates into anabolic 
pathways that generate biosynthetic precursors and reducing potential in the form of 
NADPH (99). 
 
1.4.1.5 PKM2 
 Pyruvate kinase (PK) is the rate-limiting enzyme of glycolysis, which catalyzes 
the conversion of phosphoenolpyruvate (PEP) to pyruvate in a substrate level-
phosphorylation reaction that generates ATP. Several isoforms of PK exist, the two 
most relevant to cancer are the M1 and M2 isoforms. PKM1 is a highly efficient and 
constitutively active isoform that promotes pyruvate oxidation and prevents the buildup 
of glycolytic precursors (103). In contrast, The M2 isoform is inefficient and subject to 
inhibitory phosphorylation that promotes the accumulation of intermediates upstream of 
PEP (4). Though not required for tumorigenesis, PKM2 expression confers a 
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proliferative advantage to cancer cell by promoting PPP flux, uridine diphosphate 
(UDP)-glucose, glycerol and serine synthesis (104-106). The accumulation of serine 
activates PKM2, suggesting that PKM2 functions to promote sufficient production of 
serine for biosynthesis (104). There is recent evidence to suggest that PKM2 
translocates to the nucleus where it directly activates the transcription of glycolytic 
genes including itself in a feed forward mechanism that promotes anabolic glycolytic 
metabolism (107). c-Myc is shown to preferentially induce expression of PKM2 over 
PKM1 through alternative exon splicing (108). 
 
1.4.2 Tumor Hypoxia and HIF-1⍺  
 Rapidly growing tumors require concurrent vascularization to provide nutrient 
support for growth. Unfortunately, the rate of angiogenesis does not match that of tumor 
growth and the tumor vasculature is structurally and functionally inadequate (109). This 
leads to a perfusion gradient for oxygen and nutrients within the tumor that promotes 
metabolic heterogeneity, which can be assessed in patients through magnetic 
resonance imaging (MRI) (109, 110). An ultimate consequence of this immature 
vasculature is hypoxia within areas of the tumor that are beyond the oxygen diffusion 
limit of 70µm from the blood supply (111). This can lead to regions of tumor necrosis 
when cancer cells are unable to maintain viability in the face of nutrient and oxygen 
restriction (112). 
 Tumor hypoxia contributes to the substantial activation of HIF transcriptional 
machinery seen in cancer (113). Under normoxic conditions, HIF-1⍺ is hydroxylated by 
oxygen-dependent prolyl hydroxylases (PHDs), which promotes an interaction with the 
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E3 ubiquitin ligase, von Hippel-Lindau (vHL) promoting HIF-1⍺ ubiquitination and 
subsequent proteasomal degradation (114). The reduction in oxygen tension thus 
promotes stabilization of HIF-1⍺, permitting formation of an active HIF transcription 
factor. However, this is not the only mechanism for HIF-1⍺ activation in cancer. HIF-1⍺ 
is shown to be constitutively activated through hyperactivation of mTORC1, oxidative 
stress, loss of vHL and the accumulation of metabolic intermediates that inhibit PHDs 
(115). 
 HIF activates transcriptional machinery that drive aerobic glycolysis, including the 
induction of GLUT transporters, glycolytic enzymes and PDK (113). MCT4 is also 
upregulated under hypoxia, which contributes to the Warburg phenotype (116). 
Oxidative metabolism is not necessarily lost under hypoxic conditions of <2% O2, as the 
ETC can function at full capacity at oxygen levels as low as 0.5% (117). Glutamine 
oxidation is can sustain ATP levels under hypoxia (118). Kamphorst et al. demonstrated 
that in culture, hypoxic cancer cells utilized acetate as an alternative to glucose and 
glutamine for generating acetyl-CoA (39). Moreover, it has been demonstrated that 
~40% of invasive ductal breast carcinomas have increased expression of Acyl-CoA 
synthetase short-chain family member 2 (ACSS2), which facilitates acetate metabolism 
for the purposes of acetyl-CoA production (119).  
Oxidative stress can result from a hypoxic microenvironment (120). SHMT2 
expression is upregulated under to facilitate one-carbon metabolism and NADPH 
production, maintaining redox balance (104). Extremely low oxygen tension (<0.2% O2) 
causes endoplasmic reticulum (ER) stress and promotes the unfolded protein response, 
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which provides cancer cells with an adaptive advantage to maintain viability under the 
metabolic stress associated with hypoxia (121). 
 
1.4.3 Comorbidities  
 Oncogenesis does not occur in a vacuum; even heritable cancers are influenced 
by the physiology of the patient. Recent epidemiological studies have demonstrated that 
a substantial percentage of the United States population is overweight or obese (122, 
123). These burdens impose metabolic stresses that have extensive effects on 
physiology and have been associated with an increased risk of cancer (124). Colorectal, 
kidney, pancreatic, prostate as well as postmenopausal breast, endometrial, uterine and 
ovarian cancers have been linked to increased incidence in overweight or obese 
patients (123). Moreover, an estimated 20% of cancer deaths are attributable to the 
metabolic health of the patient (125).  
  These maladies are associated with increased adipogenesis, insulin resistance, 
increased circulating glucose and type II diabetes mellitus (T2DM). Fat deposition 
imposes similar energetic stresses on adipose tissue to that of a growing tumor, 
specifically the induction of HIF signaling (126). Adipocytes are a prominent component 
of the microenvironments of breast, colorectal, kidney, and ovarian cancers and thus 
contribute to the pool of extracellular signaling factors that drive tumor growth and 
metabolism (6). The pro-inflammatory cytokine Interleukin 6 (IL-6) is among several 
cytokines released from adipose tissue that promote the chronic state of inflammation 
that is often present in metabolic disease. IL-6 is shown to enhance cancer cell 
proliferation and invasive capacity (127). The adipocyte-derived factor endotrophin is 
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upregulated in breast and colorectal tumors and is associated with increased size and 
aggressiveness of tumors (128). Moreover, endotrophin mediated cisplatin resistance 
and metastasis in a mammary tumor model (ref). The induction of tumor-associated 
lipolysis likely provides a source of exogenous fatty acids for certain cancers; this is 
mediated by Xbp1 in triple negative breast cancer (TNBC) (129). 
 The loss of blood glucose control and insulin resistance associated with T2DM 
leads to increased levels of circulating glucose, insulin and insulin-like growth factors 
(IGFs) (131). Insulin and IGF activate PI3K/Akt signaling in cancer cells, which 
enhances tumor uptake of this abundant glucose and supports the biosynthetic needs 
for tumor expansion. High levels of fasting insulin and glucose are also associated with 
increased cancer risk (132). 
 
1.4.4 Mitochondrial Dysfunction 
 Though substantial evidence for the role of mitochondrial metabolism in 
tumorigenesis has accumulated in the years since Warburg theorized that aerobic 
fermentation was a direct response to irreversible damage to oxidative capacity, there 
are also indications that mitochondrial dysfunction is present in cancer and that this 
dysfunction directs metabolism (133). Mitochondria exist as a dynamic network that 
transverse the cell to facilitate energy-demanding processes such as cell motility. The 
structural integrity of the mitochondrial network is maintained through regulated fission 
and fusion events, this morphological regulation is tightly associated with the health and 
oxidative capacity of the organelle (134). Morphological abnormalities of cancer 
mitochondria have been characterized in several tumor species (135). The mitochondria 
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also encapsulate its own genome (mtDNA) that is not associated with histone proteins 
and is thus more susceptible to oxidative damage and mutagenicity than nuclear DNA 
(136). As mtDNA encodes components of the ETC, disruption of mtDNA fidelity can 
alter oxidative capacity.  
 
1.4.4.1 Structural Abnormalities 
 Electron microscopy has been employed to study mitochondrial content and 
morphology in tumor biopsies. These studies have demonstrated that cancer 
mitochondria are often less numerous, enlarged and exhibit partial or total cristolysis, 
the loss of IMM folding (137). Mitochondrial cristae provide increased surface area for 
electron transport and ATP production, the loss of this IMM folding severely hinders 
oxidative capacity. Moreover, the analysis of over 800 breast tumor biopsies showed 
that ~60% of tumor samples lacked mitochondria altogether, which would of course 
restrict bioenergetic and biosynthetic metabolism to the cytosol of these neoplasms 
(138). The mitochondrial network of cancer cells is often more fragmented than in 
normal cells, which is indicative of increased fission as a result of mitochondrial stress 
(135). Mitophagy, the process by which cells dispense of damaged mitochondria is 
upregulated in some cancers, and is critical to viability (134). 
 The lipid and protein composition of the IMM influences ETC efficiency and ATP 
production. Phospholipid content is an especially critical factor for ETC complex 
function. The mitochondrial specific phospholipid, cardiolipin (CL) is required for optimal 
NADH oxidation at complex I (139). Kiebish et al. demonstrated that compared to 
normal brain tissue, the mitochondria of a murine brain tumor exhibited deficiencies in 
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CL production (140). Reduction in CL content can contribute to mitochondrial 
uncoupling, or the movement of H+ back into the matrix, independent of ATP production. 
Mitochondrial uncoupling is often mediated by certain uncoupling proteins (UCPs), 
whose expression is increased in some cancers (141, 142). Mitochondrial uncoupling is 
present in brown adipose tissue, where H+ flux is harnessed to generate heat for 
thermoregulation rather than the production of ATP. Similarly, tumors have been 
characterized by thermographic detection of heat production. Interestingly, heat 
production was associated with more aggressive tumors (143). 
 
1.4.4.2 Mutational Defects in Mitochondrial Metabolism 
 The studies mentioned above suggest that tumors can still thrive with 
mitochondrial deficiencies, even in the absence of mitochondria. However, work 
performed with mtDNA-deficient 𝞺° cells demonstrated that mitochondria are required 
for tumorigenesis, suggesting that the loss of mitochondria in these tumor samples 
occurred after tumor formation (144-146). Nonetheless, mutations in mtDNA-encoded 
components of the ETC are prevalent in cancer (147). The most commonly affected 
component is Complex I (133). Alteration of the rate of NADH oxidation at complex I 
affects the mitochondrial NADH/NAD+ ratio, which has whole cell effects on metabolic 
flux. Additionally, Complex I mutations were shown to promote lung and breast cancer 
metastasis in a ROS-dependent manner (148, 149). The extent of complex I deficiency 
dictates its effect on tumorigenesis; severe disruption of complex I reduced 
tumorigenesis compared to cells harboring mutations that only mildly disrupted complex 
I activity (150).  
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 Mutations or alterations of nuclear-encoded DNA (nDNA) also impact 
mitochondrial metabolism. Several TCA cycle enzymes are found to be altered in many 
cancers (133). Citrate synthase (CS) was found to be upregulated in PDAC, where it 
facilitated proliferation through enhanced fatty acid synthesis (151). In contrast, the loss 
of CS in several cervical cancer cell lines corresponded with increased EMT and 
metastatic potential, suggesting that CS necessity is context dependent (152). 
Succinate dehydrogenase (SDH) is found to be deficient in several tumor species (153). 
This results in an accumulation of succinate, which is shown to elicit profound allosteric 
regulation of PHDs. Succinate thus inhibits PHD-dependent regulation of HIF-1⍺, 
leading to HIF stabilization and the induction of its metabolic transcriptional program 
(154). Furthermore, succinate accumulation results in the inhibition of oxygen-
dependent DNA and histone demethlyases, which promotes hypermethylation of certain 
regions of nDNA (155). 
 Similarly, inactivating mutations of fumarate hydratase (FH) have been observed 
in hereditary leiomyomatosis and renal cell cancer (HLRCC) and a subset of 
pheochromocytomas (PCC) (156). Fumarate also exhibits a propensity to stimulate HIF-
1⍺ activity through allosteric PHD inhibition. Unique to fumarate is its ability to bind to 
cysteine resides through a process called succination, which modifies protein function. 
Of note, fumarate can succinate KEAP1, which prevents its inhibitory interaction with 
Nrf2 and enhances the antioxidant capacity of FH-deficient cells (157). Conversely, 
fumarate can succinate GSH, which was shown to enhance oxidative stress in HLRCC 
cells (158). 
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 An additional enzyme associated with TCA cycling and mitochondrial metabolism 
that is commonly altered in cancer is IDH2. Observed mutations in both cytosolic IDH1 
and mitochondrial IDH2 appear to be largely gain-of-function that promotes IDH 
mediated reduction of ⍺-KG to R-2-hydroxyglutarate (2-HG). 2-HG blocks hematopoietic 
differentiation and promotes leukemogenesis. This is believed to be mediated through 
2-HG inhibition of the oxygen-dependent DNA and histone demethylases that are also 
subject to fumarate and succinate inhibition (159). Again, this promotes 
hypermethylation of DNA, including regions important for cellular differentiation. IDH-
dependent generation of 2-HG is a NADPH process, therefore robust production of 2-
HG would coincide with depletion of the mitochondrial NADPH pool. This alteration of 
redox balance could promote oxidative stress through loss of reducing potential 
required to facilitate redox-cycle based antioxidant systems (160). 
 
1.5 Therapeutic Vulnerability   
 Though the intricate characterization of cancer metabolism has only relatively 
recently become of particular interest, therapeutic targeting of cancer metabolism is not 
a novel strategy. Several traditional chemotherapeutics target biosynthetic pathways 
that disrupt cell proliferation. However, the emergence of omic technology has provided 
cancer biologists with knowledge of the tumor that permits specific targeting of 
metabolic pathways with small molecules. Cellular metabolism is ultimately dependent 
on nutrient availability; thus recent therapeutic initiatives have also focused on 
nutritional and lifestyle interventions as possible adjuvant or standalone cancer 
treatments.  
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1.5.1 Traditional Chemotherapy 
 The anti-folate class of chemotherapeutics has been used in the clinic since the 
1950’s, when it was observed that folic acid supplementation enhanced leukemia 
expansion (161, 162). This led to the development of the anti-folate, methotrexate, 
which is still employed to this day. Methotrexate inhibits dihydrofolate reductase 
(DHFR), which catalyzes the conversion of dihydrofolate (DHF) to THF, a critical 
component of one-carbon metabolism (163). As described above, the folate cycle and 
one-carbon metabolism is critical to nucleotide synthesis and NADPH generation, which 
sustain cancer proliferation (27, 28). Methotrexate is approved for the treatment of 
certain leukemias, lung cancer, osteosarcoma and head and neck cancers (163). 
Furthermore, pemetrexed, another anti-folate chemotherapy, is used as a first line-
therapy for NSCLC (164).  
 The major consequence of anti-folate agents is the inhibition of nucleic acid 
synthesis as a result of nucleotide deficiencies. Nucleic acid synthesis is also the target 
of a number of other oft-used chemotherapies. 5-Fluorouracil (5-FU) is an inhibitor of 
thymidylate synthase, preventing the production of thymidine (165). Hydroxyurea 
inhibits ribonucleotide reductase (RNR) which is required for deoxynucleotide synthesis 
and is used to treat chronic myeloid leukemia (CML) (166). Furthermore, the cytidine 
analog, gemcitabine, also inhibits RNR in addition to its activity in disrupting DNA 
replication. Gemcitabine is used in advanced stage ovarian and bladder cancers as well 
as NSCLC (167). Together, these agents demonstrate the longstanding efficacy of 
targeting biosynthetic pathways as an anti-cancer strategy. 
  36 
 
1.5.2 Molecular Targeted Therapies 
 The elucidation of the metabolic derangements that support rapid and sustained 
tumor growth has proven to be incredibly fruitful for the identification of novel targets for 
cancer therapy. However, as metabolism is critical to sustaining the viability of normal 
tissue, metabolic therapies are subject to potential toxicities. It is essential to identify 
metabolic vulnerabilities that are unique to cancer or to which normal tissue can 
sufficiently adapt. The implementation of untargeted global metabolomics as well as 
isotope-labeled metabolite tracing provides phenotypic context for the genomic 
identification of alterations to metabolic pathways. These studies will be critical for 
identifying individualized therapeutic regimens based on metabolic intervention. 
 
1.5.2.1 Glycolytic Inhibitors  
 The glucose analog, 2-deoxyglucose (2-DG), is rapidly phosphorylated by 
hexokinase to 2-deoxyglucose-6-phosphate, which inhibits glycolysis through 
competitive inhibition of G6P metabolism (168). 2-DG is shown to reverse the Warburg 
effect and inhibit tumor growth. Unfortunately, clinical trials assessing the safety and 
efficacy of 2-DG in glioma patients demonstrated dose-limiting toxicities that 
compromised 2-DG efficacy, as lower doses did not demonstrate clinical benefit (169). 
Similarly, pre-clinical studies of the HK2 inhibitor, 3-bromopyruvate (3-BP), have 
demonstrated remarkable efficacy in disrupting cancer metabolism and reducing 
tumorigenesis (170). 3-BP is shown to cause HK2 dissociation from the OMM, 
preventing its interaction with VDAC and the coupling of mitochondrial ATP production 
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to glycolysis. As such, 3-BP disrupts mitochondrial oxidation in addition to glycolysis 
(171). Clinical use of 3-BP is controversial because of fears over the potential toxicity of 
inhibiting glycolysis in normal tissue (172). 
 Lactate metabolism is another potential target in cancer therapy. A study of 
human lymphoma and pancreatic xenografts demonstrated that inhibition of LDH with 
the investigative small molecule, FX11, as well as siRNA knockdown inhibited tumor 
progression. This was associated with the collapse of ATP production and induction of 
oxidative stress (173). Moreover, small molecule inhibition of MCTs disrupted glycolytic 
metabolism in cancer cells (174). Unfortunately, as addressed above, the metabolism of 
many immune cells makes them similarly susceptible to MCT inhibition (175). The 
pervasive necessity of glucose metabolism in normal physiology provides a narrow 
therapeutic window for modulators of glycolysis. 
 
1.5.2.2 Inhibitors of Glutamine Metabolism 
 Glutamine metabolism is often an essential component of tumor metabolism as 
glutamine is required for TCA cycle anaplerosis, amino acid and nucleotide biosynthesis 
as well as maintenance of redox balance. Inhibition of enzymes required for glutamine 
metabolism has elicited pre-clinical efficacy. The experimental GS inhibitors compound 
968 and BPTES disrupted glutamate production and reduced the rate of tumor growth in 
models of B cell lymphoma (176, 177). Additionally, targeting glutamate-dependent 
aminotransferases disrupted ⍺-KG-dependent TCA cycle anaplerosis and blunted 
breast cancer growth (178). Furthermore, administration of 6-diazo-5-oxo-L-norleucine 
(DON) restricted primary tumor growth and inhibited metastasis of an aggressive brain 
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tumor (179). The upregulation of glutamine metabolism in cancer often coincides with 
restricted glucose metabolism, thus dual targeting of glucose and glutamine metabolism 
may exhibit greater efficacy than either alone in certain cancers. 
 
1.5.2.3 Inhibitors of Lipid Metabolism 
 The necessity of fatty acid synthesis for proliferation dictates that cancer cells 
commit a substantial amount of carbon in the form of citrate and NADPH for de novo 
lipogenesis. Several experimental inhibitors of enzymes required for fatty acid synthesis 
(FAS) are currently under pre-clinical investigation. Interruption of cytosolic citrate 
catabolism through ATP citrate lyase (ACLY) inhibition restricted acetyl-CoA production 
for FAS and significantly reduced cancer cell proliferation (180). Inhibition of the 
subsequent enzymatic mediator of FAS, ACC, is shown to limit breast cancer 
tumorigenesis. Small molecule inhibition of fatty acid synthase (FASN), including by 
natural products such as green tea, was sufficient to initiate apoptosis in several cancer 
cell lines in addition to a reduction of xenograft tumor growth in models of NSCLC and 
ovarian cancer (181, 182). Moreover, FASN required NADPH as a cofactor, therefore 
targeting of aerobic glycolysis and/or the PPP will likely diminish cancer cell capacity for 
FAS, as the PPP is the predominant source of NADPH for FAS (183). 
 
1.5.3 Lifestyle Modifications 
 We derive energy from the nutrients present in our diet. Excess nutrient intake 
and/or insufficient energy expenditure can result in adipogenesis and dysregulation of 
insulin signaling. As discussed previously, these can contribute to tumorigenesis and 
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cancer mortality. There is accumulating evidence that dietary and lifestyle interventions 
can promote a nutritional environment that is insufficient for carcinogenesis or disease 
progression (8). Suggesting that these may not only serve as a means to mitigate 
disease progression but to also prevent tumor formation altogether.   
 
1.5.3.1 Exercise 
 Epidemiological studies have demonstrated that individuals who regularly 
exercise are at lower risk for breast, colorectal, endometrial and pancreatic cancers 
(184). Moreover, exercise may reduce the risk for disease recurrence and decrease 
cancer-related mortality (185). The mechanisms underlying these anti-cancer effects 
are not fully understood, however they are likely a result of the temporal energetic 
stress imposed by vigorous physical activity. Of particular note, is the regulation of 
insulin signaling in response to chronic exercise. Evaluation of a carcinogen-induced 
murine model of breast cancer showed that voluntary wheel running was associated 
with reduced tumor formation. The reduction in tumor incidence was associated with a 
reduction in circulating insulin and IGF-1 levels (186).  Similar results on these 
circulating factors was demonstrated in breast cancer patients following regimens of 
aerobic or resistance exercise (187). Giganti et al. recently reported that exercise 
reduced circulating levels of MMP2 and MMP9 in breast cancer survivors, suggesting 
that exercise may reduce the risk of recurrent metastases (188). 
 There is also evidence to suggest that exercise may enhance chemotherapy 
efficacy (189). As mentioned above, solid tumors exhibit immature vasculature that 
prohibits adequate perfusion of the entire tumor mass, which induces energetic stress 
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and contributes to the metabolic heterogeneity of tumors. Exercise stimulates 
angiogenesis and improves vascular function in ischemic tissue and is shown to 
enhance tumor perfusion in a model of orthotropic prostate cancer (190,191). An 
increase in tumor perfusion would enhance drug delivery throughout the tumor. 
Furthermore, enhanced perfusion would promote tumor oxygenation and potentially 
prevent hypoxia-mediated chemoresistance of ROS-dependent chemotherapies (192). 
Compliance is likely to restrict the implementation of exercise for some cancer patients. 
Many therapeutic regimens induce fatigue and weakness, and though these symptoms 
would likely be attenuated with exercise, they may be serve as barriers to adjuvant 
exercise.   
 
1.5.3.2 Caloric Restriction 
 Calorie restriction (CR), the intentional reduction of daily calorie intake by ~20-
40%, is shown to increase metazoan longevity (193). Coinciding with increased 
longevity, CR reduces or delays the onset of age-related disorders, including cancer 
(194). Similar to exercise, CR reduces circulating levels of insulin and IGF-1 as well as 
glucose, which could compromise glycolytic metabolism in cancer. Indeed, constitutive 
PI3K signaling, which is a downstream mediator insulin receptor activation, conferred 
resistance to CR in tumors (195). Suggesting that the anti-cancer effect of CR is in part 
due to downregulation of insulin signaling. Weight loss is often associated with chronic 
CR, which has restricted its clinical use. Cancer patients are susceptible to cachexia, 
which is characterized by severe weight loss, muscle atrophy and loss of appetite. Thus 
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the implementation of CR could exacerbate this condition, which is thought to be the 
immediate cause of death in about ~20% of cancer patients (196). 
 However, there is accumulating evidence that the beneficial effects of CR can be 
achieved in the absence of substantial weight loss through implementation of 
intermittent fasting. Fasting increases lifespan in model organisms and promotes 
resistance to oxidative stress through downregulation of PI3K signaling (197). This 
metabolic regulation in normal tissue is shown to promote resistance to pro-oxidant 
chemotherapy, whereas fasting is shown to potentiate chemotherapy efficacy at the 
tumor in pre-clinical models (192, 198). Furthermore, fasting is under clinical 
investigation as an adjuvant to chemotherapy because of the observation that fasting 
mitigates dose-limiting toxicities without compromising efficacy (199). 
 
1.5.3.3 Ketosis 
 A physiological consequence of the glucose restriction associated with CR and 
intermittent fasting is induction of ketosis, which is characterized by the increased 
hepatic production of ketone bodies (ketones) such as acetoacetate and β-
hydroxybutyrate (βHB), to support energy metabolism in the absence of glucose. 
Ketosis can also result from adherence to the ketogenic diet (KD), a high fat, low 
carbohydrate and adequate protein diet that restricts circulating glucose levels while 
increasing blood levels of ketones. The KD is a first line therapy for pediatric refractory 
epilepsy and has also shown efficacy in treating other neurological disorders and 
metabolic syndrome (200-202). There is also substantial evidence to suggest that the 
KD elicits anti-cancer activity (203).  
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 Similar to CR and fasting, the KD reduces circulating insulin levels. This was 
associated with reduced tumor growth and survival in a model of pancreatic cancer 
(204). Restricting glucose availability lowers the glycolytic capacity of tumors, which 
subsequently limits cancer cell proliferation due to a lack of biosynthetic precursors. 
Thus the efficacy of the ketogenic diet for highly glycolytic tumors is likely to be 
dependent on the restriction of glycolytic metabolism. Indeed, our laboratory has 
previously demonstrated that increased survival in response to the ketogenic diet was 
inversely proportional to blood glucose level in a model of glioblastoma (GBM) (205).   
 Recent evidence suggests that ketone bodies exhibit alternative functions 
beyond serving as energy metabolites. βHB is shown to act as a class I histone 
deacetlyase (HDAC) inhibitor; this activity was associated with a transcriptional 
response that suppressed oxidative stress (206). Moreover, it has been reported that 
βHB inhibits the NLRP3 inflammasome, providing a potential mechanism for the anti-
inflammatory response associated with CR and the ketogenic diet (207). The epigenetic 
and immunomodulatory effects of βHB and the ketogenic diet in regards to 
tumorigenesis are currently under investigation.  
 The ketogenic diet is currently being evaluated in numerous clinical trials, 
however clinical efficacy is likely to be hampered by patient compliance. Strict 
adherence to the ketogenic diet is required to sustain the benefits of the diet in regards 
to blood metabolite levels. Imposing dietary restrictions on cancer patients may prove 
difficult due to the development of taste aversions and the loss of appetite associated 
with the disease as well as cancer therapy (208). Therefore, exogenous ketone 
supplementation may provide an alternative to the KD for a ketogenic cancer 
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intervention. We have previously demonstrated that administration of several ketone 
supplements can increase circulating βHB levels regardless of carbohydrate intake 
(209). Furthermore, Poff et al. showed therapeutic efficacy with a ketone ester in 
prolonging survival and reducing metastasis in an aggressive model of GBM (210). This 
study further supports the notion that ketone bodies themselves possess anti-cancer 
activity that merits further investigation. 
 
1.5.4 Targeting Redox Balance 
 As described throughout this review, a fundamental consequence of cancer 
metabolism is the upregulation of pathways that contribute to the maintenance of 
cellular redox balance. It is now clear that moderate oxidative stress potentiates 
tumorigenesis and the increased antioxidant capacity of cancer cells facilitates the 
accumulation of non-toxic levels of ROS that permit oxidation-dependent signaling 
events (53). The continued utility of radiotherapy and pro-oxidant chemotherapeutics 
demonstrates efficacy in targeting redox balance. Rational targeting of cancer redox 
balance can be achieved through bidirectional modulation of oxidative stress. 
 Antioxidant supplementation has been suggested as therapeutic strategy to 
restrict ROS signaling in tumorigenesis. A series of large scale clinical trials have been 
conducted to evaluate the cancer preventative effects of a number of antioxidant 
cofactors. The Linxian trial demonstrated that a cocktail of β-carotene, vitamin E and 
selenium reduced total patient mortality as well as mortality associated with gastric 
cancer (211).  In contrast, subsequent trials evaluating β-carotene in combination with 
vitamin E or A showed that antioxidant supplementation increased the risk for lung 
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cancer (212, 213). Moreover, the “Selenium and Vitamin E Cancer Prevention Trial” 
(SELECT) was initially lauded for demonstrating that selenium supplementation reduced 
prostate cancer incidence. However, further analysis of the >33,000 patient trial 
revealed that this was only true for a small subset of rare forms of prostate cancer. 
Furthermore, it was shown that vitamin E supplementation actually increased the risk for 
prostate cancer in men (214). Additional studies evaluating the green tea extract, 
epigallo-catechin-3-gallate (EGCG), curcumin and choline have demonstrated pre-
clinical efficacy, however these results have yet to be replicated in the clinic. 
Gorrini et al. have posited that ROS levels increase as tumors develop and 
become more aggressive, bringing them closer to the threshold for apoptotic induction. 
Thus as a tumor becomes more aggressive, they become susceptible to even small 
perturbations of redox balance (215). This has informed the development of small 
molecules that induce oxidative stress in cancer cells. The proteasome inhibitor 
bortezomib promotes the accumulation damaged protein that promotes oxidative stress 
and mitochondrial dysfunction in mantle cell lymphoma (MCL) (216). Subsequent 
studies with bortezomib demonstrated that it also disrupted ER function through 
exacerbation of oxidative stress and induction of the unfolded protein response (217, 
218). 
Similar to inducing ROS production, reducing antioxidant capacity enhances 
oxidative stress. The anti-inflammatory agent sulphasalazine exhibits inhibitory activity 
towards xCT, preventing the uptake of cysteine and restricting GSH synthesis. 
Sulphasalazine induction of oxidative stress is associated with a reduction of cell 
viability and tumor growth in models of pancreatic and small cell lung cancers (SCLC) 
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(219, 220). Additionally, the gold-based compound auranofin inhibits TXR and 
potentiates pro-oxidant therapies in head and neck cancer (221). Furthermore, inhibition 
of G6PDH with 6-anicotinamide restricted GSH production due to a lack of PPP-derived 
NADPH and reversed antioxidant-mediated resistance to doxorubicin in colon cancer 
cells (222). Together, these studies support a pro-oxidant approach to modulating 
cancer redox balance and inform the rationale for the therapeutic regimen evaluated in 
this thesis.  
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CHAPTER 2: GLIOMA AS A TARGET FOR METABOLIC CANCER THERAPY 
 
2.1 Chapter Synopsis 
This chapter serves to address the characteristics of malignant brain cancers that 
suggest that these tumors may be responsive to metabolic therapies. The VM-M3 
mouse model of glioblastoma is discussed as an appropriate model for evaluating the 
efficacy of metabolic therapies. Lastly, we introduce dichloroacetate and metformin as a 
potential metabolic therapy for gliomas and discuss the central hypothesis and project 
aims for this dissertation.  
 
2.2 Glioma Biology  
 Glioma is a collective term for brain cancers arising from cells of glial origin. 
Though gliomas account for only about a third of all central nervous system (CNS) 
tumors, they represent for the majority of malignant brain cancers (1). The detection and 
diagnosis of glioma is often delayed due to initial asymptomatic tumor initiation and 
growth. Detection often occurs upon presentation of neurological symptoms such as 
headache, depression, motor function deficits, hearing and vision loss, and the onset of 
seizures (2). These occur as a result of physiological stresses imposed by the growing 
tumor. The standard of care for glioma employs debulking surgery when feasible, 
followed by concurrent radiation and chemotherapy (3). Gliomas present distinct 
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morphologies and pathologies that have led to classification at the histological and 
morphological level. The robust effort in elucidating the process of gliomagenesis has 
identified several molecular hallmarks of gliomas that implicate metabolism as a 
potential driver of tumor progression (4). 
 
2.2.1 Clinical Characteristics  
 Primary glioma nomenclature is dependent on the cell of origin. There are three 
glial cell types that yield tumors; astrocytes (astrocytomas), oligodendrocytes 
(oligodendrogliomas), and ependymal cells (ependymomas). There are also tumors that 
are composed of multiple glial cells in high proportion; the most common of these mixed 
gliomas are oligoastrocytomas (5). The World Health Organization (WHO) has 
developed a classification system for glioma diagnosis based on both phenotypic and 
genotypic characteristics. Gliomas are assigned a grade from I-IV based on the 
perceived aggressiveness of the tumor (6). As such, tumors of higher grades are more 
aggressive and are associated with a poorer prognosis. Low-grade gliomas are 
common in children, whereas high-grade gliomas are more frequent in adults. 
 Astrocytic gliomas span the complete range of WHO tumor grades. Pilocytic 
astrocytomas are juvenile grade I tumors that are distinct from other astrocytomas in 
that they are fully circumscribed and thus do not spread from the area of tumor initiation. 
The diffuse astrocytic gliomas (WHO grades II-IV) infiltrate the surrounding tissue. Low-
grade diffuse astrocytomas (WHO grade II) are slow growing tumors that display 
moderate cellularity and no anaplasia. Anaplastic astrocytomas (WHO grade III) exhibit 
rapid growth and a high degree of dedifferentiation. The most aggressive astrocytic 
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tumor is glioblastoma multiforme (GBM; WHO grade IV), which in addition to rapid 
growth and anaplasia, also present with microvascularization of the bulk tumor and 
regions of necrosis. GBMs can be further typified as either primary, which are de novo 
tumors, or secondary, which progress from an established lower-grade tumor (7).  
Oligodendrogliomas (WHO grades II or III) are also classified as diffuse gliomas 
and are differentiated based on the presence of anaplastic growth. Ependymomas are 
difficult to classify based on WHO recommendations but fall within grades I-III (5). The 
most recent WHO classification guidelines discourage against the diagnosis of 
oligoastrocytomas, as recent studies have identified molecular markers that can 
differentiate if a mixed glioma more closely resembles an astrocytoma or 
oligodendroglioma (6).  
 Gliomas can arise throughout the brain and spinal cord region of the CNS. 
Astrocytes are a ubiquitous constituent of the CNS and thus astrocytic tumors are 
frequently found in the brainstem, cerebellum, cerebrum and spinal cord (8). Whereas, 
oligodendrogliomas are most typically found in the frontal and temporal lobes of the 
cerebrum (9). Ependymal cells associate with the ventricles of the brain and the spinal 
cord, which is determinant for the location of ependymoma formation (10).  
 Gliomas account for 80% of malignant brain tumors despite only representing 
27% of total CNS tumors. The most common malignant brain tumor is GBM, which 
account for ~46% of total malignant tumors with an incidence rate of 3.20 per 100,000 
people in the United States (US) (1). The less aggressive diffuse astrocytomas are the 
second most common brain malignancies. Malignant gliomas are more prevalent in 
males than females and are also more common in Caucasian individuals than non-
  60 
whites (1). Moreover, the familial risk for individuals with a family history of glioma is 
twice that of individuals without previously reported familial incidence (11). The median 
age at diagnosis for GBM is 65, whereas the age at diagnosis for other gliomas tends to 
be 10-15 years younger. The prognosis for glioma patients is negatively correlated with 
age at diagnosis (12). 
 The focal nature of pilocytic astrocytomas typically allows for near-total resection 
of the tumor and is associated with a 10-year survival rate of 92.1%. The prognosis for 
low-grade and anaplastic astrocytomas is considerably worse, as only 47.9% and 
27.9% of patients achieve 5-year survival, respectively. GBM patients face the grimmest 
prognosis, as only 5.1% of patients achieve 5-year survival post-diagnosis. Moreover, 
median survival for patients receiving radiation alone after debulking surgery is 12.1 
months, whereas the addition of concurrent temozolomide (TMZ) chemotherapy only 
increases median survival to 14.6 months (3, 12).  
 Though diffuse gliomas display an exquisite propensity for invasion, marked by 
the extensive spread of tumor cells throughout the brain, extracranial metastasis is rare 
in malignant glioma (13). For instance, extracranial metastases are present in only 
~0.5% of GBM cases, and the median survival of these patients is only 10.2 months (3, 
14). It has been proposed that GBM metastasis from the brain is hindered by a lack of a 
disseminating lymphatic system in the brain, poor intravasation of intracranial 
vasculature due to the presence of dense dura, and that glioma cells find the 
microenvironment of extracranial tissue incompatible for metastases formation (13). 
However, GBM metastasis to bone, liver, and lung is consistently reported, suggesting 
that these tissues provide a sufficient niche for metastatic tumor formation (14, 15). 
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Rather, it is likely that the infrequency of extracranial metastasis is in part a result of the 
rapid mortality associated with the disease. This restricts the time for metastases 
formation and detection, as the average survival from time of metastases detection is 
only 1.5 months (13).  
 
2.2.2 Molecular Pathology 
 Traditional glioma diagnosis has been dependent on histological and pathological 
markers that allow for the identification of a specific tumor species. For instance, GBM 
diagnosis has depended in part on the presence of glial fibrillary acid protein (GFAP), 
which is determined through histological staining (16).   However, the integration of 
techniques that permit study of the underlying molecular changes in tumorigenesis have 
identified specific genetic and transcriptional characteristics of gliomas that allows for 
more discrete diagnosis. 
 Large-scale risk analyses and analysis of single nucleotide polymorphisms 
(SNPs) in adult gliomas has identified a possible link between childhood immunogenic 
events and glioma incidence. There is an apparent inverse association between 
childhood chicken pox incidence and glioma incidence as an adult, as the presence of 
IgG antibodies against the varicella-zoster virus is inversely correlated with glioma 
formation (17-19). Moreover, SNPs in genes associated with asthma, such as the 
interleukin-13 (IL-13) SNP C1112T CT, TT are inversely associated with GBM incidence 
(20). 
 Further studies have identified several glioma-associated SNPs in genes that 
participate in DNA repair and cell cycle regulation, both of which are dysregulated in 
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cancer. Variants in the excision repair cross-complementing genes ERCC1 and 
ERCC2, which code for the DNA excision repair proteins ERCC-1 and ERCC-2, 
respectively, have been found in oligodendrogliomas (21, 22). SNPs in O-6-
methylguanine-DNA methyltransferase (MGMT) have also been implicated in glioma 
formation (23). Moreover, MGMT is often deleted or repressed in GBM, which actually 
confers susceptibility to the alkylating activity of TMZ and results in greater response to 
treatment (24). Variants of SNP309 in the promoter region of the mouse double minute 
2 homolog (MDM2) gene have been implicated with astrocytoma formation in patients 
with Li-Fraumeni syndrome (25). MDM2 codes for an E3-ubiquitin ligase that is a 
negative regulator of p53 and facilitates cell cycle progression.  
 Additional genetic alterations in genes coding for p53 and retinoblastoma protein 
(Rb), another negative regulator of the cell cycle, result in the dysregulation of the cell 
cycle in gliomas. Several studies have demonstrated that the loss of either facilitates 
glioma formation in various mouse models (26, 27). Inactivating mutations in p53 are 
frequent in low-grade astrocytomas as well as secondary GBMs (28). Inactivation of Rb 
or the upregulation of its negative regulator cyclin-dependent kinase 4 (CDK4) are 
frequently reported in high-grade astrocytomas or oligodendrogliomas (29, 30). For 
instance, a study associated with the cancer genomes atlas (TCGA) project showed 
that of 91 secondary GBMs p53 and Rb were dysregulated in 87% and 78% of cases, 
respectively (31). Moreover, Rb is shown to be a target of the microRNA miR-26a, 
which is overexpressed in 12% of GBMs and is implicated in gliomagenesis through this 
repression of Rb (32). 
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 Aberrant receptor tyrosine kinase signaling is another molecular hallmark of 
gliomas. In fact, the majority of GBM cell lines exhibit coactivation of at least 3 RTKs 
(33). The most common RTK alteration in glioma is epidermal growth factor receptor 
(EGFR) amplification, which was shown in two separate studies to be present in 36% of 
analyzed samples (23, 34). EGFR amplification is most prevalent in primary GBMs (1). 
Moreover, heterogeneous expression of distinct oncogenic variants of EGFR are 
present within single tumors. The most common mutational variant is EGFR vIII, which 
lacks a portion of the extracellular binding domain and is implicated in the enhanced 
response of certain GBMs to the EGFR inhibitor erlotinib (35). 
Enhanced platelet derived growth factor receptor (PDGFR) signaling is common 
to low-grade astrocytomas and oligodendrogliomas (36, 37). This is resultant from 
enhanced expression of both PDGFR and its ligand PDGFβ, permitting autocrine and 
paracrine activation of the receptor within tumors (38). The enhanced activation of these 
RTKs stimulates signaling through the Ras-MAPK and PI3K-Akt-mTORC1 axises, 
which are shown to be constitutively activated in about 90% of GBMs (31). The aberrant 
signaling through both pathways is also mediated through PTEN loss, which is shown to 
be present in 36% of GBMs (31). These pathways drive tumor growth and are required 
for gliomagenesis (38).  
Another common alteration in gliomas is the missense mutation of IDH1 at R132. 
This arginine residue resides in the active site of IDH1 and mutations of this residue 
result in the loss of H+-bonding with isocitrate and promotes gain of function catalysis of 
⍺-KG to 2-HG (39). IDH1 mutations are present at very high proportions of grade II/III 
astrocytomas and oligodendrogliomas as well as secondary GBMs, but are rare in 
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primary GBMs (40). Consistently, IDH mutations appear to mutually exclusive with the 
amplification of EGFR (39). IDH1 mutant tumors tend to occur in patients that are nearly 
20 years younger than those with wild type IDH1 tumors; this corresponds with a three-
fold greater survival for patients with mutant IDH1 (41). 
Similar to other tumor species, gliomas harbor a small population of cells that 
exhibit stem-like properties that have been implicated in tumor initiation and 
chemoresistance (42). Glioma stem cells (GSCs) often express the neural stem cell 
marker cluster of differentiation 133 (CD133). CD133+ GSCs are shown to secrete 
vascular endothelial growth factor (VEGF), which likely contributes the high vascularity 
of GBMs (43, 44). Moreover, GSCs display an ability to transdifferentiate into 
endothelial cells and pericytes further enhancing vessel deposition. The depletion of 
endothelial cells restricted GBM xenograft growth in mice, suggesting that GSC-
mediated vascularization is essential to tumor growth (45). GSC stemness is suggested 
to be a result of the increased Akt activity associated with gliomagenesis (46).  
Collectively, the identification of these common molecular hallmarks and genetic 
alterations have provided for sub-classification of GBMs. Phillips et al. proposed that 
GBMs can be classified into three categories: proneural, proliferative, or mesenchymal 
(47). Under their parameters, proneural tumors display intact PTEN and normal EGFR 
expression. These tumors are more common in younger individuals, which corresponds 
with increased survival. Proliferative tumors show loss of PTEN, Akt activation and 
amplification of EGFR. Mesenchymal tumors are also marked by loss of PTEN, 
activation of Akt and EGFR amplification. These tumors also display increased CD44 
and VEGF expression, which corresponds with increased vascularization (47, 48). 
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Verhaak et al. have subsequently provided rationale for a classification system 
with four distinct categories (49). They too propose proneural and mesenchymal classes 
of GBM, but also present evidence for the presence of classical and neural GBMs.  
Their proneural classification was based on a high frequency of PDGFR⍺ and IDH1 
mutations. Mesenchymal tumors exhibited increased expression of CD44 and chitinase-
3-like protein 1 (YKL-40), which stimulates angiogenesis and astrocyte migration. 
Classical GBMs were marked by EGFR amplification and neural tumors showed 
increased expression of several neuron markers, such as the neurofilament light 
polypeptide (NEFL) and synaptotagmin 1 (SYT1) (49). These classification systems 
may serve to inform individualized GBM therapy, in hopes of improving the prognosis of 
the deadly disease. 
 
2.2.3 Metabolism  
 The molecular factors that influence gliomagenesis are implicated in many of the 
metabolic dependencies exhibited by tumors. EGFR amplification and loss of p53 
contribute to the highly glycolytic nature of gliomas. Enhanced EGFR signaling induces 
HK2 expression in GBM; increased HK2 expression is negatively correlated with patient 
survival (50). EGFR is also shown to stimulate NF-κB induction of HIF-1⍺ activity in 
glioma. This is associated with increased PKM2 expression and nuclear translocation 
(51, 52). HIF-1⍺ is likely a critical driver of glycolytic metabolism in mutant IDH1 
gliomas. The reductive carboxylation of ⍺-KG to 2-HG restricts ⍺-KG availability. This 
inhibits ⍺-KG-dependent enzymes such as PDHs, permitting accumulation of HIF-1⍺.  
HIF1 activity is responsible for increased PDKII expression in glioma (53). The glycolytic 
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capacity of astrocytomas is evidenced by FDG-PET imaging. Tumor grade can be 
predicted based on 18F-deoxyglucose (18FDG) uptake; GBMs show enhanced 18FDG 
uptake compared to low-grade astrocytomas (54). Furthermore, gliomas are susceptible 
to MCT1 inhibition by ⍺-cyano-4-hydroxycinnamate, which inhibits tumor growth and 
potentiates TMZ efficacy (55). 
 Glioma cells in culture exhibit robust glutamine metabolism that permits growth in 
the absence of glucose (56). Moreover, glutamine levels in the brain of GBM patients is 
shown to be significantly higher than that of normal brain (57). However, glutamine 
metabolism may not be as prevalent in vivo. Marin-Valencia et al. utilized 13C-glucose 
tracing to demonstrate glucose-dependent TCA cycle anaplerosis as well as the 
synthesis of glutamine from glucose carbon in an orthotopic model of high-grade glioma 
(58). This is consistent with the observation that decreased glutamine synthetase (GSN) 
expression is associated with increased GBM patient survival (59). 
 GBM tumors also exhibit increased levels of unsaturated fatty acids compared to 
normal brain (60). EGFR stimulation of Akt activates sterol regulatory element-binding 
protein-1 (SREBP-1), promoting its nuclear translocation where it activates the 
transcription of ACC and FASN, which facilitate fatty acid synthesis (61).  SREBP-1 also 
induces low-density lipoprotein receptor (LDLR) expression, facilitating enhanced 
exogenous lipid uptake in gliomas (62). SREBP-1 is also activated as a consequence of 
increased glycolytic metabolism. Increased flux through the hexosamine pathway 
cooperates with enhanced expression of O-linked-N-aceytlglucosaminyltransferase 
(OGT) to promote O-glycosylation (63). SREBP-1 is activated by OGT-mediated 
glycosylation and this increases with increasing tumor grade (64). Certain GBM cells 
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require fatty acid oxidation to maintain cytosolic NADPH levels in order to mitigate 
oxidative stress (65). Alternatively, analysis of patient GBMs showed a reliance on 
acetate oxidation to sustain acetyl-CoA levels for fatty acid synthesis and NADPH 
production (66). 
 Mitochondrial abnormalities are frequent in gliomas (67). Glioma mitochondria 
are characteristically hyperpolarized and this is most evident in CD133+ GSCs, likely 
enhancing their chemoresistance (68). Glioma mitochondria are also shown to exhibit 
swelling and partial or total cristolysis (69). Yet mitochondrial metabolism is still required 
to maintain glioma integrity. Mitochondrial SHMT2 and glycine decarboxylase (GLDC) 
activity is required to prevent toxic accumulation of glycine during hypoxic conditions. 
This is particularly evident in pseudopalisading cells that border necrotic foci, which are 
a pathological hallmark of GBM (70). 
 The establishment of non-targeted metabolomics has permitted large-scale 
studies of glioma metabolism in patients. Chinnaiyan et al. established and analyzed the 
metabolomic profile of 69 glioma samples that included tumors of WHO grades II-IV 
(71). They noted that high-grade gliomas exhibited a distinct anabolic phenotype that 
corresponded with rewiring of glycolytic flux. This was evidenced by accumulation of 3-
phosphoglycerate (3-PG), serine, and glycine suggestive of increased flux through the 
serine biosynthesis pathway. Additionally, GBMs had increased ribose-5-phosphate 
(R5P) and GSH, which indicates enhanced PPP activity. This was mediated through 
increased PKM2 expression in these tumors, which was associated with accumulation 
of PEP. This was particularly evident in mesenchymal GBMs. Moreover, this group was 
able to differentiate between low-grade and high-grade gliomas based on the level of 2-
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HG present in the tumor, which corresponds with IDH1 mutant status and is again a 
characteristic of low-grade gliomas (39, 40, 71). 
 Subsequently, Zhao et al. analyzed 87 plasma samples from glioma patients to 
determine circulating metabolite profiles (72). They achieved >90% success in 
classifying patients with respect to grade and IDH1 status based on metabolomic 
profile. Circulating arginine levels were decreased in patients with high-grade glioma, 
which was suggested to be a result of increased demand as arginine metabolism is 
enhanced in GBMs and increases invasiveness (73). Serum lactate levels were also 
elevated in patients with high-grade gliomas, likely associated with the robust glycolytic 
metabolism of GBMs. Creatine metabolism distinguished mutant and wild-type IDH1 
tumors. A reduction in creatine synthesis intermediates and an increase in the 
creatinine metabolite sarcosine were observed in the plasma of patients with mutant 
IDH1 tumors. Creatine levels have previously been reported to be low in high-grade 
gliomas, which typically harbor wild-type IDH1 (74). Interestingly, circulating 2-HG levels 
could not differentiate between wild-type and mutant IDH1 tumors, suggesting that 2-
HG can accumulate within gliomas as was reported in the previous study. These studies 
can serve to provide new therapeutic targets as well as inform personalized metabolic 
therapy based on the metabolic dependencies of a particular patient’s tumor. 
 
2.3 The VM-M3 Model of Metastatic Glioblastoma Multiforme (GBM) 
 Though infrequently reported, metastasis worsens the already dire prognosis 
associated with GBM. Metastasis is associated with 90% of all cancer-related deaths, a 
direct consequence of the lack of current therapeutic efficacy towards metastatic 
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disease (75). A mitigating factor in the development of therapies that can effectively 
prevent metastasis or target the systemically disseminated tumor cells is a lack of 
appropriate pre-clinical models. The syngeneic VM-M3 model, which was developed by 
Dr. Thomas Seyfried, is derived from a spontaneous brain tumor in the VM/dk inbred 
strain of mice and mimics the metastatic cascade exhibited by human metastases (76, 
77). VM/dk mice display an increased incidence rate of spontaneous brain tumors, 
which typically resemble astrocytomas (78). The original M3 tumor was adapted to cell 
culture to yield the VM-M3 cell line. These VM-M3 cells were transduced with a lentiviral 
vector containing a firefly luciferase transgene, which permits non-invasive in vivo 
imaging. Luciferase catalyzes the oxidation of luciferin to oxyluciferin through which light 
is generated. This bioluminescence can be detected and quantified to as a 
representation of tumor burden.  
 Orthotopic transplantation of VM-M3 cells into the brain of immunocompetent 
VM/dk mice results in the formation of a primary tumor that exhibits aggressive GBM 
pathology. These tumors are extraordinarily invasive, generating secondary tumors 
throughout the brain parenchyma of both the ipsilateral and contralateral hemispheres 
of transplantation. Moreover, VM-M3 cells are shown to migrate in a perivascular 
fashion as well as along white matter tracts, which is characteristic of GBM (79). 
Orthotopic transplantation is also accompanied by extracranial metastasis throughout 
the animal. Furthermore, subcutaneous transplantation of VM-M3 cells into the visceral 
fat pad of VM/dk mice results in systemic metastasis to the brain, liver, lungs, kidneys 
and spleen. 
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 Though VM-M3 tumors present pathologically as GBMs, VM-M3 cells exhibit 
characteristics of microglia, the resident macrophages on the brain. These cells are 
shown to be phagocytic, a fundamental characteristic of macrophages (80). VM-M3 
cells express ionized calcium-binding adaptor molecule 1 (Iba1), which is an established 
cell surface marker of microglia. Moreover, VM-M3 cells show expression of the 
macrophage markers, CD11b, CD45, CD68, and EGF-like module-containing muncin-
like hormone receptor 1 (EMR1, also known as F4/80). These cell surface proteins are 
implicated in cell migration, cell-cell interactions and immunomodulation (81-83). For 
instance, CD45 disrupts antigen receptor signaling in lymphocytes and F4/80 facilitates 
interactions with T-cells and promotes their differentiation to Tregs (82, 83). Together 
these factors likely promote an immunosuppressive tumor microenvironment. VM-M3 
tumors do not stain positive for the astrocyte marker GFAP, which is also generally 
associated with astrocytomas. However, GFAP expression is not universal in mature 
astrocytes and is very often absent in primary cultures of adult human brain tissue (84).   
  The confluence of these characteristics may suggest that VM-M3 tumors may 
closely resemble another class of brain tumor, such as microglioma, which is more 
commonly referred to as primary central nervous system lymphoma (PCNSL). PCNSLs 
are Non-Hodgkin lymphomas of the CNS derived from B cells. These tumors also 
contain an infiltrating population of CD3+-T Cells. VM-M3 cells are negative for CD3 as 
well as the pan-B cell marker CD19, which is present in up to 98% of PCNSLs, 
suggesting that VM-M3 tumors are not PCNSLs (85, 86). Rather, VM-M3 behavior 
agrees with the observation that metastatic cells often resemble macrophages and that 
fusion events occur between macrophages and neoplastic cells (87-89). Huse and 
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Holland propose that gliomas incorporate a substantial number of non-neoplastic cells 
that become transformed in the tumor microenvironment and thus contribute to the 
proliferating tumor mass and influence disease progression (38). 
Microglia/macrophages would very likely be co-opted through this process as 
macrophages are very prominent components of the tumor microenvironment. 
 Glioma-associated macrophages (GAMs) can constitute up to 30% of the total 
tumor mass (90). Upon activation, macrophages undergo immunogenic polarization 
towards either a pro-inflammatory M1 or anti-inflammatory M2 phenotype. GAMs tend to 
present the M2 phenotype, which contributes to the immunosuppressive tumor 
microenvironment (91). Moreover, GAMs are shown to promote local invasion through 
degradation of the ECM (92). Consistent with the observation that mesenchymal GBMs 
display enhanced invasive capacity, increased GAM density is associated with this 
subclass of GBM (93). Thus it is likely that GAM activity contributes to the shorter 
median survival seen in patients with mesenchymal GBMs.  
 VM-M3 cell metabolism is distinctly reflective of highly glycolytic nature of GBM. 
Still, these cells exhibit a 2-fold preference for glucose carbon over that provided by 
glutamine for lipid biosynthesis suggesting that mitochondrial glucose metabolism is 
employed to generate the citrate required for fatty acid synthesis (94). However, 
consistent with the literature, glutamine metabolism increases under hypoxic conditions 
to combat the energetic stress (95). Moreover, VM-M3 cells synthesize triacylglycerols 
(TAGs) under hypoxia, likely to prevent toxic accumulation of free fatty acids such as 
palmitate, which is shown to induce apoptosis (94, 97). Glutamine metabolism also 
appears to be required for VM-M3 durability in vivo, as pharmacological inhibition of 
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GLS blunted tumor growth and inhibited metastasis (94). Though VM-M3 cells can 
withstand the stress imposed by hypoxia, they are shown to be susceptible to glucose 
restriction. Therapeutic implementation of the ketogenic diet with or without caloric 
restriction significantly prolongs and blunts metastasis in VM-M3 burdened mice (97, 
98). This suggests potential utility for the VM-M3 model in screening potential cancer 
therapies that modulate glucose metabolism. 
 
2.4 Dichloroacetate (DCA) and Metformin as a Therapeutic Combination for GBM 
 The highly glycolytic nature of gliomas suggests that they would be susceptible to 
perturbations in flux through glycolysis and its subsidiary pathways. However, glycolytic 
inhibitors have largely been ineffective in managing the disease due to drug resistance 
and toxicity in targeting the ubiquitous pathway. Rather than inhibiting glycolysis, the 
activation of mitochondrial glucose oxidation provides an alternative to rewiring 
glycolytic flux. As the PDH complex is the critical regulator of oxidative glucose 
metabolism, it provides a potential therapeutic target for altering cancer metabolism.  
 
2.4.1 Dichloroacetate 
 Most cells within the body are fully differentiated and do not proliferate. These 
cells employ oxidative glucose metabolism to generate the ATP to maintain cellular 
homeostasis. This requires the full activation of the PDH complex to facilitate optimum 
incorporation of pyruvate carbon into the TCA cycle. The PDH complex is subject to 
allosteric and post translational modification-dependent regulation, the most important 
of which is phosphorylation of PDH. Inhibitory phosphorylation of PDH is mediated by 
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PDK and is removed by pyruvate dehydrogenase phosphatase (PDP). As discussed 
above, PDK expression is enhanced in cancer as a result of aberrant signaling. 
Increased PDK activity enhances Warburg metabolism and contributes to 
chemoresistance (53). The small-molecule pyruvate mimetic, dichloroacetate (DCA) is 
shown to inhibit PDK activity and is under investigation as a potential modulator of 
cancer metabolism. Accumulating evidence suggests that GBM may be particularly 
sensitive to DCA treatment (68, 99). 
 
2.4.1.1 Mechanism of Action  
 The PDH complex is composed of three multi-protein enzymatic subunits 
localized within the mitochondrial matrix. PDH (E1 subunit) requires vitamin B1 and 
lipoic acid to catalyze the rate-limiting decarboxylation of pyruvate to generate CO2 and 
an acyl-lipoate molecule. Dihydrolipoyl transacetylase (E2 subunit) transfers the acetyl 
group from the lipoate moiety to coenzyme A (CoASH), generating acetyl-CoA and 
reduced lipoate. Finally, dihydrolipoyl dehydrogenase (E3 subunit) oxidizes lipoate to 
regenerate lipoic acid. FADH2 is generated in the process and this is subsequently 
oxidized back to FAD+ in a reaction coupled to the generation of NADH (100).  
Excessive sustained activity will result in abundant NADH and acetyl-CoA 
production, both of which are negative allosteric regulators of the PDH complex. 
Moreover, induction of PDKs promotes phosphorylation of the E1⍺ subunit at a series of 
serine residues (S232, S293, S300) that renders PDH inactive (101). PDK itself is 
subject to allosteric regulation as increases in the ATP/ADP as a result of excessive 
oxidative phosphorylation stimulate its kinase activity. Furthermore, increases in the 
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acetyl-CoA/CoASH and NADH/NAD+ ratios stimulate PDK activity. Conversely, 
accumulation of pyruvate, NAD+ and CoASH inhibit PDK (102). PDK is also subject to 
regulatory tyrosine phosphorylation (103). Fibroblast growth factor receptor, which is 
upregulated in cancer, exhibits promiscuous activating phosphorylation of PDK1. 
Additionally, aberrant stimulation of Ras signaling induces phosphoglycerate kinase 
translocation to the mitochondria, where it activates PDK (104). 
DCA is a dichloronated organic acid that is structurally similar to pyruvate and 
mimics its inhibitory effects on PDK activity. Co-crystallization of DCA and PDK shows 
that DCA occupies the pyruvate binding site on the N-terminal regulatory domain of 
PDK (105). PDK sensitivity to DCA is isoform dependent; PDK2 (Ki = 200uM) is the 
most sensitive and PDK4 is the most resistant (Ki = 8mM) (106). DCA inhibition of PDK 
results in the activation of the PDH complex, increased glucose oxidation and a 
reduction in lactate production (107). As such, DCA reduces circulating lactate levels 
and is employed clinically in disorders associated with lactic acidosis such as 
mitochondrial encephalomyopathy and lactic acid syndrome (MELAS) (101). Moreover, 
DCA increases PDH complex activity in PDH complex deficiency disorders, which 
results in mitigation of some of the chronic neurological symptoms associated with 
these diseases (101, 108).  
DCA is dehalogenated and biotransformed to glyoxylate by glutathione 
transferase zeta 1 (GSTZ1). GSTZ1 also functions as maleylacetoacetate isomerase 
(MAAI), catalyzing the penultimate reaction of tyrosine catabolism. Prolonged DCA 
exposure leads to the accumulation of tyrosine and DCA due to inhibition of GSTZ1 
(109). DCA is a common contaminant of the water supply and prolonged exposure to 
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concentrated DCA can result in hepatotoxicity and increases the risk for liver cancers 
(110). However, persistent therapeutic administration of DCA is well tolerated with 
minimal side effects and DCA maintains FDA orphan drug status that permits clinical 
evaluation of its potential anti-cancer activity (111). 
 
2.4.1.2 Anti-Cancer Activity 
 DCA stimulation of glucose oxidation in cancer cells is associated with inhibition 
of Warburg metabolism. This is characterized by reductions in both glucose uptake and 
lactate export (112). Though lactate production is shown to be reduced by DCA in many 
instances, it is not universal across cancer species. In fact, DCA induced both LDH 
activity and MCT1 expression as a means to compensate for the stimulation of 
mitochondrial pyruvate metabolism in several pancreatic and colorectal cell lines (113). 
Lactate efflux was still reduced in these cells leading to an increase in intracellular pH. 
This was likely as a result of competitive inhibition of MCT1, which facilitates DCA 
uptake (113). Associated with the more common observation of reduced lactate 
production is an increase in the cellular NADH/NAD+ ratio, which is a strict negative 
regulator of LDH activity (114).    
   As described previously, oxidative metabolism and the stimulation of the ETC is 
intrinsically linked with ROS production. Consistently, DCA is shown to induce oxidative 
stress in cancer cells as a result of increased electron leakage from the ETC (115). This 
oxidative stress is shown to be cytotoxic in the vast number of studies that have 
evaluated DCA in cancer (114-123). Bonnet et al. intricately linked DCA-stimulation of 
mitochondrial ROS with induction of cancer cell death (114). They show that DCA 
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stimulated mitochondrial ·O2- dependent cytosolic accumulation of H2O2, which led to 
the oxidation of the plasma membrane-associated voltage-gated potassium (K+) 
channel Kv1.5. This resulted in K+ efflux and a reduction in intracellular K+ 
concentration [K+]I, releasing tonic inhibition of pro-apoptotic caspases (124). This was 
coupled with the depletion of ΔΨm and loss of mitochondrial integrity. Thus culminating 
with the release of cytochrome c from the intermembrane space and the activation 
caspase-dependent apoptosis. The induction of oxidative stress and subsequent cell 
death was only seen in cancer cell lines. DCA displayed no cytotoxicity towards 
Immortalized, but non-transformed fibroblasts, smooth muscle and epithelial cells (114). 
This cancer-specific cytotoxicity has been consistently reported in subsequent studies 
(115, 120, 121). This DCA tolerance is a result of inherent reliance on glucose oxidation 
in most normal cells, characterized by basal flux through the PDH complex, rendering 
DCA ineffective in modulating their metabolism. 
 DCA cytotoxicity is concentration dependent (112, 114-116). At subcytotoxic 
concentrations, DCA inhibits cancer cell proliferation (114, 115, 117, 119, 120). This is 
likely mediated by a restriction of biosynthetic glucose metabolism resultant from 
increased oxidation. Moreover, DCA induces autophagy in colorectal tumor cells 
through inhibition of mTOR, which inhibits autophagy to prevent unnecessary 
accumulation amino acids (113). The autophagy pathway is responsive to changes in 
oxidative stress as mTOR is subject to direct and indirect inactivation as a result of 
protein oxidation (125).  
As described previously, the rewiring of cancer cell metabolism has profound 
effects on the tumor microenvironment. DCA inhibition of lactate export results in an 
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increase in extracellular pH, which was associated with reduction in the expression of 
HIF targets such as GLUTs and MCT1 in a mouse model of Dalton’s lymphoma (118). 
Moreover, DCA promoted infiltration of tumor associated macrophages (TAMs) and 
induced M1 polarization. This resulted in greater TAM tumoricidal activity, marked by 
increased NO production and release of the pro-inflammatory cytokines IL-1, IL-6 and 
tumor necrosis factor ⍺ (TNF⍺) (118). These modifications of the microenvironment 
would render a solid tumor less aggressive. As such, DCA is shown to promote 
leucocyte infiltration and reduce metastatic breast cancer growth (123).  
The propensity for DCA to induce oxidative stress in cancer cells suggests that it 
may be an attractive adjuvant to conventional pro-oxidant chemotherapies. Indeed, 
DCA is shown to potentiate the efficacy of several chemotherapies through 
exacerbation of oxidative stress (112, 115-119, 123). The hyperpolarization of cancer 
mitochondria as a result of Warburg metabolism contributes to therapeutic resistance 
through inhibition of apoptosis. DCA reverses hepatocellular carcinoma resistance to 
the RTK inhibitor sorafenib through reduction of ΔΨm (119). Moreover, DCA sensitized 
radiation-resistant prostate cancer cells to irradiation through reversal of IMM 
hyperpolarization (126). Furthermore, DCA treatment reversed hypoxia-mediated 
chemoresistance to 5-FU and bevacizumab in models of gastric cancer and GBM, 
respectively (116, 117). Importantly, the use of glycolytic inhibitors was insufficient to 
reverse resistance, highlighting the necessity of activating mitochondrial glucose 
metabolism in overcoming the protective effects of enhanced glycolytic flux.   
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2.4.1.3 Clinical Implementation for Glioma 
Expounding on their previous work demonstrating the cytotoxic effects of DCA on 
cancer cells (114), Michaelakis and colleagues conducted a pilot study evaluating DCA 
in 5 primary GBM patients (68). Three patients received DCA treatment following 
recurrence after debulking surgery, radiation and TMZ administration. One patient 
received DCA for three months prior to surgery and then continued following surgery 
with the addition of radiation and TMZ. DCA treatment was initiated at the time of 
radiation and TMZ after surgery in the last patient. Despite the differences in regimen, 
DCA reduced tumor cell proliferation, increased apoptosis and inhibited angiogenesis in 
these 5 patients. DCA treatment also reduced the proportion of GSCs compared to pre-
surgery biopsy samples (68). 
A phase I trial of 15 patients with recurrent malignant brain tumors demonstrated 
the safety and tolerability of DCA administration for cancer patients.  No dose-limiting 
toxicities were observed, however low-grade fatigue was reported by a few patients. 
Eight of the fifteen patients remained on DCA for at least one 4-week cycle during which 
they all remained clinically stable (99). A subsequent dose-escalation phase I trial for 
various solid tumors demonstrated mild, yet dose-limiting toxicities at a dose of 
25mg/kg/day, which included nausea, diarrhea and reversible non-demyelinating 
peripheral neuropathy. Patients that experienced early onset of these side effects were 
shown to express the homozygous EGM variant of GSTZ1, which was associated with 
increased serum trough levels of DCA. Unfortunately, there were no partial or complete 
responders to DCA, leading the investigators to hypothesize that DCA would not be 
effective as a monotherapy. Specifically, they proposed that it would be best utilized in 
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combination with agents that would benefit from increased glucose oxidation such as 
pro-oxidant chemotherapies (127).  
 
2.4.2 Metformin 
Metformin is a synthetic biguanide, an organic molecule containing two imine 
groups derived from Galega officinalis, or French lilac. Metformin is a first-line therapy 
for T2DM due to its activity in normalizing circulating levels of glucose and insulin. It is 
estimated that over 100 million patients worldwide take metformin daily (128). It displays 
robust physiological effects that suggest it may have therapeutic utility beyond T2DM. 
Metformin improves the lipid profile of patients at risk for cardiovascular disease, 
reduces chronic inflammation and potentially reduce cancer incidence, especially in 
patients with T2DM (129-131). Moreover, metformin is shown to reduce systemic 
estrogen levels and is being utilized in the clinic for poly-cystic ovary syndrome (PCOS) 
(132). 
 
2.4.2.1 Mechanism of Action  
 Metformin exists physiologically as a cation, which restricts its diffusion across 
cellular membranes. As such, metformin is predominantly imported into the cell via a 
member of the family of organic cation transporters (OCTs), OCT1 (133). Within the 
cell, metformin is shown to accumulate within the mitochondria due to the negative 
membrane potential across the IMM (134). Within the mitochondrial matrix, metformin is 
shown to inhibit complex I of the ETC, leading to restriction of NADH oxidation (134, 
135). This complex I inhibition is associated with an increase in uncoupled respiration 
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and partial depletion of ΔΨm, which restricts ATP production from oxidative 
phosphorylation (136). This stimulates compensatory adenylate kinase generation of 
ATP and subsequent accumulation of adenosine monophosphate (AMP) (134). 
Together, with inhibition of AMP deaminase, metformin treatment increases the 
AMP/ATP ratio, which induces an energetic crisis (137). The energetic crisis resultant 
from metformin treatment is central to the anti-diabetic effects elicited from metformin 
treatment.   
 OCT1 is highly expressed on the basolateral membrane of hepatocytes, which 
facilitates significant liver uptake of metformin (138). A consequence of robust hepatic 
uptake is a reduction in gluconeogenesis, mediated in large part by the increase in 
AMP/ATP ratio (139). Gluconeogenesis is stimulated by glucagon, which induces G-
protein coupled receptor signaling coupled to adenylate cyclase (AC) generation of 
cyclic AMP (cAMP). cAMP generation by AC is dependent on ATP and is inhibited by 
increases in the AMP/ATP ratio. Metformin-induced accumulation of AMP thus restricts 
cAMP production and prevents activation of protein kinase A, which mediates signaling 
initiated by glucagon receptor activation. Thus, metformin activity opposes glucagon 
signaling.  
 Glucagon restricts efficient glycolytic flux to promote the accumulation of the 
glycolytic intermediate DHAP, a gluconeogenic substrate. Metformin enhances 
glycolytic metabolism and is shown to reduce hepatic levels of DHAP and other 
intermediates in the middle of the glycolytic pathway (140).  Moreover, metformin is 
shown to inhibit mitochondrial glycerol-3-phosphate dehydrogenase (mGPD) in the liver, 
which promotes an increase in cytosolic NADH levels. This increase in NADH restricts 
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the reverse reaction of lactate to pyruvate catalyzed by LDH and thus inhibits the Cori 
cycle, which involves hepatic uptake of lactate for gluconeogenesis. 
 The increase in AMP/ATP ratio associated with metformin treatment also leads to 
the activation of AMP-activated protein kinase (AMPK) (139). Allosteric binding of AMP 
promotes a conformational change in AMPK that permits activating phosphorylation by 
liver kinase B1 (LKB1). AMPK is a critical energy sensor that has pleiotropic effects on 
cellular metabolism to restore energy balance. For instance, AMPK mediates metformin 
stimulation of glycolysis (141). Metformin is also shown to promote insulin sensitivity 
through AMPK-mediate normalization of insulin signaling. This stimulates Akt-mediated 
translocation of GLUT4 to the plasma membrane of myocytes, which permits peripheral 
glucose uptake (142). Though AMPK downstream targets inhibit expression of some 
gluconeogenesis-related genes, AMPK activation is shown to be dispensable for the 
reduction in hepatic gluconeogenesis associated with metformin treatment (143). 
Ultimately, metformin action results in the reduction of hepatic glucose output, increased 
peripheral glucose uptake and reversal of insulin insensitivity in diabetic patients. As 
T2DM is associated with cancer incidence, metformin is under extensive investigation 
for potential indications in cancer. 
 
2.4.2.2 Anti-Cancer Activities 
 The totality of studies evaluating metformin in cancer suggest that metformin 
elicits both indirect and cancer call autonomous activities (128). The systemic changes 
in metabolism promoted by metformin treatment in patients with T2DM antagonize the 
release of various endocrine factors as well as energy substrates that promote 
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tumorigenesis. Inhibition of hepatic gluconeogenesis leads to lower circulating glucose 
levels, potentially starving pre-neoplastic cells of their preferential energy source. 
Moreover, restoring insulin sensitivity is associated with reductions in circulating insulin, 
limiting its mitogenic effects on insulin sensitive cancers. It has recently been 
appreciated that metformin also has effects on additional cell types (132, 144).  
OCT1 expression in adipocytes is shown to be enhanced in obese patients, and 
response to metformin is positively correlated with body mass index (145). Metformin 
activates AMPK in subcutaneous and visceral white adipose, which results in depletion 
of TAG levels and increased FAO and is marked by reduction in adipocyte size (144). 
Adipocytes are shown to drive ovarian cancer metastasis. Omental adipose release of 
adipokines and cytokines is implicated in homing of metastatic ovarian cancer cells to 
the omentum, where adipocyte lipolysis provides fatty acids as a source of energy for 
these cells (146). Metformin inhibits the release of these endocrine signals, limiting 
ovarian cancer cell migration and proliferation (147). Metformin is also shown to 
downregulate the NF-κB pathway in leukocytes, restricting the production of the pro-
inflammatory cytokine IL-6 (148). IL-6 signaling is shown to promote EMT and 
metastasis through activation of signal transducer and activator of transcription 3 
(STAT3) (149). Metformin reversed IL-6 mediated EMT in NSCLC cells and prevented 
metastasis in lung-tumor bearing mice (150).  
Metformin is also shown to activate AMPK in cancer cells, which has profound 
effects on their metabolism (141, 151). To restore energy balance in the face of a 
deficit, AMPK promotes a shift from anabolic to catabolic metabolism (142). This is 
marked by increases in glycolytic metabolism with concomitant restriction of glucose 
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oxidation in favor of FAO. Moreover, AMPK inhibits mTORC1, preventing its stimulation 
of protein synthesis. Metformin also disrupts the Ragulator complex, which activates 
mTORC1 in the presence of excess amino acids (152). Activated AMPK imparts 
inhibitory phosphorylation on ACC, restricting FAS and lipogenesis (153). Independently 
of AMPK, metformin is shown to disrupt the folate cycle, inhibiting one-carbon 
metabolism and nucleotide biosynthesis (154). Collectively these effects account for the 
cytostatic activity that metformin exhibits towards cancer cells. Despite increasing 
aerobic glycolysis in tumor cells, the restriction of anabolic processes prevents 
proliferation. 
Strikingly, the metabolic rewiring induced by metformin reduces the energetic 
flexibility of cancer cells. In the absence of glucose, metformin exhibits cytotoxicity 
towards cancer cells and this cannot be rescued with other carbohydrate sources such 
as galactose or maltose (151). Metformin reduces oxidative and enhances reductive 
glutamine metabolism to generate acetyl-CoA without promoting ATP production. IDH1 
mutant tumor cells are unable to efficiently use glucose to maintain TCA cycling and 
upregulate glutamine oxidation to compensate. As such, the presence of this mutation 
sensitized breast cancer cells to metformin’s cytostatic activity (155).  
Retrospective studies of T2DM patients treated with metformin have suggested 
that metformin treatment is associated with reduced risk for certain cancers in diabetic 
patients. In particular, metformin treatment has been linked to lower incidence rates in 
breast, colorectal, prostate and endometrial cancer (156-160). However, recent 
commentary on these meta-analyses has proposed that these studies suffer from 
several forms of reporting and selection biases that confound the results. Reanalysis of 
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these data sets have often not replicated the original findings, thus metformin’s impact 
on cancer risk is still controversial (161, 162). Nevertheless, many of metformin’s effects 
could inhibit tumorigenesis.  
The energetic stress induced by metformin stimulates DNA reparatory systems 
even in the absence of DNA damage. This likely would prevent the genomic instability 
necessary for cellular transformation and prevent tumorigenesis.  Moreover, metformin 
stimulation of the DNA-repair protein ataxia-telangiectasia mutated (ATM) inhibits 
nucleotide synthesis through LKB1-independent activation of AMPK, restricting the 
nucleic acid synthesis required for rapid proliferation (163). Furthermore, metformin 
inhibition of folate metabolism likely selects against transformation through nucleotide 
restriction and reduction in DNA methylation. Again, the reduction in circulating insulin 
associated with metformin treatment limits the propensity for stimulation of the PI3K-
Akt-mTORC1 axis associated with insulin receptor activation.  
Recent evidence suggests that metformin specifically targets GSCs in models of 
GBM (164-166). Metformin inhibits the self-renewal capacity of GSCs and exhibits 
greater potency in reducing GSC proliferation compared to glioma cells, which is 
associated with reduced GSC xenograft growth (166). Moreover, metformin potentiates 
the cytotoxicity of TMZ towards glioma cells in part through induction of the miRNAs 
miR-124 and Let-7 (164). As CSCs exhibit enhanced antioxidant capacity and inherent 
chemoresistance, metformin may be a beneficial adjuvant to pro-oxidant therapies such 
as DCA to simultaneously target the bulk tumor and CSC subpopulation. 
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2.5 Central Hypothesis and Project Aims 
 As described, the metabolic derangements exhibited by cancer cells are 
intrinsically linked to the proliferative capacity and aggressiveness of tumors. Targeting 
specific genetic alterations in the cell cycle or signaling cascades associated with 
cancer has failed to yield adequate clinical efficacy as cancer is on the verge or passing 
heart disease as the leading cause of death in the US despite remarkable progress 
made in screening and detection. As anabolic metabolism is fundamental to every 
tumor species, it is a more promising target for therapy development. The metabolic 
agents DCA and metformin each exhibit anti-cancer activities dependent on the 
modulation of anabolic capacity. We propose that the mechanistic overlap in altering 
mitochondrial function in cancer suggests potential synergy between DCA and 
metformin. Specifically, that metformin inhibition of complex I will potentiate DCA-
induced oxidative stress as a result of increased PDH activity. We hypothesize that co-
administration of DCA and metformin will induce a metabolic shift towards mitochondrial 
oxidation in the presence of ETC dysfunction that is unsustainable in cancer cells, thus 
promoting cell death and blunting disease progression. The major goals of this study 
were to characterize the synergistic effects of DCA and metformin on VM-M3 cell 
metabolism and viability in vitro and tumor growth in vivo, to determine the systemic 
metabolic effects of DCA and metformin in Vm/dk mice, and to evaluate the efficacy of 
enhancing the pro-oxidant capacity of this combination. If effective, this combination 
would provide an alternative strategy for targeting cancer metabolism without the 
toxicity exhibited by previously established metabolic therapies. 
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CHAPTER 3: METFORMIN ENHANCES DCA CYTOTOXICITY TOWARDS VM-M3 
CELLS THROUGH POTENTIATION OF OXIDATIVE STRESS 
 
3.1 Chapter Synopsis 
 Here we present data indicating the effect of a DCA and metformin combination 
on the viability of VM-M3 cells in vitro and progression of VM-M3 tumors in vivo. We 
show that metformin enhances DCA cytotoxicity towards VM-M3 cells in an oxidative 
stress-dependent fashion. While both metformin and DCA prolong survival of VM-M3-
burdened animals as single agents, we do not demonstrate a synergistic effect of the 
combination on VM-M3 disease progression. The materials and methods used for the 
studies presented in this chapter are described in Appendix A. 
 
3.2 Metformin Enhances DCA Cytotoxicity Towards VM-M3 Cells in vitro  
 As described, DCA exhibits anti-cancer activity towards a range of tumor species 
through induction of oxidative stress resultant from increased glucose oxidation. As 
ROS production is linked to ETC function, inhibiting ETC efficiency is likely to enhance 
ROS production. We hypothesized that metformin inhibition of complex I would cause 
energetic stress resulting in a compensatory reduction in glucose oxidation. However, 
we posited that the addition of DCA would overcome this compensatory response and 
induce glucose oxidation despite the complex I inhibition. This would result in an 
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increase in matrix NADH production in the presence of reduced complex I efficiency and 
allow for premature reduction of oxygen and enhanced production of ·O2-. Thus, we 
suggest that metformin will enhance the pro-oxidant anti-cancer activity of DCA towards 
neoplastic cells.  
 
3.2.1 Figures 
 
 
 
 
 
Figure 3.2.1: DCA activates the PDH complex in VM-M3 cells. (A) Western blot analysis of p-PDH-
E1α (Ser293) and PDH-E1α in VM-M3 lysates following 4-hour treatment with DCA. (B) Quantification of 
lactate concentration in culture medium following 24-hour incubation with indicated treatment.                
(C) Quantification of average MitoSox Red fluorescence intensity as an indication of VM-M3 superoxide 
production following 1-hour incubation with DCA. (D) Quantification of average tetramethylrhodamine 
(TMRE) fluorescence intensity as an indication of mitochondrial membrane potential following 4-hour DCA 
treatment.  (B) Error bars represent standard error of the mean (SEM) of three experimental replicates. 
(C-D) Error bars represent SEM of a single experiment replicated in triplicate; * p<0.05, and ***p<0.001.  
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Figure 3.2.2 DCA exhibits oxidative stress-dependent cytotoxicity towards VM-M3 cells.               
(A) Analysis of VM-M3 proliferation over a 96-hour incubation with DCA. (B) Analysis of VM-M3 viability 
following 24-hour treatment with DCA. Bars represent fraction of cells stained positively for ethidium 
homodimer-I (Ethd-1). (C) Quantification of the concentration of reduced GSH in VM-M3 cells following a 
4-hour incubation with NAC. (D) Evaluation of VM-M3 viability following 24-hour DCA treatment in the 
presence of modulators of glutathione availability. (E) Quantification of average TMRE fluorescence 
intensity following 4-hour DCA treatment ± N-acetylcysteine (NAC). (F) Representative merged 
immunofluorescent images of VM-M3 cells following 12-hour treatment with DCA ± NAC. Fixed cells were 
probed for cytochrome c (green) and mitochondrial complex Vα (red) with fluorescent antibodies and 
counterstained with DAPI (blue). (A-D) Error bars represent SEM of three experimental replicates (E) 
Error bars represent SEM of a single experiment replicated in triplicate; * p<0.05 and ***p<0.001. 
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Figure 3.2.3 Metformin uncouples VM-M3 mitochondria independently of cytotoxicity.                  
(A) Quantification of the phosphorylation state (p-Thr172) of AMPK in VM-M3 cells following a 24-hour 
incubation with metformin. (B) Determination of the lactate concentration in culture medium following 24-
hour incubation with vehicle or metformin. (C) Analysis of VM-M3 proliferation over a 96-hour incubation 
with metformin. (D) Quantification of average TMRE fluorescence in VM-M3 cells following a 4-hour 
metformin treatment. (E) Determination of VM-M3 cell ΔΨm following a 4-hour incubation with FCCP.    
(F) Analysis of VM-M3 viability following 24-hour treatment with a range of metformin concentrations.    
(A, D-E) Error bars represent SEM of a single experiment replicated in triplicate. (B-C, F) Error bars 
represent SEM of three experimental replicates; **p<0.01 and ***p<0.001. 
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Figure 3.2.4 Metformin enhances DCA cytotoxicity towards VM-M3 cells. (A) Western blot analysis 
of p-PDH-E1α (Ser293) and PDH-E1α in VM-M3 cell lysates following 4-hour treatment with 5mM DCA 
and 100μM metformin. (B) Determination of lactate in the VM-M3 cell culture medium over a 48-hour 
incubation period with DCA and metformin. (C) Determination of VM-M3 cell viability after combinatorial 
treatment with DCA and metformin in increasing concentrations. (D) Quantification of superoxide 
production with MitoSox Red following 1-hour treatment with DCA and metformin. (E) Determination of 
the [GSH]:[GSSG] ratio in VM-M3 cell lysates following a 4-hour treatment with DCA and metformin.       
(F) Determination of cell death following 24-hour treatment with DCA and metformin ± NAC. (B, D) Error 
bars represent SEM of a single experiment replicated in triplicate (C, E-F) Error bars represent SEM of 
three experimental replicates; *p<0.05, **p<0.01, and ***p<0.001. 
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Figure 3.2.5: Complex I Inhibition, but not AMPK activation is required for metformin enhancement 
of DCA cytotoxicity (Continued on Next Page). 
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Figure 3.2.5 Complex I inhibition, but not AMPK activation is required for metformin enhancement 
of DCA cytotoxicity. (A) Average VM-M3 superoxide production following 1-hour treatment with DCA 
and rotenone. (B) Determination of the [GSH]:[GSSG] ratio in VM-M3 cell lysates following 4-hour 
treatment with DCA and rotenone. (C) Analysis of VM-M3 viability following a 24-hour incubation with 
DCA and rotenone ± NAC. (D) Quantification of the fraction of dead VM-M3 cells following a 24-hour 
treatment with DCA and AICAR. (E) Representative merged immunofluorescent images depicting 
cytochrome c localization in VM-M3 cells following 12-hour treatment with DCA ± AICAR or metformin. (F) 
Analysis of metformin ± compound C modulation of DCA cytotoxicity towards VM-M3 cells. (G) In-cell 
ELISA analysis of p-AMPKα (Thr172), and AMPKα in VM-M3 cells following 4-hour treatment with 
modulators of AMPK activation. (A, G) Error bars represent SEM of a single experiment replicated in 
triplicate (B-D, F) Error bars represent SEM of three experimental replicates; *p<0.05, **p<0.01 and 
***p<0.001. 
 
3.2.2 Results & Discussion 
As is seen with GBM, VM-M3 cells exhibit robust basal phosphorylation of the 
pyruvate dehydrogenase complex (Fig. 3.2.1A). Consistent with its mechanism of 
action, DCA treatment reduced phosphorylation of the E1 subunit of the PDH complex 
in a concentration dependent manner. As PDH complex phosphorylation is associated 
with Warburg metabolism, we sought to determine if DCA treatment alters VM-M3 
lactate production (1).  A 24-hour incubation with 5mM DCA resulted in a 28.1% 
reduction in lactate present in the culture medium, suggesting a shift towards glucose 
oxidation and away from glucose fermentation (Fig. 3.2.1B).  
Given that oxidative metabolism is intrinsically linked to ROS generation, we 
evaluated whether DCA activation of pyruvate dehydrogenase altered ROS production 
in VM-M3 cells. MitoSox Red fluorescent microscopy indicated a concentration-
dependent increase in superoxide production following 1-hour DCA treatment (Fig. 
3.21C). This suggests that DCA increases ROS production in VM-M3 cells through 
activation of the PDH complex.  
Changes in flux through the ETC can alter mitochondrial membrane potential, 
therefore we utilized tetramethylrhodamine (TMRE) fluorescence microscopy to 
determine changes in m associated with DCA activity (2). A 4-hour incubation with 
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5mM DCA resulted in significant mitochondrial depolarization, whereas treatment with a 
lower concentration of 500M promoted hyperpolarization of VM-M3 mitochondria (Fig. 
3.2.1D). The increase in m observed with 500M DCA treatment is indicative of 
increased ETC flux and associated movement of protons into the IMS, again suggesting 
activation of glucose oxidation. DCA-induced mitochondrial depolarization occurred 
after treatment with a concentration that also promoted superoxide production. As 
described previously, abundant oxidative stress can damage membrane lipids and thus 
disrupt mitochondrial membrane integrity, ultimately leading to loss of  m and 
apoptotic initiation (3). Indeed, we show that the addition of the antioxidant N-
acetylcysteine (NAC) maintained m in the presence of DCA (Fig. 3.2.2E), suggesting 
that the loss of membrane potential with 5mM DCA treatment is associated with the 
observed increase in superoxide. 
Moreover, we found that DCA-induced ROS production coincided with 
cytotoxicity in a concentration-dependent fashion (Fig. 3.2.2B). Treatment with 5mM 
DCA was only mildly cytotoxic towards VM-M3 cells whereas 20mM induced significant 
cell death despite no apparent difference in the magnitude of ROS induction. Thus, the 
difference in cytotoxicity is likely resultant from sustained inhibition of PDK with the 
higher concentration of DCA, permitting continuous flux of pyruvate into the 
mitochondria. In agreement with the observed loss of membrane potential at cytotoxic 
concentrations, 20mM DCA promoted mitochondrial release of cytochrome c after a 12-
hour incubation (Fig. 3.2.2F).  
Whereas vehicle-treated controls exhibit diffuse cytochrome c and mitochondrial 
complex V co-localized fluorescence, indicative of an extensive mitochondrial network, 
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VM-M3 cells treated with 5mM DCA display punctate co-localized fluorescence that 
suggests enhanced mitochondrial fission (Fig.3.2.2F). DCA has been shown to induce 
mitophagy at non-cytotoxic concentrations in response to increases in oxidative stress 
(4). Mitophagy permits cell resilience in the presence of mitochondrial stress through 
enhanced mitochondrial fission facilitating the degradation of damaged portions of the 
mitochondrial network (5). Together, these results suggest that DCA induces oxidative 
stress that at upon reaching a certain threshold promotes the loss in mitochondrial 
integrity subsequently leading to the initiation of caspase-dependent VM-M3 cell death, 
which is consistent with the mechanism of cytotoxicity previously described for DCA (6-
13). Below this threshold, VM-M3 cells likely employ cell survival mechanisms such as 
mitophagy to persist under DCA-induced oxidative stress, however these compensatory 
pathways likely restrict proliferative capacity. As such, treatment with 5mM DCA blunted 
VM-M3 proliferation, whereas treatment with 20mM completely inhibited proliferation 
(Fig. 3.2.2A)  
To further show an association between the observed increases in oxidative 
stress and cell death with DCA treatment, we evaluated the effects of modifying 
antioxidant capacity on DCA cytotoxicity. Co-incubation of 5mM DCA with the 
glutathione synthesis inhibitor buthionine sulfoximine (BSO) significantly enhanced 
cytotoxicity. Conversely, addition of NAC, which provides an exogenous cysteine 
substrate for glutathione synthesis attenuated the modest increase in cell death 
associated with 5mM DCA treatment (Fig. 3.2.2D). This was confirmed through 
immunofluorescent microscopy, which showed retention of an expansive mitochondrial 
network with resident cytochrome c following incubation with both DCA and NAC (Fig. 
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3.2.2F). NAC treatment corresponded with increased levels of reduced GSH in VM-M3 
cells (Fig. 3.2.2C).  
We next sought to characterize the effect of metformin on VM-M3 cells. 
Metformin increased the proportion of phosphorylated AMPK in a concentration 
dependent manner, suggesting that metformin treatment promoted energetic stress in 
VM-M3 cells (Fig. 3.2.3A). Typical of AMPK activation, metformin enhanced lactate 
export, indicating an increase in glycolytic metabolism (Fig. 3.2.3B). Furthermore, VM-
M3 proliferation was blunted with metformin treatment, which is consistent with the 
previously reported cytostatic activity of metformin resultant from restricted anabolic 
metabolism (Fig. 3.2.3C) (14, 15). 
At a concentration of 100uM, metformin promoted mitochondrial 
hyperpolarization, whereas VM-M3 m decreased at a concentration of 1mM after a 4-
hour incubation (Fig. 3.2.3D). This is indicative of complex I inhibition; whereby acute 
treatment with lower concentrations of metformin restrict electron flux, leading to 
accumulation of H+ in the IMS following NADH oxidation. Increasing the concentration of 
metformin enhances the rate of this inhibition, resulting in a more rapid induction of 
energetic stress. The compensatory restriction of glucose oxidation associated with 
AMPK activation, leads to a reduction in ETC flux and a subsequent decrease in m. 
Moreover, metformin is shown to slightly uncouple mitochondria to relieve the buildup of 
H+ in the IMS (16). VM-M3 cells respond to the uncoupler carbonyl cyanide 4-
(fluoromethoxy)phenylhydrazone (FCCP) suggesting that it is possible that metformin’s 
effect on VM-M3 m is a result of multiple converging mechanisms (Fig. 3.2.3E). 
Unlike with DCA treatment, metformin depletion of m is independent of cytotoxicity 
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(Fig 3.2.3F).  Collectively, these results suggest that metformin imposes energetic 
stress on VM-M3 cells through inhibition of complex I that results in AMPK activation 
and a rewiring of metabolism to restrict growth yet sustain viability. 
As enhanced glucose oxidation is central to the anti-cancer activity exhibited by 
DCA towards VM-M3 cells, metformin restriction of mitochondrial glucose metabolism 
could prohibit any potential synergy achieved with the combination. However, we show 
that DCA reduces PDH phosphorylation even in the presence of metformin (Fig. 
3.2.4A). Moreover, DCA attenuates the increase in lactate production associated with 
metformin treatment, suggesting that DCA reverses the compensatory enhancement of 
aerobic glycolysis induced by metformin (Fig. 3.2.4B).  
Consistent with our hypothesis, the addition of metformin significantly enhanced 
superoxide production in DCA treated cells even though metformin alone reduces ROS 
levels (Fig.3.2.4D). Metformin inhibition of complex I is associated with a restriction of 
ROS production in the reverse direction, preventing electrons released at complex II 
from FADH2 oxidation to reduce iron sulfur clusters associated with complex I (16). 
Sustained TCA cycle-dependent NADH production in the presence of complex I 
inhibition leads to an increase in the NADH/NAD+ ratio, which diminishes reducing 
potential (17). In an attempt to maintain redox balance, electrons are prematurely lost 
from the ETC and generate ROS in the forward direction as a consequence (18, 19). As 
such, DCA induction of glucose oxidation in the presence of metformin inhibition of 
complex I led to the observed increase in superoxide production. 
Coinciding with the increase in ROS production, DCA ± metformin reduced the 
[GSH]/[GSSG] ratio in VM-M3 cells, indicating an increase in oxidative stress (Fig. 
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3.2.4E). Strikingly, metformin treatment significantly reduced the proportion of reduced 
[GSH] despite the noted reduction in superoxide production. Rather, this is likely a result 
of diminished glutathione synthesis, which has been previously demonstrated with 
metformin treatment (20). This restriction of GSH production would mimic an increase in 
oxidative stress.  
The addition of metformin significantly enhanced DCA cytotoxicity towards VM-
M3 cells that was amplified with increasing concentrations of either agent (Fig. 3.2.4A). 
The increase in oxidative stress promoted by metformin addition to DCA treatment was 
shown to be necessary for this enhanced cytotoxicity as addition of NAC attenuated the 
loss of VM-M3 viability associated with the DCA and metformin combination (Fig. 
3.2.4F). This is consistent with recent reports that demonstrated that metformin 
enhanced DCA cytotoxicity towards breast cancer cells in an oxidative stress-
dependent manner (21, 22). 
To further elucidate the contribution of complex I inhibition to metformin’s 
enhancement of DCA cytotoxicity, we examined the impact of rotenone, a bona fide 
complex I inhibitor, on DCA activity. Rotenone treatment did not affect VM-M3 
superoxide production alone, but significantly enhanced the pro-oxidant effect of DCA 
(Fig. 3.2.5A). In contrast to metformin, rotenone treatment increased the [GSH]/[GSSG] 
ratio in VM-M3 cells (Fig. 3.2.5B). However, like metformin, the addition of rotenone 
significantly augmented DCA cytotoxicity. Additionally, rotenone enhancement of DCA 
anti-cancer activity was partially attenuated by the antioxidant NAC, suggesting a 
requirement for the observed increase in oxidative stress (Fig. 3.2.5C). These results 
show that metformin and rotenone have a strikingly similar effect on DCA activity. 
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As metformin’s cellular activity is traditionally associated with AMPK activation, 
we sought to determine if AMPK is required for metformin amplification of DCA 
cytotoxicity towards VM-M3 cells. The addition of DCA, which alone did not modify 
AMPK phosphorylation, attenuated metformin modulation of AMPK activation (Fig. 
3.2.5F). 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) is an analog of 5’-
AMP and is a known activator of AMPK (23). We too show that AICAR increases 
stimulatory phosphorylation of AMPK and that this is blunted by DCA co-treatment (Fig. 
3.2.5F). AICAR treatment did not promote VM-M3 cell death and was slightly 
cytoprotective in combination with DCA (Fig. 3.2.5D). This was further evidenced in 
immunofluorescent detection of cytochrome c localization, which depicts a reduction in 
mitochondrial stress with the combinatorial treatment (Fig. 3.2.5E). This is in contrast to 
metformin co-treatment, which increased cytochrome c release in DCA treated cells 
(Fig. 3.2.5E).  Moreover, use of the AMPK inhibitor, compound c, further enhanced the 
efficacy of dichloroacetate and metformin in combination (Fig. 3.2.5F). Collectively, 
these results suggest that complex I inhibition, but not AMPK stimulation is necessary 
for metformin enhancement of DCA cytotoxicity. In fact, AMPK activation likely 
diminishes the synergy between the two agents, which is consistent with AMPK’s role 
as an energy sensor and survival mediator (24). This suggests that the combination 
may be most effective in the absence of AMPK, such as in LKB1-deficent tumors (25).  
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3.3 DCA and Metformin Inhibit VM-M3 Tumor Progression As Individual Agents, 
But Do Not Exhibit Synergy in vivo 
 
3.3.1 Figures 
 
Figure 3.3.1 DCA treatment slows tumor growth in VM-M3 tumor-burdened mice. (A) Average 
weekly change in weight from baseline for control and DCA-treated animals for the first 4 weeks of 
treatment. (B) Average daily food intake of control and DCA-treated animals. (C) Average weekly blood 
glucose levels of control and DCA-treated mice for the first 4 weeks of treatment. (D) Representative 
bioluminescent images of control, 125mg/kg DCA and 250mg/kg DCA-treated animals at 4 weeks post 
VM-M3 cell implantation. (E) Quantification of individual weekly bioluminescent signals from (i) control (ii) 
125mg/kg DCA and (iii) 250mg/kg DCA treated mice. (A-C) Error bars represent SEM of the treatment 
group. 
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Figure 3.3.2 DCA treatment prolongs survival in VM-M3 tumor-burdened mice. (A) Kaplan-Meier 
survival curve of treatment groups. (B) Mean survival time of control and DCA-treated animals. Error bars 
represent SEM for each group; ***p<0.001. 
 
 
Figure 3.3.3 Metformin treatment slows tumor growth in VM-M3 tumor-burdened mice. (A) Average 
weekly change in weight from baseline for control and metformin-treated animals for the first 4 weeks of 
treatment. (B) Average daily food intake of control and metformin-treated animals. (C) Average weekly 
blood glucose levels of control and metformin-treated mice for the first 4 weeks of treatment. (D) 
Representative bioluminescent images of control, 125mg/kg metformin and 250mg/kg metformin-treated 
animals at 4 weeks post VM-M3 cell implantation. (E) Quantification of individual weekly bioluminescent 
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signals from (i) 125mg/kg DCA and (ii) 250mg/kg DCA treated mice. (A-C) Error bars represent SEM of 
the treatment group. 
 
 
 
Figure 3.3.4 Metformin treatment prolongs survival in VM-M3 tumor-burdened mice. (A) Kaplan-
Meier survival curve of control and metformin treatment groups. (B) Mean survival time of control and 
metformin-treated animals. Error bars represent SEM for each group; **p<0.01. 
 
 
Figure 3.3.5 Metformin co-treatment does not diminish lactate-reducing effect of DCA (Continued 
on Next Page).  
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Figure 3.3.5 Metformin co-treatment does not diminish lactate-reducing effect of DCA. (A) Average 
weekly change in weight from baseline for control and treatment groups for the first 3 weeks of treatment. 
(B) Average daily food intake of control and treated animals. (C) Average weekly blood glucose levels of 
control and treated mice over the first 3 weeks of treatment. (D) Average blood glucose levels at baseline 
and after one week of treatment for each group. (E) Average blood lactate levels of control and treated 
animals over the first 3 weeks of treatment. (F) Average blood lactate levels of control and treated mice at 
baseline and following one week of treatment. Error bars represent SEM of the treatment group; **p<0.01 
and ***p<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.6 The combination of DCA and metformin does not provide further survival benefit over 
either individual treatment. (A) Kaplan-Meier survival curves for control, 250mg/kg DCA, 250mg/kg 
metformin and 250mg/kg combination treatment groups. (B) Notation of cohort size, median and mean 
survival times, and the percent increase from control for those measures. 
 
 
 
 
 
Cohort N 
Median 
Survival 
% Increase in 
Median Survival 
Mean 
Survival 
% Increase in 
Mean Survival 
 Control 12 21.0 - 25.8 - 
 250mg/kg DCA 8 46.5 121.4% 46.0 78.6% 
 250mg/kg Metformin 8 52.0 147.6% 51.5 100.0% 
 250mg/kg Combination 8 43.0 104.8% 44.6 73.2% 
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3.3.2 Results & Discussion 
 To establish if our observations of in vitro efficacy of a DCA and metformin 
combination towards VM-M3 cells translated to an in vivo environment, we utilized the 
VM-M3 model of metastatic glioblastoma. As both of these agents are delivered orally in 
the clinic, we chose to integrate these agents into a standard rodent diet (2018 Teklad 
Global 18% Protein Rodent Diet; Harlan Laboratories) at a defined dose based on 
previous observation that a 30g mouse of this strain eats 5-6g of food per day. The 
addition of either agent did not alter the palatability of the diet and animals ate the 
expected amount of food throughout the study until near end of life (Figs. 3.3.1B, 
3.3.3B, 3.3.5B). This is indicative of the anorexia associated with cancer cachexia, the 
multi-modal syndrome marked by debilitating loss of adipose and muscle mass seen in 
patients near end of life. This was further evidenced by a drop in body weight observed 
towards the end of life, especially in the control and 125mg/kg-dosed groups (Figs. 
3.3.1A, 3.3.3A).  
Both DCA and metformin were well tolerated by VM/dk mice. We did not observe 
any alterations in animal behavior or obvious gross physiological changes in cancer-free 
VM/dk mice following DCA and/or metformin treatment. Moreover, DCA and metformin 
treatments did not promote weight loss in these mice (Figs. 3.3.1A, 3.3.3A).  
In an attempt to achieve efficacious dosing in this model, we tested low 
(125mg/kg) and high (250mg/kg) doses of each agent based on the findings of previous 
reports (10, 11, 26-28). As both DCA and metformin are established modulators of 
systemic metabolism, we evaluated the effects of these agents on circulating blood 
glucose. We did not observe an effect of DCA on systemic glucose levels during these 
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dosing studies (Fig. 3.3.1C). Likewise, metformin did not affect blood glucose levels at 
either dose (Fig. 3.3.3C). Though metformin is used clinically in T2DM patients for its 
activity in reducing circulating glucose, it does not always reduce blood glucose in non-
diabetic patients (29).  
In regards to VM-M3 tumor growth and the survival of tumor-burdened VM/dk 
mice, DCA and metformin behaved similarly. Low dose treatment of DCA and metformin 
resulted in reduced tumor burden at 4 weeks post tumor cell implantation. (Figs. 3.3.1D, 
3.3.3D, Appendix B). This was associated with a reduction in bioluminescent indications 
of metastasis, marked by a lack of signal separate from the site of injection. 125 mg/kg 
DCA treatment caused a delay in VM-M3 tumor expansion (Fig. 3.3.1Eii). However, this 
only resulted in a non-significant 12.5% increase in survival (Fig 3.3.2B). Similarly, 
125mg/kg metformin treatment promoted a slight delay in tumor expansion but only 
prolonged survival by 16.4% (Figs. 3.3.3Ei, 3.3.4B).  
Strikingly, high doses of both DCA and metformin had a remarkable tumor 
suppressive effect. 250mg/kg DCA treatment likely interfered with the initial take of VM-
M3 cells, as the bioluminescent signal for these animals at week 1 is markedly lower 
than controls (Fig. 3.3.1Ei, iii). High-dose DCA treatment prohibited expansion of 
primary VM-M3 tumors and distant metastasis, shown by a near complete lack of 
diffuse signal at 4 weeks post tumor cell implantation (Figs. 3.3.1D, 3.3.1Eiii, Appendix 
B).  This was associated with a significant 48.8% increase in mean survival of tumor-
burdened mice (Fig. 3.3.2B). These data are consistent with the cytostatic effect of DCA 
observed in several other solid tumor models (9, 12). Alternatively, DCA increased 
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apoptosis in a model of Dalton’s Lymphoma, suggesting that DCA likely elicits tumor-
specific effects in vivo (10). 
Administration of metformin at a dose of 250mg/kg had a mixed effect on VM-M3 
tumor cell take. High-dose metformin reduced the intensity of the typical spike in signal 
upon injection for some of the cohort, but mimicked DCA in restricting early primary 
tumor growth for a greater proportion of this group (Fig. 3.3.3Eii). 250mg/kg metformin 
attenuation of VM-M3 tumor growth was associated with a significant 55.1% in mean 
survival (Fig. 3.3.4B). Metformin dosing of 250mg/kg has previously been shown to 
reduce tumor growth in models of colon and lung cancer (14, 30). 
As the high doses of both agents were most effective in our model, we next 
evaluated the efficacy of a combination of DCA and metformin at doses of 250mg/kg. 
During this study we were forced to alter the protocol for preparing VM-M3 cells for 
implantation. With great frequency we began to lose bioluminescent signal from mice 
regardless of treatment group two weeks post-injection, suggesting a substantial host 
response towards the VM-M3 cells that eradicated the tumors. We hypothesized that 
despite washing with PBS prior to injection, residual FBS in the injection volume was 
promoting an antigenic response towards the VM-M3 cells (31). Thus, we serum-
starved the VM-M3 cells overnight prior to injection. Indeed, this led to retention of a 
bioluminescent signal beyond week 2 post-injection. However, this did alter the 
aggressiveness of the model, as control animals succumbed to VM-M3 tumor burden 
quicker than before.  
Median survival for control animals under the new injection protocol was 21 days 
compared to 34 days for the original protocol (Figs 3.3.2A, 3.3.6A). Though the model 
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was more aggressive, it did not present other overt differences. Control animals still 
exhibited signs of cachexia following initial maintenance of baseline weight, food intake 
and blood glucose levels until nearing end of life (Figs. 3.3.5A-C). Furthermore, the new 
protocol did not diminish the effects of DCA and metformin previously observed, in fact 
we report greater efficacy with these agents at a dose of 250mg/kg. Again, neither DCA 
or metformin treatment promoted weight loss or affected the dietary intake of treated 
animals (Figs. 3.3.5A-B).  
Differing from our previous findings, both DCA and metformin promoted a 
significant reduction in circulating glucose levels after one week of treatment (Fig. 
3.3.5D). This was maintained in the DCA-treated animals but not in metformin-treated 
animals suggesting that the non-diabetic mice may become tolerant to the hepatic 
effects of metformin over time. It has been hypothesized that DCA may influence blood 
glucose through activation of peripheral glucose utilization, which may be particularly 
useful for diabetic patients (32). The differential effects of these agents on blood 
glucose in mice under the two protocols may be linked to the presumed inflammation 
associated with our original protocol. VM-M3 cell stimulation of the host immune system 
may be associated with induction of the hypothalamic-pituitary-adrenocorticoid axis that 
results in glucocorticoid release (33, 34). These steroid hormones promote maintenance 
of glucose levels during immune responses in part to meet the energetic requirements 
of immune mediators (34). This activity may have blunted the effects of DCA and 
metformin on blood glucose during our dose-response studies. 
As both of these agents alter glucose metabolism, we evaluated their effects on 
circulating lactate levels as an indicator of their respective activities. The blood lactate 
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levels of control animals increased with disease progression (Fig. 3.3.5E). This is likely 
a result of liver metastasis and disruption of hepatic function leading to inhibition of the 
Cori cycle. Moreover, substantial tumor burden may contribute to the increase in blood 
lactate as a result of the robust glycolytic metabolism of VM-M3 cells. Consistent with its 
mechanism of action, DCA significantly reduced blood lactate levels from baseline 
following one week of treatment (Fig. 3.3.5F). Metformin did not affect blood lactate 
levels in VM-M3 tumor-burdened mice, which is consistent with the literature despite 
clinical fears over lactic acidosis with metformin treatment (35). Phenformin, which is 
structurally similar to metformin, is 30 times more potent due to increased lipophilicity 
has been removed from the clinic because it induces lactic acidosis. However, reports 
of lactic acidosis with metformin treatment have only been associated with co-morbid 
kidney dysfunction (36, 37). 
DCA treatment significantly prolonged survival on VM-M3 tumor-burdened mice, 
increasing mean survival 78.6% over controls (Figs. 3.3.6A-B). Likewise, metformin had 
a significant effect on the survival of cancer-burdened mice (Fig. 3.3.6A). In fact, 
metformin administration doubled the survival time of these mice (Fig. 3.3.6B). 
However, the combination of DCA and metformin did not provide a further survival 
benefit over either individual agent. The combination did however mimic DCA treatment 
in reducing both blood glucose and blood lactate levels, which suggests that similar to 
our in vitro findings, DCA can bypass the potential compensatory increase in glycolysis 
associated with metformin treatment. 
The lack of observed synergy with the combination is likely a result of therapeutic 
resistance, which as previously described contributes the clinical failure of most cancer 
  118 
therapies (38). The confluence of genetic heterogeneity and the tumor 
microenvironment contribute to heterogeneity in tumor metabolism. This is 
characterized by distinct regions of the tumor that exhibit differential glucose 
metabolism. Though the nature of the tumor vasculature system contributes to Warburg 
metabolism characteristic of the bulk tumor, those regions of the tumor that are well 
perfused often exhibit robust oxidative metabolism (39). Those regions may be 
inherently resistant to the effects of the combination and upon selection against the rest 
of the tumor, would be allowed to expand and drive progression of VM-M3 tumors. 
Moreover, those tumor cells that have a more robust antioxidant capacity may persist in 
response to the oxidative stress induced by DCA and metformin, allowing that fraction 
of the tumor to drive resistance. Therefore, any synergistic effect in targeting VM-M3 
tumors with the combination could have been lost as a function of rapidly eradicating 
the susceptible proportion of the tumor population, allowing for proliferation of resistant 
tumor cells, ultimately leading to disease progression. 
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CHAPTER 4: SYSTEMIC METABOLIC EFFECTS OF DCA AND METFORMIN 
TREATMENT IN VM/DK MICE 
 
4.1 Chapter Synopsis 
 In this chapter we present the findings of a metabolomics study evaluating the 
global effects of DCA and metformin treatment on cancer-free VM/dk mice. Changes in 
metabolite levels following DCA treatment suggest an increase in oxidative glucose 
metabolism, which is consistent with its mechanism of action. In contrast, metformin 
treatment restricted glucose oxidation in favor of FAO. The data also indicates that DCA 
modulation of glucose metabolism predominates when DCA and metformin are 
administered in combination. The materials and methods used for the studies presented 
in this chapter are described in Appendix A. The fold changes of all isolated analytes in 
each of the analyzed tissues is provided in Appendix C. 
 
4.2 Metabolomics Analysis 
 To achieve a better understanding of the metabolic effects of DCA and 
metformin, we had global metabolomics analysis performed on tissue harvested from 
cancer-free VM/dk mice following a 3-week treatment regimen with 250mg/kg DCA, 
250mg/kg metformin or the 250mg/kg combination. We collected brain, heart, kidney, 
liver, serum, skeletal muscle, and spleen from these mice and sent the frozen samples 
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to the University of Utah Health Sciences Metabolomics Core for coupled gas 
chromatography-mass spectroscopy (GC/MS) metabolomics. A total of 135 unique 
analytes were isolated from these samples and their relative concentrations were 
subsequently determined. We then analyzed the fold changes from control for each 
analyte present for all treatment groups.  
 One-way analysis of variance (ANOVA) with a post-hoc Tukey’s multiple 
comparisons test was performed for each analyte present in each tissue type. This 
statistical analysis identified many significantly altered metabolites with widely variable 
fold changes. As the field of metabolomics is a relatively new, the biological relevance 
of fold changes in metabolite abundance determined from these analyses is still being 
elucidated (1). However, it is likely that even relatively small changes in abundance will 
have profound effects on cellular homeostasis for many metabolites given the 
overarching complexity and interconnectedness of cellular metabolism. For instance, a 
slight decrease in serine could precipitate deficiencies in lipid, nucleotide and protein 
metabolism as the amino acid is integrated into many divergent pathways.  
 GC/MS global metabolomics provides a snapshot of the tissue-wide effects of a 
particular treatment on a large series of metabolites. However, this method of analysis 
is not appropriate for the definitive determination of metabolic flux as the relative 
concentrations generated are from a single point in time (2). Yet, inferences of flux can 
still be made from these results that inform our understanding on the effects of 
metabolic treatments on different classes of metabolites. The concurrent analysis of 
multiple tissues allows for better elucidation of metabolite usage, as it is difficult to 
determine why a metabolite may be increased or decreased compared to controls from 
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serum or a single tissue type. Subsequent studies are required to investigate the 
functional consequences of the metabolic changes induced by agents such as DCA and 
metformin (3). 
 
4.3 DCA Alteration of Glucose Metabolism Associated with a Decrease in 
Biosynthetic Precursors  
 
4.3.1 Data Tables & Figures 
Table 4.3.1 Fold changes in glycolytic and TCA cycle intermediates following DCA treatment.       
T-tests were performed for every analyte in each of the sample types from which it was detected. Dark 
green shading signifies significant decrease (p<0.05) and light green shading signifies a trend towards 
significant decrease (p<0.10). Red shading signifies significant increase (p<0.05) and pink shading 
indicates a trend towards a significant increase (p<0.10). Gray shading signifies that the analyte was not 
identified in that particular tissue. 
 
Analyte Brain Heart Kidney Liver Muscle Serum Spleen 
Glucose   0.95 0.97   0.90 0.99 0.96 
Glucose-6-phosphate 0.96 1.01 1.02 0.87 1.01 1.04 0.86 
Fructose-6-phosphate 0.94 1.00 0.99 0.86 1.00   0.87 
DHAP 0.73   1.19 
 
      
Glycerol-3-phosphate 1.02 1.00 0.99 1.05 1.02 1.00 1.04 
1,3-bisphosphoglycerate 1.02 0.96 1.05     0.99 1.06 
3-Phosphoglycerate 1.03 1.07 0.94 0.94 1.03   0.79 
2-Phosphoglycerate   1.10 1.03 0.93 1.06     
Phosphoenolpyruvate 1.17 1.03 0.91 0.76 0.97   0.68 
Pyruvic Acid 1.01 0.99 1.03 1.03 0.91 0.91 1.03 
Lactic Acid 1.02 0.93 0.99 0.97 0.96 1.00 1.02 
                
Citric Acid 0.97 1.10 1.36 0.99 1.06 0.94 0.96 
cis-Aconitic Acid 1.01 1.03 1.20 0.75 0.95 0.85 0.88 
Isocitric Acid 0.97 1.03 2.16 0.93   0.92 0.94 
a-Ketoglutarate 1.12 1.03 1.30 1.06 1.77 0.66 0.99 
Succinic Acid 1.06 0.97 1.01 1.05 1.06 1.02 1.32 
Fumaric Acid 0.99 0.98 0.99 0.84 0.95 0.97 0.97 
Malic Acid 0.99 1.00 1.01 0.85 0.95 0.98 0.97 
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Table 4.3.2 Fold changes in amino acids and related metabolites following DCA treatment. T-tests 
were performed for every analyte in each of the sample types from which it was detected. Dark green 
shading signifies significant decrease (p<0.05) and light green shading signifies a trend towards 
significant decrease (p<0.10). Red shading signifies significant increase (p<0.05) and pink shading 
indicates a trend towards a significant increase (p<0.10). Gray shading signifies that the analyte was not 
identified in that particular tissue. 
 
Analyte Brain Heart Kidney Liver Muscle Serum Spleen 
Glutamine 1.03 1.08 1.02 1.08 0.97 0.99 0.99 
Glutamate 1.03 1.05 0.99 1.06 1.06 0.85 1.04 
N-acetylglutamate 1.07 
 
1.54 0.94 
  
1.45 
Ornithine 1.11 1.05 1.00 1.00 0.93 0.96 0.96 
Urea 0.99 0.99 1.00 0.98 0.98 0.92 0.99 
Putrescine 
  
1.20 
    Methionine 0.99 1.00 0.96 0.85 0.95 1.04 0.94 
Homocysteine 1.14 1.15 1.04 
 
0.89 0.97 0.69 
Cysteine 0.95 1.06 1.13 1.06 0.87 0.98 1.01 
Serine 0.98 1.02 0.98 0.91 0.98 1.01 0.94 
Homoserine 0.98 0.86 0.98 0.89 1.02 1.11 0.94 
2-HG 1.03 1.11 1.16 1.17 1.10 0.71 1.13 
Glycine 0.99 1.05 0.97 0.97 0.93 1.02 0.96 
Sarcosine 1.04 1.03 1.12 0.91 1.01 0.91 1.11 
Proline 1.02 1.02 0.96 0.94 0.96 1.02 0.93 
4-hydroxyproline 1.02 1.08 1.07 0.91 1.04 1.03 0.98 
Phenylalanine 1.00 1.01 0.97 0.94 0.96 1.01 0.95 
Histidine 1.03 1.01 0.90 
 
0.96 0.92 0.90 
Asparagine 1.02 1.07 0.91 0.91 0.94 1.00 0.92 
Lysine 1.05 1.04 0.96 
 
0.91 0.86 0.95 
Threonine 1.01 0.99 0.96 0.88 0.93 1.04 0.94 
Tyrosine 0.99 0.99 0.96 1.12 0.94 1.10 0.92 
Alanine 0.95 0.97 0.97 1.00 0.91 1.03 0.90 
Aspartate 1.02 1.05 0.99 0.99 0.98 1.01 1.00 
N-acetylaspartate 1.01 1.09 1.39 0.47 0.93 
 
1.03 
Valine 1.01 1.00 0.97 0.98 0.99 1.00 0.97 
Leucine 1.00 1.02 0.96 0.97 
 
1.00 0.97 
Isoleucine 1.01 1.00 0.96 0.98 0.99 1.01 0.97 
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Table 4.3.3 Fold changes in fatty acids and related lipid metabolites following DCA treatment.      
T-tests were performed for every analyte in each of the sample types from which it was detected. Dark 
green shading signifies significant decrease (p<0.05) and light green shading signifies a trend towards 
significant decrease (p<0.10). Red shading signifies significant increase (p<0.05) and pink shading 
indicates a trend towards a significant increase (p<0.10). Gray shading signifies that the analyte was not 
identified in that particular tissue. 
 
Analyte Brain Heart Kidney Liver Muscle Serum Spleen 
Lauric Acid 1.01 0.97 0.92 0.87 0.94 0.99 0.95 
Myristic Acid 0.97 0.94 0.95 0.91 0.90 1.03 0.92 
Palmitic Acid 0.99 1.00 0.97 0.99 0.95 0.97 0.97 
Palmitelaidic Acid   0.86   0.94 0.95 1.07 0.89 
Heptadecanoic Acid   1.01   0.90 0.88 0.96 0.91 
Stearic Acid 0.98 1.01 1.01 0.98 0.94 0.98 0.98 
Oleic Acid 0.96 0.99 0.96 1.00 0.98 0.96 0.96 
Elaidic Acid 0.96 1.01 0.96 0.99 0.95 0.87   
Linoleic Acid 1.01 0.96 0.95 0.94 0.97 0.98   
Nonadecanoic Acid 0.75 1.04 0.93 0.86 0.84 0.97 0.89 
Arachidonic Acid 0.99 0.99 0.99 0.93 0.82 0.93 0.97 
                
1-palmitoyl-glycerol 1.00 1.02 1.00 1.02 0.95 0.96 0.99 
1-stearoyl-glycerol 1.05 1.02 1.00 1.01 0.92 0.96 0.99 
2-stearoyl-glycerol   0.90   0.73   1.15   
1-oleoyl-glycerol 0.98 0.95 0.97 1.03 0.99 0.81 0.94 
2-oleoyl-glycerol 1.11 0.95 0.99 1.02 0.95 0.94 0.88 
1-linoleoyl-glycerol 1.06 0.95 0.98 1.08 0.96 0.95 0.91 
Glycerol 1.00 0.97 0.94 0.98 0.97 0.96 0.97 
Cholesterol 1.05 1.03 0.98 0.96 0.89 0.97 1.01 
β-hydroxybutyrate 1.08 1.00 1.08       1.08 
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Table 4.3.4 Fold changes in nucleotides and related metabolites following DCA treatment. T-tests 
were performed for every analyte in each of the sample types from which it was detected. Dark green 
shading signifies significant decrease (p<0.05) and light green shading signifies a trend towards 
significant decrease (p<0.10). Red shading signifies significant increase (p<0.05) and pink shading 
indicates a trend towards a significant increase (p<0.10). Gray shading signifies that the analyte was not 
identified in that particular tissue. 
 
Analyte Brain Heart Kidney Liver Muscle Serum Spleen 
Adenine 1.01 1.00 1.01 1.02 0.89 1.06 1.05 
Adenosine 1.00 1.03 1.31 1.08 1.13 0.90 1.46 
5'-AMP 1.04 0.99 1.10 1.00 1.06   1.35 
Inosine 0.99 0.93 1.00     0.92 1.03 
Hypoxanthine 0.98 1.00 0.98 0.90 0.92 0.85 0.95 
Xanthine 0.97 1.01 0.97 0.94 0.94 0.96 0.96 
Uric Acid   1.04 1.05 0.95 1.07 0.90 1.01 
Cytosine       0.96       
Thymine 0.92 1.06 1.11       1.03 
Uracil 1.00 1.05 1.01 0.85 1.03 0.93 0.97 
 
 
Table 4.3.5 Fold changes in PPP intermediates following DCA treatment. T-tests were performed for 
every analyte in each of the sample types from which it was detected. Dark green shading signifies 
significant decrease (p<0.05) and light green shading signifies a trend towards significant decrease 
(p<0.10). Red shading signifies significant increase (p<0.05) and pink shading indicates a trend towards a 
significant increase (p<0.10). Gray shading signifies that the analyte was not identified in that particular 
tissue. 
 
Analyte Brain Heart Kidney Liver Muscle Serum Spleen 
Ribose-5-phosphate       0.96 0.88     
Ribose 1.00 1.01 0.94 0.85 0.66 0.79 0.91 
Sedoheptulose-7-
phosphate 0.94 1.00 0.99 0.96 0.57 
 
0.96 
Sedoheptulose   0.92         0.78 
Eryhthrose-4-
phosphate       0.84       
Erythrose 0.98   0.97     0.93   
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Figure 4.3.1 Schematic of biosynthetic metabolism. Representation of metabolic flux that supports biosynthesis and ultimately growth and 
proliferation. Black arrows represent canonical flux and red arrows represent reductive carboxylation of glutamine carbon.
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4.3.2 Results & Discussion 
 Metabolomic analysis of tissue from VM/dk mice treated with 250mg/kg DCA 
indicate that DCA promotes an increase in mitochondrial glucose metabolism in these 
mice, which is consistent with its mechanism of action (Table 4.3.1). This is particularly 
evident in the liver, the predominant site of DCA action (4). DCA treatment promoted a 
significant reduction in early glycolytic intermediates in the liver compared to controls. 
This was independent of changes in hepatic lactate or pyruvate levels. However, DCA 
treatment did have an impact on the subsidiary pathways associated with glycolytic 
intermediates. We observed a significant decrease in ribose coupled with non-
significant decreases in other PPP intermediates as well as a significant reduction in 
serine  (Tables 4.3.1, 4.3.5). This was coupled with a significant increase in 2-HG, 
which is generated in wild-type IDH cells through a PGHDH-dependent mechanism, 
suggesting that DCA may restrict serine synthesis and promote alternate PGHDH 
function (5). This increase in 2-HG was also seen in heart, kidney and spleen samples 
from DCA treated mice. Furthermore, this overall change in glycolytic metabolism was 
mirrored in spleen (Table 4.3.1). 
 Coinciding with the change in glycolytic intermediates was an alteration to the 
TCA cycle in DCA treated liver samples. We observed a slight but significant increase in 
succinate, coupled with significant decreases in the subsequent intermediates, fumarate 
and malate (Table 4.3.1). This suggests a potential blockade of TCA cycling that may 
be resultant from excess glucose oxidation leading to saturation of complex II of the 
ETC and preventing efficient oxidation of succinate. Succinate was also elevated in the 
spleen and several TCA cycle intermediates upstream of succinate were significantly 
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increased in the kidney. Among them was ⍺-KG, which can serve as a substrate for 
glutamate and glutamine production. Glutamine and glutamate levels were increased in 
several of the analyzed tissues suggesting diversion of excess ⍺-KG for the generation 
of these amino acids (Table 4.3.2). Moreover, N-acetylglutamate was significantly 
increased in the kidney and was also elevated in the spleen. N-acetylglutamate is 
derived from acetyl-CoA and glutamate, thus the observed increase may be resultant 
from abundant PDH complex production of acetyl-CoA. Collectively these results 
suggest DCA activates glucose oxidation, likely restricting the diversion of glycolytic 
intermediates into biosynthetic pathways.   
 Interestingly, despite general increases in glutamine and glutamate levels, many 
non-essential amino acids derived from these two metabolites were decreased with 
DCA treatment (Table 4.3.2). Asparagine and proline were reduced in liver and spleen 
samples respectively, and alanine was reduced in muscle and spleen. This suggests 
that glutamine and glutamate are not being used for amino acid synthesis under DCA 
treatment. Moreover, most essential amino acids were also decreased in the kidney and 
spleen (Table 4.3.2). In contrast to the general decrease in tissue amino acids levels 
was a significant increase in serum tyrosine levels. This is a strong indicator of DCA 
action in the liver; as described above, DCA inhibits hepatic GSTZ1 and promotes 
tyrosine accumulation in the circulation (6). 
 DCA treatment decreased fatty acid levels in most tissues (Table 4.3.3). Given 
the observed indications of glucose oxidation, this likely is a result of reduced fatty acid 
uptake. Increased glucose oxidation suppresses the need for FAO to generate acetyl-
CoA, thus the PDH complex is a native regulator of FAO (7). As such DCA treatment 
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reduces the necessity for fatty acids as an energy source. Except for slight increases in 
myristic and palmitelaidic acids, DCA treatment did not alter circulating levels of 
saturated fatty acids, suggesting no effect on adipocyte lipolysis and free fatty acid 
release. Moreover, despite indications of increased acetyl-CoA production, DCA did not 
alter palmitate levels, indicating no effect on FAS in the analyzed tissues (Table 4.3.3). 
 Finally, DCA treatment altered constituents of purine metabolism. We observed 
increases in adenosine in the kidney and spleen as well as an elevation of AMP in the 
spleen (Table 4.3.4). This coincided with decreases in intermediates in the purine 
salvage pathway in the liver and spleen. The indications of increased glucose oxidation 
and apparent diversion of ⍺-KG for the generation of glutamate and glutamine suggest 
that DCA does not precipitate an energetic crisis. Moreover, our in vitro data suggest 
that DCA actually reduced levels of activated AMPK (Fig 3.3.5G). Thus the increase in 
AMP is not necessarily an indication of an energetic deficiency. Rather, it may suggest 
an increase in the purine nucleotide cycle, which generates fumarate for TCA cycle 
anaplerosis and may be induced by DCA treatment to compensate for the observed 
decreases in fumarate and malate (8). 
 Together, these data suggest that DCA activates mitochondrial glucose oxidation 
in VM/dk mice. This is most evident in kidney, liver and spleen tissue, whereas we show 
that DCA has marginal effects on brain, heart and muscle. Associated with this 
alteration in glucose metabolism was a general reduction in the biosynthetic precursors 
required for growth (Fig. 4.3.1). As biosynthesis is critical to tumor formation, the 
systemic metabolic effects of DCA may prevent tumorigenesis. 
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4.4 Metformin Treatment Alters Fuel Choice For Oxidative Metabolism 
 
4.4.1 Data Tables 
Table 4.4.1 Fold changes in glycolytic and TCA cycle intermediates following metformin treatment. 
T-tests were performed for every analyte in each of the sample types from which it was detected. Dark 
green shading signifies significant decrease (p<0.05) and light green shading signifies a trend towards 
significant decrease (p<0.10). Red shading signifies significant increase (p<0.05) and pink shading 
indicates a trend towards a significant increase (p<0.10). Gray shading signifies that the analyte was not 
identified in that particular tissue. 
 
Analyte Brain Heart Kidney Liver Muscle Serum Spleen 
Glucose   1.06 1.04   0.93 0.98 0.95 
Glucose-6-phosphate 0.94 1.35 1.01 0.96 1.06 0.96 0.96 
Fructose-6-phosphate 0.89 1.40 0.93 0.92 1.10   0.97 
DHAP 0.86   1.21 1.00       
Glycerol-3-phosphate 1.02 0.99 0.97 1.06 0.99 1.02 0.96 
1,3-bisphosphoglycerate 1.02 0.94 0.98     0.99 0.98 
3-Phosphoglycerate 0.99 1.14 0.97 1.06 1.08   0.78 
2-Phosphoglycerate   1.38 0.95 0.96 1.14     
Phosphoenolpyruvate 0.85 1.12 0.95 1.09 1.05   0.67 
Pyruvic Acid 0.99 1.03 1.04 0.98 0.97 1.06 0.96 
Lactic Acid 1.00 0.91 0.93 0.98 0.94 0.99 0.99 
                
Citric Acid 0.97 0.99 1.14 1.27 1.10 1.03 0.94 
cis-Aconitic Acid 1.02 0.96 1.45 1.41 0.98 1.07 0.88 
Isocitric Acid 0.97 0.89 1.53 1.17   1.21 0.90 
a-Ketoglutarate 0.91 1.68 1.05 1.12 0.96 1.15 0.63 
Succinic Acid 1.06 1.02 0.98 1.03 0.96 0.93 0.99 
Fumaric Acid 0.98 0.92 0.97 1.05 0.96 1.01 0.96 
Malic Acid 0.98 0.96 0.96 1.05 0.98 1.00 0.96 
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Table 4.4.2 Fold changes in amino acids and related metabolites following metformin treatment. T-
tests were performed for every analyte in each of the sample types from which it was detected. Dark 
green shading signifies significant decrease (p<0.05) and light green shading signifies a trend towards 
significant decrease (p<0.10). Red shading signifies significant increase (p<0.05) and pink shading 
indicates a trend towards a significant increase (p<0.10). Gray shading signifies that the analyte was not 
identified in that particular tissue. 
 
Analyte Brain Heart Kidney Liver Muscle Serum Spleen 
Glutamine 1.00 0.99 0.99 0.98 0.99 1.04 0.97 
Glutamate 1.00 0.99 0.96 1.03 0.98 1.29 0.98 
N-acetylglutamate 1.00 
 
0.96 1.00 
  
1.60 
Ornithine 0.99 0.95 0.91 0.95 0.98 1.08 0.91 
Urea 0.98 0.96 0.98 0.96 0.98 1.10 0.97 
Putrescine 
  
1.05 
    Methionine 0.99 1.00 0.98 0.98 0.99 0.99 0.97 
Homocysteine 0.97 0.81 0.83 
 
1.03 0.79 0.83 
Cysteine 0.88 1.01 1.01 0.92 0.92 0.88 0.91 
Tryptophan 0.97 0.96 0.99 0.99 0.98 1.02 0.97 
Serine 1.00 1.01 0.98 1.03 1.02 1.03 0.96 
Homoserine 0.99 0.81 1.00 1.00 1.17 0.94 0.94 
2-HG 1.02 0.98 1.00 0.96 0.95 1.13 0.93 
Glycine 0.98 1.03 0.97 0.98 1.03 1.04 0.99 
Sarcosine 1.03 0.92 0.94 0.90 0.98 0.96 0.95 
Proline 1.00 0.96 0.95 0.97 0.98 1.00 0.94 
4-hydroxyproline 1.01 0.97 0.96 1.04 0.99 1.14 0.95 
Phenylalanine 0.98 0.98 0.97 0.97 0.98 0.97 0.97 
Histidine 0.98 0.92 0.85 
 
1.04 1.14 0.96 
Asparagine 1.02 1.01 0.90 0.95 1.01 1.07 0.97 
Lysine 1.00 1.02 1.00 
 
0.98 1.24 0.97 
Threonine 1.00 1.00 0.98 0.96 1.00 0.99 0.97 
Tyrosine 0.99 1.00 0.98 1.11 0.99 0.92 0.96 
Alanine 0.97 0.98 0.98 0.98 1.01 0.96 0.97 
Aspartate 1.00 1.02 1.01 1.09 1.06 1.08 0.98 
N-acetylaspartate 1.02 1.02 1.17 1.13 0.87 
 
0.97 
Valine 0.99 1.00 0.96 0.97 1.00 0.99 0.98 
Leucine 0.99 1.03 0.96 0.98 
 
0.99 0.98 
Isoleucine 0.99 1.00 0.96 0.98 1.00 0.98 0.98 
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Table 4.4.3 Fold changes in fatty acids and related lipid metabolites following metformin 
treatment. T-tests were performed for every analyte in each of the sample types from which it was 
detected. Dark green shading signifies significant decrease (p<0.05) and light green shading signifies a 
trend towards significant decrease (p<0.10). Red shading signifies significant increase (p<0.05) and pink 
shading indicates a trend towards a significant increase (p<0.10). Gray shading signifies that the analyte 
was not identified in that particular tissue. 
 
Analyte Brain Heart Kidney Liver Muscle Serum Spleen 
Lauric Acid 1.00 0.87 1.03 0.99 1.16 0.89 0.92 
Myristic Acid 0.97 0.89 0.98 0.95 1.02 0.87 0.89 
Palmitic Acid 0.97 0.97 0.97 0.99 0.98 0.97 0.96 
Palmitelaidic Acid   0.87   0.91 1.03 0.83 0.87 
Heptadecanoic Acid   0.91   1.07 0.97 0.95 0.91 
Stearic Acid 0.98 0.97 1.00 1.00 0.97 0.97 0.96 
Oleic Acid 0.93 0.94 0.96 0.97 1.03 0.94 0.93 
Elaidic Acid 0.93 0.92 0.96 0.91 1.00 0.86   
Linoleic Acid 1.04 0.97 0.98 1.02 1.02 0.95   
Nonadecanoic Acid 0.87 0.91 0.96 0.96 0.94 0.94 0.90 
Arachidonic Acid 0.98 0.93 0.98 0.99 0.84 0.93 0.91 
                
1-palmitoyl-glycerol 0.98 0.97 0.97 0.99 0.97 1.02 0.99 
1-stearoyl-glycerol 1.01 0.97 0.99 1.01 0.93 1.04 0.98 
2-stearoyl-glycerol   0.98   0.90   1.60   
1-oleoyl-glycerol 0.93 0.95 1.00 0.95 1.05 0.81 0.88 
2-oleoyl-glycerol 1.20 0.98 1.06 1.05 1.06 0.83 0.82 
1-linoleoyl-glycerol 1.10 0.99 1.04 1.08 1.06 0.91 0.85 
Glycerol 0.99 0.95 0.92 0.99 0.97 0.96 0.97 
Cholesterol 0.99 0.98 0.91 1.04 0.92 0.96 1.00 
β-hydroxybutyrate 1.01 1.00 1.01       1.03 
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Table 4.4.4 Fold changes in nucleotides and related metabolites following metformin treatment. T-
tests were performed for every analyte in each of the sample types from which it was detected. Dark 
green shading signifies significant decrease (p<0.05) and light green shading signifies a trend towards 
significant decrease (p<0.10). Red shading signifies significant increase (p<0.05) and pink shading 
indicates a trend towards a significant increase (p<0.10). Gray shading signifies that the analyte was not 
identified in that particular tissue. 
 
Analyte Brain Heart Kidney Liver Muscle Serum Spleen 
Adenine 0.99 0.91 0.99 0.97 0.96 0.85 0.99 
Adenosine 0.97 0.86 1.37 1.04 1.01 1.14 1.25 
5'-AMP 1.04 0.99 1.15 1.03 1.07   1.19 
Inosine 0.99 0.94 1.01     0.93 1.01 
Hypoxanthine 0.98 0.95 0.95 0.97 0.92 1.35 0.98 
Xanthine 0.96 0.95 0.91 0.98 0.92 1.12 0.97 
Uric Acid   1.02 0.98 1.00 1.08 0.95 0.97 
Cytosine       0.92       
Thymine 0.97 0.82 1.01       1.03 
Uracil 0.98 0.95 0.98 0.96 1.07 0.93 0.94 
 
 
Table 4.4.5 Fold changes in PPP intermediates following metformin treatment. T-tests were 
performed for every analyte in each of the sample types from which it was detected. Dark green shading 
signifies significant decrease (p<0.05) and light green shading signifies a trend towards significant 
decrease (p<0.10). Red shading signifies significant increase (p<0.05) and pink shading indicates a trend 
towards a significant increase (p<0.10). Gray shading signifies that the analyte was not identified in that 
particular tissue. 
 
Analyte Brain Heart Kidney Liver Muscle Serum Spleen 
Ribose-5-phosphate       1.03 1.00     
Ribose 0.96 0.89 0.94 0.97 0.78 1.13 0.87 
Sedoheptulose-7-
phosphate 0.92 0.83 1.00 1.01 0.77 
 
1.01 
Sedoheptulose   0.83         0.94 
Eryhthrose-4-phosphate       1.10       
Erythrose 0.93   0.88     0.98   
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4.4.2 Results & Discussion 
 The antidiabetic activity of metformin has been attributed largely to its action in 
hepatic tissue. However, metformin treatment did not have robust effects on liver 
metabolism in VM/dk mice. Yet, those hepatic metabolites that were altered following 
metformin treatment are established hallmarks of metformin activity. Metformin 
treatment promoted a trend towards increased AMP levels, which is often associated 
with metformin inhibition of complex I (Table 4.4.4) (9). We also observed a trend 
towards increased Glycerol-3-phosphate levels in the liver, which is consistent with the 
report that metformin inhibits hepatic mGPD to further induce an energetic crisis (Table 
4.4.2) (10). This inhibition restricts the utilization of both glycerol and lactate as 
gluconeogenic substrates and may also explain the significant decrease in glycerol 
levels seen in many tissues following metformin treatment (Table 4.4.3). It has been 
proposed that metformin control of circulating glucose levels is also mediated through 
enhanced peripheral glucose uptake, especially in muscle (11). However, we show that 
metformin has very little impact on muscle metabolism. In contrast, metformin treatment 
had significant effects on heart and kidney metabolism.  
 Metformin promoted an accumulation of glycolytic intermediates upstream of 
pyruvate in cardiac samples (Tables 4.4.1). This could indicate an increase in glycolytic 
flux, which would be consistent with AMPK activation. However, it is more likely a 
function of reduced PK activity, resulting in this accumulation. Cardiac tissue utilizes 
FAO as a primary means of energy production, necessitating concurrent restriction of 
glucose oxidation (12). Metformin significantly reduced levels of several fatty acids in 
the cardiac samples, which coupled with the accumulation of glycolytic intermediates 
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suggests that metformin enhanced FAO in the heart. This is in line with the induction of 
FAO associated with metformin treatment (13). Circulating levels of fatty acids and 
monoacylglycerols, which are derived from TAG metabolism, were significantly 
decreased in VM/dk mice treated with metformin (Table 4.4.3). This is consistent with 
previous reports of reductions in free fatty acids with metformin treatment (9, 14). 
Metformin alteration of fatty acid levels is likely resultant from enhanced tissue utilization 
and decreases in free fatty acid release from adipocytes, which is shown to be a 
function of metformin stimulation of FAO in these cells (15).  
 Metformin treatment is also shown to alter glutamine metabolism, particularly 
through induction of reductive carboxylation of glutamine carbon in favor of oxidation 
(16). We show an accumulation of TCA cycle intermediates upstream of succinate in 
liver and kidney and a decrease in fumarate and malate in heart and spleen samples 
(Table 4.4.1). This is similar to our findings with DCA treatment, however we did not 
observe an increase in glutamate and glutamine. In fact, we observed a trend towards 
decreased glutamate in the kidney. this suggests against ⍺-KG diversion for generation 
of these amino acids, rather supporting the notion of increased reductive carboxylation 
that would lead to increases in ⍺-KG, isocitrate, cis-Aconitate and citrate. 
 In addition to the noted alterations in catabolic metabolism, metformin treatment 
also affected metabolites associated with anabolic processes. Despite the observed 
increases in glycolytic intermediates in cardiac tissue, metformin treatment was 
associated with a trends towards decreases in PPP intermediates in heart samples 
(Table 4.4.5). Furthermore, we report slight increases in circulating serine and glycine 
levels along with a decrease in the glycine derivative sarcosine in the liver (Table 4.4.3). 
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This may indicate a decrease in serine/glycine metabolism, which is consistent with a 
previous metabolomics study demonstrating metformin exhibits anti-folate activity (17). 
As serine/glycine metabolism is intricately linked to the folate cycle and one-carbon 
metabolism, disruption of the folate cycle also interferes with the metabolism of 
serine/glycine. A disruption of one-carbon metabolism could explain the observed 
reduction in nucleotide levels given its necessity for nucleotide synthesis (Table 4.4.4).  
Together, these results suggest that consistent with the literature, metformin reduces 
anabolic metabolism in VM/dk mice. Similar to DCA, this restriction of biosynthesis 
would disrupt tumorigenesis and likely contributes to the apparent reduction in cancer 
incidence with metformin discussed previously (18-22).   
 
4.5 DCA modulation of glucose metabolism predominates in a DCA and 
metformin combination 
 
4.5.1 Data Tables 
Table 4.5.1 Fold changes in glycolytic and TCA cycle intermediates following treatment with a 
DCA and metformin combination. T-tests were performed for every analyte in each of the sample types 
from which it was detected. Dark green shading signifies significant decrease (p<0.05) and light green 
shading signifies a trend towards significant decrease (p<0.10). Red shading signifies significant increase 
(p<0.05) and pink shading indicates a trend towards a significant increase (p<0.10). Gray shading 
signifies that the analyte was not identified in that particular tissue. 
 
Analyte Brain Heart Kidney Liver Muscle Serum Spleen 
Glucose   1.02 1.02   1.10 0.99 1.00 
Glucose-6-phosphate 0.93 1.21 1.05 0.95 0.84 1.00 1.00 
Fructose-6-phosphate 0.87 1.24 1.21 0.97 0.78   1.01 
DHAP 1.04   1.06 
 
      
Glycerol-3-phosphate 0.99 1.03 1.01 1.02 0.90 0.97 0.95 
1,3-bisphosphoglycerate 0.92 1.38 1.12     0.99 1.03 
3-Phosphoglycerate 0.92 1.05 1.04 0.94 0.82   1.02 
2-Phosphoglycerate   1.11 0.94 0.94 0.71     
Phosphoenolpyruvate 0.90 1.13 1.08 0.81 0.85   1.03 
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Pyruvic Acid 0.96 0.96 1.01 0.98 1.10 0.98 0.99 
Lactic Acid 0.97 0.97 0.96 0.96 1.04 1.02 0.98 
                
Citric Acid 0.93 1.01 0.99 0.70 1.10 0.99 0.99 
cis-Aconitic Acid 0.93 1.05 1.00 0.62 1.01 0.94 0.91 
Isocitric Acid 0.89 1.13 1.28 0.99   1.14 0.98 
a-Ketoglutarate 0.77 0.59 0.94 1.01 2.20 1.02 1.11 
Succinic Acid 0.99 0.94 1.00 1.00 0.90 0.99 1.00 
Fumaric Acid 0.97 1.06 1.02 0.94 1.03 0.98 0.99 
Malic Acid 0.97 1.07 1.10 0.91 1.05 0.99 0.98 
 
 
Table 4.5.2 Fold changes in amino acids and related metabolites following treatment with a DCA 
and metformin combination. T-tests were performed for every analyte in each of the sample types from 
which it was detected. Dark green shading signifies significant decrease (p<0.05) and light green shading 
signifies a trend towards significant decrease (p<0.10). Red shading signifies significant increase 
(p<0.05) and pink shading indicates a trend towards a significant increase (p<0.10). Gray shading 
signifies that the analyte was not identified in that particular tissue. 
 
Analyte Brain Heart Kidney Liver Muscle Serum Spleen 
Glutamine 0.95 1.02 1.00 1.08 1.05 1.02 1.01 
Glutamate 0.96 1.02 0.98 1.00 1.16 0.96 1.00 
N-acetylglutamate 0.95   1.06 0.85     1.11 
Ornithine 0.90 1.04 1.03 0.97 1.04 1.03 1.01 
Urea 0.93 0.98 0.97 0.95 0.99 1.02 0.95 
Putrescine     1.06         
Methionine 0.96 1.01 1.00 0.93 1.01 0.96 1.01 
Homocysteine 0.61 1.32 1.24   0.84 0.73 1.04 
Cysteine 1.03 1.24 1.12 1.09 1.10 1.08 1.01 
Tryptophan 0.96 1.03 1.00 0.98 1.02 1.00 1.04 
Serine 0.95 1.03 1.03 0.99 1.05 1.02 1.01 
Homoserine 0.87 0.85 0.93 0.82 1.18 0.81 0.89 
2-HG 0.94 1.11 1.08 1.05 1.09 1.05 0.96 
Glycine 1.02 1.07 0.99 1.00 1.02 0.99 1.00 
Sarcosine 0.96 1.02 1.06 0.89 1.07 1.04 1.00 
Proline 0.96 1.04 1.04 0.95 1.02 0.99 1.02 
4-hydroxyproline 1.01 1.08 0.99 0.92 1.05 1.07 0.96 
Phenylalanine 0.97 1.04 1.01 0.96 1.03 0.98 1.01 
Histidine 0.91 1.05 1.04   1.03 1.00 1.04 
Asparagine 0.96 1.08 1.06 0.97 1.07 1.02 1.04 
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Lysine 0.99 1.07 1.04   1.04 1.04 1.02 
Threonine 0.94 0.99 0.99 0.93 0.99 0.95 0.99 
Tyrosine 0.93 1.02 1.01 1.14 0.99 0.93 1.01 
Alanine 0.94 1.02 1.00 0.99 1.00 0.98 0.99 
Aspartate 0.97 0.97 1.01 0.98 1.07 0.92 0.99 
N-acetylaspartate 0.96 0.93 0.89 
 
1.05   0.99 
Valine 0.97 1.00 0.99 0.96 1.03 0.99 1.00 
Leucine 0.98 1.04 1.00 0.97   0.99 1.00 
Isoleucine 0.97 1.02 0.99 0.96 1.04 0.99 1.01 
 
 
Table 4.5.3 Fold changes in fatty acids and related lipid metabolites following treatment with a 
DCA and metformin combination. T-tests were performed for every analyte in each of the sample types 
from which it was detected. Dark green shading signifies significant decrease (p<0.05) and light green 
shading signifies a trend towards significant decrease (p<0.10). Red shading signifies significant increase 
(p<0.05) and pink shading indicates a trend towards a significant increase (p<0.10). Gray shading 
signifies that the analyte was not identified in that particular tissue. 
 
Analyte Brain Heart Kidney Liver Muscle Serum Spleen 
Lauric Acid 0.98 1.07 0.96 0.98 1.09 0.87 0.91 
Myristic Acid 0.96 0.99 0.98 0.88 1.02 0.87 0.96 
Palmitic Acid 0.98 1.07 1.04 1.00 1.02 0.98 0.99 
Palmitelaidic Acid   0.95   0.90 1.04 0.85 0.96 
Heptadecanoic Acid   1.15   0.98 1.09 0.92 0.97 
Stearic Acid 0.95 1.08 1.06 1.01 1.04 0.99 0.99 
Oleic Acid 1.01 1.09 1.02 1.00 1.10 0.98 1.01 
Elaidic Acid 1.01 1.12 1.02 1.01 1.10 0.98   
Linoleic Acid 1.00 1.06 1.01 0.97 1.09 0.97   
Nonadecanoic Acid 0.66 1.17 1.14 0.90 1.17 0.85 0.91 
Arachidonic Acid 0.98 1.10 1.01 0.98 1.15 0.99 0.99 
                
1-palmitoyl-glycerol 0.95 1.08 1.06 1.03 0.99 0.98 1.01 
1-stearoyl-glycerol 0.92 1.09 1.07 1.04 0.99 1.01 1.03 
2-stearoyl-glycerol   0.97   0.93   1.39   
1-oleoyl-glycerol 0.99 1.04 1.02 1.04 1.14 0.97 1.01 
2-oleoyl-glycerol 0.87 0.99 1.01 0.99 1.16 0.83 1.04 
1-linoleoyl-glycerol 0.91 1.00 1.01 1.03 1.13 0.86 1.01 
Glycerol 0.98 1.03 0.98 0.98 1.04 0.96 1.01 
Cholesterol 0.93 1.10 1.04 1.00 1.05 1.01 1.02 
β-hydroxybutyrate 1.00 1.02 1.04       1.04 
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Table 4.5.4 Fold changes in nucleotides and related metabolites following treatment with a DCA 
and metformin combination. T-tests were performed for every analyte in each of the sample types from 
which it was detected. Dark green shading signifies significant decrease (p<0.05) and light green shading 
signifies a trend towards significant decrease (p<0.10). Red shading signifies significant increase 
(p<0.05) and pink shading indicates a trend towards a significant increase (p<0.10). Gray shading 
signifies that the analyte was not identified in that particular tissue. 
 
Analyte Brain Heart Kidney Liver Muscle Serum Spleen 
Adenine 0.98 1.03 0.97 1.00 0.94 0.88 1.00 
Adenosine 0.98 0.96 0.97 1.00 0.75 0.22 1.02 
5'-AMP 0.90 0.97 1.00 1.00 0.97   0.92 
Inosine 0.94 0.98 1.02     0.98 1.02 
Hypoxanthine 0.99 1.07 0.99 1.01 1.09 0.96 1.01 
Xanthine 0.98 1.04 0.99 0.99 1.07 0.98 1.00 
Uric Acid   1.02 1.00 0.95 1.00 1.02 0.98 
Cytosine       0.98       
Thymine 0.89 1.09 0.92       1.02 
Uracil 0.96 1.07 1.00 1.06 1.06 0.92 0.99 
 
 
Table 4.5.5 Fold changes in PPP intermediates following treatment with a DCA and metformin 
combination. T-tests were performed for every analyte in each of the sample types from which it was 
detected. Dark green shading signifies significant decrease (p<0.05) and light green shading signifies a 
trend towards significant decrease (p<0.10). Red shading signifies significant increase (p<0.05) and pink 
shading indicates a trend towards a significant increase (p<0.10). Gray shading signifies that the analyte 
was not identified in that particular tissue. 
 
Analyte Brain Heart Kidney Liver Muscle Serum Spleen 
Ribose-5-phosphate       0.97 1.12     
Ribose 0.96 1.09 1.02 0.97 1.13 1.04 1.01 
Sedoheptulose-7-
phosphate 0.90 1.24 1.06 1.02 1.14 
 
1.0 
Sedoheptulose   1.10         1.06 
Eryhthrose-4-phosphate       0.93       
Erythrose 0.81   1.00     0.97   
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4.5.2 Results & Discussion 
 Central to the mechanisms of action of DCA and metformin is an opposing effect 
on glucose oxidation. Indeed, we show that as individual treatments, DCA and 
metformin differentially influence glucose metabolism. However, in combination we 
propose that DCA activation of the PDH complex overcomes the compensatory 
suppression of glucose oxidation resultant from metformin inhibition of complex I. The 
metabolomics analysis of tissue from VM/dk mice treated with a DCA and metformin 
combination support that hypothesis. 
 We report tissue specific differences in intermediates associated with glucose 
metabolism that are not mutually exclusive with an increase in glucose oxidation. 
Combinatorial treatment promotes a significant decrease in glycolytic intermediates 
independent of a decrease in glucose or pyruvate in muscle samples, suggesting 
efficient flux through the pathway. Similar to DCA treatment, we observed a decrease in 
succinate coupled with increases in ⍺-KG and glutamate (Tables 4.5.1, 4.5.2). 
Moreover, fumarate and malate levels were decreased and glutamine was increased in 
liver samples, which is consistent with DCA treatment alone (Tables 4.3.1, 4.5.1).  
 In contrast, we observed an accumulation of both glycolytic and TCA cycle 
intermediates, including fumarate and malate following treatment with the combination 
in cardiac samples (Table 4.5.1). Metformin treatment promoted a similar accumulation 
of glycolytic intermediates, which was likely a consequence of increased FAO, marked 
by a decrease in fatty acid levels (4.4.1). However, many fatty acids were significantly 
increased in the heart with DCA and metformin. This increase was also seen in muscle 
and kidney tissue and coincided with a decrease in serum levels of several fatty acids 
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and monoacylglycerols (Table 4.5.3). These data suggest a preservation of metformin 
activity in lowering circulating lipid levels with the combinatorial treatment. Yet, they also 
indicate a restriction of FAO in favor of glucose oxidation. This is further supported by 
the lack of hepatic increase in glycerol-3-phosphate or AMP elevation with the 
combination, indicating an absence of AMPK activation in the presence of both DCA 
and metformin (Tables 4.5.1, 4.5.4). This is consistent with our in vitro finding that DCA 
attenuates metformin activation of AMPK in VM-M3 cells (3.2.5G).  
 The observed elevation in glycolytic intermediates in the heart coincided with 
increases in the PPP-associated metabolites ribose and sedoheptulose-7-phosphate 
suggesting a potential diversion of accumulated glucose-6-phosphate (Table 4.5.5). 
However, the combinatorial treatment did not generally alter the levels of PPP 
intermediates in other tissues. Nucleotide metabolism was also largely unaffected by 
the combination where the individual treatments reduced constituents of the purine 
salvage pathway (Table 4.5.4). Strikingly, the combination treatment promoted a 
significant reduction in a large number of metabolites in the brain, which may be 
indicative of an overall reduction in brain metabolism. Moreover, whereas the individual 
treatments had a significant influence over spleen metabolism, the combination had no 
discernable effect on the spleen of VM/dk mice. As the spleen is a dynamic organ that is 
a critical component of the immune system, the general reduction in spleen metabolite 
levels with individual DCA and metformin treatments may be resultant from changes in 
inflammation. Both DCA and metformin are shown to promote an anti-inflammatory 
response, which may be disrupted when administered in combination (23-25).  
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The efficacy of DCA and metformin as an anti-cancer therapy is dependent on 
active mitochondrial oxidation of glucose. Our findings suggest that DCA induces 
glucose oxidation even when co-administered with metformin, though this may be more 
pronounced in particular tissues.  
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CHAPTER 5: HYPERBARIC OXYGEN DOES NOT COOPERATE WITH THE 
COMBNATION OF DCA & METFORMIN 
 
5.1 Chapter Synopsis 
 In this chapter we present data depicting the effect of hyperbaric oxygen on the 
efficacy of our DCA and metformin combination. Hyperbaric oxygen treatment 
enhanced the cytotoxicity of DCA in the presence of complex I inhibition in vitro. 
However, administration of hyperbaric oxygen to VM-M3 tumor-burdened mice did not 
enhance the efficacy of the DCA and metformin combination. The materials and 
methods used for the studies presented in this chapter are described in Appendix A. 
 
5.2 Hyperbaric Oxygen Therapy as an Adjuvant to Cancer Therapy 
 As we’ve shown, the in vitro efficacy of DCA and metformin in combination is 
dependent on oxidative stress. To improve upon the lack of observed effect with the 
combination in the VM-M3 model, we hypothesized that further stimulation of oxidative 
stress would enhance the efficacy of DCA and metformin in vivo. As such, we chose to 
employ hyperbaric oxygen therapy as a pro-oxidant adjuvant to our proposed 
combinatorial anti-cancer therapy. 
 Hyperbaric oxygen therapy (HBOt) employs 100% O2 at elevated pressure (>1 
atm) to increase the proportion of dissolved O2 in plasma. This overcomes the need for 
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hemoglobin transport of oxygen and results in increased O2 diffusion in tissue beyond 
the capacity of red blood cells (1). HBOt is administered in specialized chambers that 
allow for pressurization to 2-3 atm absolute (ATA). Pure oxygen can be fed directly into 
the chamber or delivered by oxygen mask or endotracheal tube. HBOt treatments 
typically last for 1.5 – 2 hours (2). The clinical use of HBOt is regulated by the Undersea 
and Hyperbaric Medicine Society and has approved the use of HBOt for carbon 
monoxide poisoning, decompression sickness, non-healing wounds among other 
disorders (3). 
 There is also clear evidence that HBOt promotes a physiological response that 
would be detrimental to cancer, and many studies have been performed to evaluate the 
potential utility of HBOt as a stand-alone therapy (4). As described, the tumor 
vasculature is immature and inadequate, leading to incomplete perfusion of the tumor 
mass (5). This contributes to the HIF-1 signaling that drives many of the processes 
required for tumor progression. Increasing tumor perfusion promotes O2-mediated 
degradation of HIF-1⍺, inhibiting its’ tumor promoting effects. Moreover, HBOt saturation 
of the tumor restricts angiogenesis independent of HIF-1 through inhibition of growth-
factor dependent pro-angiogenic signaling (6). Administration of HBOt in a rat mammary 
tumor model reduced blood vessel density, which was associated with reductions in 
VEGF and PDGF levels (6, 7). 
Increasing tissue O2 perfusion results in elevated O2-tension at the cellular level. 
Elevating intracellular O2 levels increases the likelihood of premature O2 oxidation by 
prematurely lost electrons from the ETC. Thus, HBOt should increase superoxide 
production and the potential for oxidative stress. Indeed, we have previously shown that 
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hyperbaric oxygen increases ROS production in VM-M3 cells (8). The propensity for 
HBOt to enhance oxidative stress has led to its utilization as an adjuvant to chemo- and 
radiotherapies (4). The efficacy of platinum-based chemotherapeies appears to be 
particularly enhanced by HBOt, which is to be expected based on the ROS-promoting 
nature of those treatments.  HBOt enhanced carboplatin activity in a mouse model of 
osteosarcoma and the efficacy of cisplatin in a human ovarian cancer xenograft (9, 10). 
In patients with colorectal cancer, administration of HBOt as an adjuvant to radiation 
significantly increased survival outcomes (11). Clinical implementation of HBOt and 
radiation for head and neck cancers has also proven to improve tumor control (12). 
HBOt-mediated oxygenation may not merely enhance the efficacy of radiotherapy at the 
tumor level, evidence suggests that HBOt protects normal tissue from radiation damage 
(13). 
Gliomas have also been shown to be sensitive to HBOt. Administration of HBOt 
improved tumor response to carboplatin in patients with high-grade gliomas (14). As an 
adjuvant to radiotherapy, HBOt doubled mean survival of patients from one to two years 
over radiation alone (15). Moreover, our lab has demonstrated that HBOt enhances the 
anti-cancer effect of a ketogenic diet as well as ketone supplementation in the VM-M3 
model (8, 16).  
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5.3 Metformin May Protect VM-M3 Cells Against the Pro-Oxidant Effects of 
Hyperbaric Oxygen in the Presence of DCA. 
 
5.3.1 Figures 
 
 
Figure 5.3.1 HBOt diminishes the effect of DCA on circulating lactate levels in tumor-burdened 
mice. (A). Average weekly change in weight from baseline for HBOt and metabolic therapy treatment 
groups for the first 6 weeks of treatment.  (B) Average weekly blood glucose levels of control and treated 
mice over the first 6 weeks of treatment. (C) Average blood lactate levels of control and treated animals 
over the first 3 weeks of treatment. (D) Kaplan-Meier survival curves for HBOt, HBOt + 250mg/kg DCA, 
HBOt + 250mg/kg metformin and HBOt + 250mg/kg combination treatment groups. (B) Notation of cohort 
size, median and mean survival times, and the percent increase from control for those measures. (A-C) 
Error bars represent SEM of the treatment group. 
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Figure 5.3.2 HBOt co-treatment provides a slight survival benefit to DCA treated VM-M3 burdened mice. (A) Kaplan-Meier survival curves 
depicting the effect of HBOt on (i) 250mg/kg DCA (ii) 250mg/kg metformin and (iii) 250mg/kg combination treatment. (B) Notation of cohort size, 
median and mean survival times, and the percent increase from control for all treatment groups. (B) Error bars represent SEM of the treatment 
group; *p<0.05.
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Figure 5.3.3 Hyperbaric oxygen enhancement of DCA cytotoxicity is temporal. (A) Quantification of 
VM-M3 superoxide production following a 1-hour treatment with hyperbaric oxygen (2.5 ATA). (B) 
Analysis of MitoSox Red fluorescence following 1-hour hyperbaric oxygen treatment (2.5 ATA) in the 
presence of DCA and/or metformin. (C) Analysis of the temporal effect of 1-hour hyperbaric oxygen 
treatment (2.5 ATA) on DCA ± metformin cytotoxicity towards VM-M3 cells. (D) Analysis of VM-M3 
viability following a 1-hour treatment with hyperbaric oxygen at the onset of a 24-incubation with DCA ± 
rotenone. (A, B) Error bars represent SEM of a single experiment replicated in triplicate (C, D) Error bars 
represent SEM of three experimental replicates; *p<0.05 and ***p<0.001. 
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5.3.2 Results & Discussion 
 To assess the impact of HBOt on our DCA and metformin combination, we 
employed a previously tested therapeutic regimen (8, 16). Animals received HBOt at 2.5 
ATA for 90 minutes three times a week (M, W, F) for the duration of the study starting 
on day 1 post tumor cell implantation. We report here that HBOt treatment significantly 
increased median and mean survival of VM-M3-burdened mice compared to controls 
(Fig. 5.3.2C). This deviates from our previous finding that showed no beneficial effect of 
HBOt on VM-M3 survival (8). This could be a function of variation in the subcutaneous 
implantation of VM-M3 cells between experiments. If VM-M3 cells enter the circulation 
immediately upon implantation, then they bypass the requirement for EMT. HBOt has 
been shown to promote a mesenchymal-to-epithelial transition that restricts the 
metastatic potential of tumor cells (7). Thus, if VM-M3 cells were strictly restricted to the 
site on implantation, HBOt treatment may inhibit VM-M3 metastasis and prolong survival 
in tumor-burdened mice. 
  Administration of HBOt was not detrimental to animal health and did promote 
weight loss (Fig. 5.3.1A). Consistent with our previous findings, metformin treatment 
promoted an initial decrease in blood glucose compared to HBOt-treated animals (Fig. 
5.3.1B). However, DCA treatment did not alter blood glucose or blood lactate levels 
when administered with HBOt (Figs. 5.3.1B, 5.3.1C). We have demonstrated that DCA 
increases glucose oxidation in VM/dk skeletal muscle, which suggests that DCA 
reduction in blood lactate levels is mediated by enhancing oxidative efficiency in 
peripheral muscle tissue. As hyperoxia is shown to reduce lactate production in muscle 
during transient and steady-state exercise, it is possible that chronic HBOt increases 
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oxidative capacity of muscle tissue and diminishes DCA activity (17, 18). Consistent 
with the increase in survival, HBOt treatment delayed the increase in blood lactate that 
accompanies VM-M3 tumor progression (Fig. 5.3.1C).  
 Of the three therapeutic regimens, adjuvant HBOt was most beneficial to 
250mg/kg DCA treatment. The addition of HBOt increased mean survival of DCA 
treated mice by 4.8 days (10.4%) (Fig. 5.3.2C). HBOt did not provide a benefit to 
metformin-treated or combination-treated animals, rather there was a slight decrease in 
efficacy associated with adjuvant HBOt (Fig 5.3.2C). VM-M3 tumors are extremely 
aggressive and metastasize rapidly upon subcutaneous transplantation (19). VM-M3 
mortality is tightly associated with metastasis, thus treatment efficacy is dependent on 
inhibition or delay of tumor spread (8, 16, 20). DCA, metformin, and combination 
treatments prolong survival of tumor-burdened mice, which is exhibited in a right-shift in 
the survival curves of these groups. However, these Kaplan-Meier survival curves also 
show that these agents do not significantly alter the rate of cohort mortality, rather they 
delay the time to initial mortality event for the treatment cohort (Fig. 5.3.2Ai-iii). This 
suggests that these metabolic therapies delay onset of metastasis but do not alter the 
metastatic cascade upon VM-M3 dissemination. As such HBOt enhancement of DCA 
treatment was associated with a further delay in cohort mortality (Fig. 5.3.2Ai).  
 Since we hypothesized that adjuvant HBOt would enhance oxidative stress with 
the DCA and metformin combination, we sought to characterize the effect of hyperbaric 
oxygen on VM-M3 ROS production. Consistent with our previous findings, a 1-hour 
treatment with hyperbaric oxygen (2.5 ATA) significantly enhanced superoxide 
production in VM-M3 cells (Fig. 5.3.3A) (8). Incubation with DCA or metformin during 
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hyperbaric oxygen treatment further enhanced ROS production in VM-M3 cells (Fig. 
5.3.3B). Unexpectedly, superoxide production following hyperbaric oxygen treatment 
was significantly lower when combined with the combination of DCA and metformin 
compared to either agent alone. Hyperbaric oxygen treatment also augmented the 
cytotoxicity of DCA and rotenone in combination (Fig.5.3.3D). This too occurred without 
an apparent increase in ROS production above the levels promoted by concurrent non-
toxic hyperbaric oxygen treatment (Fig. 5.3.3B). Analysis of the temporal effect of 
hyperbaric oxygen on this combination was inconclusive (DNS).   
 Induction of ROS by hyperbaric oxygen treatment alone was not associated with 
VM-M3 cytotoxicity (Figure 5.3.3C). This is largely consistent with the literature as most 
studies have demonstrated that hyperbaric oxygen treatment is cancer cell neutral or 
cytostatic as a standalone therapy (4). We next evaluated whether the time of 
hyperbaric oxygen treatment had an impact on the efficacy of our metabolic agents. 
Elevation of the partial pressure of oxygen (pO2) within tumors is shown to be sustained 
for 30-minutes following HBOt administration, thus we examined if hyperbaric oxygen 
pre-treatment would alter DCA and/or metformin cytotoxicity (21). Hyperbaric oxygen 
pre-treatment had no effect on any of the metabolic treatments following a 24-hour 
incubation (Fig. 5.3.3C). Delivery of hyperbaric oxygen at the onset of metabolic agent 
incubation significantly enhanced the cytotoxicity of DCA and the combination, whereas 
hyperbaric oxygen treatment 12-hours into the metabolic agent incubation only 
enhanced DCA cytotoxicity alone (Fig 5.3.3C). This not only suggests that the effect of 
hyperbaric oxygen on DCA and metformin is temporal but also that metformin is slightly 
protective to VM-M3 cells under hyperbaric oxygen stress.  
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 Prolonged hyperoxia is shown to simultaneously reduce complex I/II efficiency 
and glycolytic capacity in the lung (2). Thus, metformin stimulation of glycolytic 
metabolism may protect against the potential metabolic stress induced by HBOt. We 
show that DCA does not fully attenuate metformin stimulation of glycolytic metabolism in 
VM-M3 cells over a period of 48 hours (Figure 3.2.4B). This suggests that prolonged 
treatment with DCA and metformin may result in a progressive increase in 
compensatory glycolysis that protects against the delayed delivery of hyperbaric 
oxygen. While we did not see increased ROS production with concurrent treatment of 
the combination and hyperbaric oxygen, we did observe an increase in cytotoxicity 
associated with this therapeutic scheme (Figs. 5.3.3B, C). This would indicate that the 
delivery of hyperbaric oxygen at the onset of metabolic agent treatment prevents the 
protective compensatory effect of metformin. These data are consistent with our in vivo 
observation that adjuvant HBOt treatment slightly reduced the efficacy of metformin and 
the combination (Fig. 5.3.2B). Therefore, it is necessary to consider the therapeutic 
regimen design in hopes of achieving translatable efficacy with this combinatorial 
therapy. Bolus delivery of DCA alone or the combination just prior to HBOt 
administration may elicit the greatest therapeutic benefit while preventing the potential 
delayed compensation associated with metformin treatment.  
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1 Chapter Synopsis 
Herein we address the major findings of this dissertation project and the 
implications of these findings on the field. We also discuss logical extensions of these 
studies to be conducted in the future. 
 
6.2 Conclusions and Future Directions 
The goal of this dissertation project was to evaluate the potential synergy 
between DCA and metformin and the potential utility of the combination as an anti-
cancer therapy. In line with the literature, we demonstrate a need for supraphysiological 
concentrations of DCA to elicit an anti-cancer effect (1-11). As dichloroacetate exists 
physiologically as an anion, it is relatively membrane impermeable despite its small size 
and requires the mitochondrial pyruvate carrier for mitochondrial uptake (12, 13). 
Pathak et al. reported that conjugating DCA to a lipophilic carrier enhanced 
mitochondrial transport and reduced the IC50 value of DCA from millimolar to the low 
micromolar range (14). This is well within achievable serum trough levels associated 
with DCA administration and reflective of the Ki of PDK2 (~200µM), the most ubiquitous 
isoform (12, 15, 16). Suggesting that a conjugated form of DCA may elicit a more robust 
anti-cancer effect at physiological concentrations. 
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 Our in vitro findings suggest that complex I inhibition cooperates with DCA 
activation of oxidative glucose metabolism to promote catastrophic oxidative stress in 
VM-M3 glioblastoma cells. As described, there is extraordinary interest in targeting 
cancer mitochondria as a therapeutic strategy as recent evidence suggests 
mitochondrial metabolism is required for tumorigenesis and to meet the bioenergetics 
demands or rapidly proliferating tumor cells (17-19).  
As mitochondrial metabolism is intrinsically linked to redox balance, a known 
sensitivity of cancer, targeting the organelle is likely to prove successful (20). Schöckel 
et al. recently reported that inhibition of complex I with an experimental small molecule 
induced cytotoxic oxidative stress and inhibited tumor growth in a model of melanoma, a 
highly aggressive tumor species (21). Our results also demonstrate efficacy in targeting 
the efficiency of electron transport in an aggressive cancer, as GBM is a highly 
malignant brain tumor associated with an extremely poor prognosis (22). Along those 
lines, Shen et al. have shown efficacy in the dual-targeting of GBM metabolism with 
DCA and a mitochondrial poison (23). Rotenone had a greater effect on VM-M3 viability 
in combination with a modestly cytotoxic concentration of DCA than metformin (Fig. 
3.2.5C). This is likely an effect of the degree of complex I inhibition as metformin is 
thought to be only a mild inhibitor of complex I (24). As such, VM-M3 cells may be more 
sensitive to phenformin enhancement of DCA activity. Though phenformin has been 
removed from the clinic for induction of lactic acidosis, the activity of DCA is likely to 
attenuate lactate production associated with phenformin treatment (25).  
While we report disappointing results in regard to the efficacy of the combination 
in vivo, Jiang et al. have recently reported that DCA enhanced the efficacy of 
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phenformin in prolonging survival in an orthotopic GSC model (25). Though we 
preferentially employ subcutaneous transplantation of VM-M3 cells in the abdominal fat 
pad, these cells can also be transplanted orthotopically (26). Future studies evaluating 
DCA and metformin efficacy in treating orthotopic VM-M3 tumors should be conducted 
before definitively discounting the potential utility of the combination. Orthotopic models 
allow for tumor growth in the tissue of tumor origin, which is most clinically translatable. 
Our metabolomics data indicate that the combination of DCA and metformin reduce 
overall brain metabolism in healthy VM/dk mice (Tables 4.5.1-5). This would likely alter 
the tumor environment and metabolic niche that supports VM-M3 tumor growth in the 
brain, potentially leading to a more pronounced effect of the combination on VM-M3 
progression.  
Additionally, manipulation of our therapeutic regimen is likely necessary to 
achieve optimal efficacy. Chemoresistance is an inevitability of current cancer therapies 
and this is often exacerbated by clinical utilization of maximally tolerated doses to 
promote rapid remission (27, 28). Using lower doses to maintain stable disease may be 
more beneficial to many patients and delay or even prevent the expansion of resistant 
tumor cell populations. This may also be achieved through periodic cycling of therapies 
that target divergent pathways, inducing differential selective pressures over the course 
of treatment (29, 30). Analysis of VM-M3 tumors that develop resistance to DCA and 
metformin can inform our selection of complementary therapies for this altered strategy.  
Overall, these results support the assertion that GBMs are vulnerable to 
modulations of glucose metabolism (31). However, this study also highlights that 
metabolic therapies are susceptible to the development of chemoresistance.  Thus, the 
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combination of DCA and metformin may be most useful as an adjuvant to current pro-
oxidant therapies, for which efficacy is often fleeting due to chemoresistance 
mechanisms that restrict mitochondrial oxidation (3, 4, 6, 10). Our findings are 
consistent with several recent reports demonstrating that metformin enhances DCA 
efficacy in multiple cancers (32-37). 
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APPENDIX A: MATERIALS AND METHODS 
 
A.1 Ethical Statement in Regard to Animal Use 
All animal used for the studies performed and analyzed in this dissertation were 
approved by and preformed with strict adherence to the University of South Florida’s 
Institutional Animal Care and Use Committee (IACUC) protocol R0228.  
 
A.2 Materials and Methods 
A.2.1 Cell Culture 
VM-M3/Fluc (VM-M3) cells were obtained as a gift from Dr. Thomas Seyfried 
(Boston College, Chestnut Hill, MA). VM-M3 cells were cultured in D-glucose, L-
glutamine, and sodium pyruvate-free Dulbecco’s Modified Eagle Medium (Gibco, Life 
Technologies) supplemented with 10% fetal bovine serum (Invitrogen), 25mM D-
glucose (Fisher Scientific), 2mM L-glutamine (Gibco, Life Technologies), 1% penicillin-
streptomycin (Invitrogen), and 10mM HEPES buffer (Gibco, Life Technologies). Cells 
were maintained at 37C in 95% air, 5% CO2 in a humidified incubator.  
 
A.2.2 Western Blot Analysis 
VM-M3 cells were seeded on 35-mm 6-well plates for 24 hours at a density of 106 
cells/well. The culture media was then replaced and treatment applied. Cells were 
collected and lysed in 200µL of RIPA lysis buffer containing complete protease and 
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phosphatase inhibitors (ThermoFisher). Lysates were centrifuged at 13,200g for 15 
minutes at 4C and the supernatant collected. Protein concentration was determined by 
BCA assay (ThermoFisher) and 20ug of protein was loaded into a 10% Mini-PROTEAN 
TGX precast polyacrylamide SDS-PAGE gel (BIO-RAD). Protein was transferred to 
nitrocellulose membranes, blocked with 5% non-fat dairy milk in Tris-buffered saline and 
tween (TBS-T) and incubated overnight at 4C with primary antibodies for PDH-E1 
(Abcam, ab110330) and phospho-PDH-E1 (Ser293; Abcam, ab92696). Blots were 
washed with TBS-T and incubated with goat-anti-mouse and goat-anti-rabbit secondary 
antibodies coupled to horseradish peroxidase (HRP). HRP substrate was then applied 
to the blots and antibody signal was detected with the ChemiDoc MP Imaging System 
(BIO-RAD). 
 
A.2.3 Lactate Export 
VM-M3 cells were seeded for 24 hours on 22-mm 12-well plates in triplicate at a 
density of 50,000 cells/well. The culture media was then replaced and treatment 
applied. To determine lactate export, 10µL of treated culture media was aspirated and 
applied to a lactate detection strip and lactate concentration determined with a 
LACTATE PLUS Lactate Meter (Nova Biomedical) at time of treatment application and 
every 12 hours over a period of 48 hours.  
 
A.2.4 ROS Production 
Mitochondrial superoxide production was measured using the fluorescent probe, 
MitoSOX Red (Molecular Probes, Invitrogen). 50,000 VM-M3 cells were seeded on 18-
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mm glass coverslips in 22-mm 12-well plates for 24 hours. Culture media was then 
replaced and treatment applied. Coverslips were then rinsed with D-PBS and stained 
with 2.5µM MitoSOX Red in Hank’s Balanced Salt Solution (HBSS) with Ca2+/Mg2+ 
(Gibco, Life Technologies) for 10 minutes at 37C. Coverslips were then inverted and 
mounted on glass microscope slides and MitoSOX Red fluorescence (Ex/Em: 510:580 
nm) was detected with a TRITC filter and a Nikon TE2000E fluorescence microscope 
and a 40X objective lens. The average relative fluorescence intensity of individual cells 
within 8-10 fields of view were determined for each treatment. 
 
A.2.5 Mitochondrial Membrane Potential 
Mitochondrial membrane potential (m) was measured using the cationic 
fluorescent probe tetramethylrhodamine (TMRE; Molecular Probes, Life Technologies). 
50,000 VM-M3 cells were seeded on 18-mm glass coverslips in 22-mm 12-well plates 
for 24 hours. Culture media was then replaced and treatment applied. Coverslips were 
then rinsed with D-PBS and stained with 250nM TMRE in culture medium for 30 
minutes at 37C. Coverslips were counterstained with 100nM MitoTracker Green 
(Molecular Probes, Invitrogen) in culture media for 20 minutes at 37C and then inverted 
and mounted on glass microscope slides. Cells were visualized with a Nikon TE2000E 
fluorescence microscope and a 40X objective lens. TMRE fluorescence (Ex/Em: 
549/575 nm) was detected with a TRITC filter and MitoTracker Green fluorescence 
(Ex/Em: 490/516 nm) was detected with a FITC filter. The average relative fluorescence 
intensity of individual cells within 10 fields of view were determined for each treatment. 
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A.2.6 Proliferation 
105 VM-M3 cells were seeded on 6-well plates and treated with DCA or 
metformin for 12-96 hours. At each designated time point cells were collected by 
physical detachment. 20µL of the cell suspension was mixed with 20µL of 0.4% Trypan 
blue solution (Sigma) to produce a total volume of 40uL. 20uL of the solution was 
applied to a hematocytometer and visualized by light microscope for cell counting. 
Trypan blue does not pass through the intact cell membrane of live cells and thus only 
stains dead cells a dark blue, permitting the identification and quantification of live cells. 
The number of cells present in each well was determined by standard hematocytometry.  
 
A.2.7 Cell Viability 
 Cell viability was assayed with the LIVE/DEAD Viability/Cytotoxicity Kit 
(Invitrogen). VM-M3 cells were seeded for 24 hours on 18-mm glass coverslips in 22-
mm 12-well plates at a density of 20,000 cells/well. The culture media was then 
replaced and treatment applied for 24 hours. Following the 24-hour treatment, cells 
were washed with D-PBS (Gibco, Life Technologies) and then incubated with 800µL of 
2µM Calcein AM and 4µM Ethidium Homodimer-1 (EthD-1) in D-PBS for 30 minutes. 
Coverslips were then inverted and mounted onto glass microscope slides and cells 
visualized with a Nikon TE2000E fluorescence microscope and a 10X objective lens. 
Calcein-AM readily passes through the membrane of intact cells and is digested by 
cellular esterases that yield a fluorescent calcein product (Ex/Em: 495/515 nm) that can 
be detected with a FITC filter as an indicator of live cells. EthD-1 (Ex/Em: 525/590 nm) 
is cell-impermeable but emits a red fluorescence upon association with nucleic acid 
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following loss of membrane integrity that can be detected with a TRITC filter as an 
indicator of dead cells. The live/dead ratios of 8-10 distinct fields of view were 
determined via direct cell count for each treatment.  
 
A.2.8 Determination of [GSH]:[GSSH] 
The ratio of reduced/oxidized glutathione (GSH:GSSG) was assayed with the 
Glutathione Fluorometric Assay Kit (BIoVision). 106 VM-M3 cells were seeded in 35-mm 
6-well plates for 24 hours. Culture media was then replaced and treatment applied. 
Cells were collected and homogenized in 100µL of ice cold Glutathione Assay Buffer. 
Homogenates were then transferred to pre-chilled microcentrifuge tubes containing 
20µL of 6N perchloric acid (PCA) and vortexed for 10 seconds. Homogenates were 
spun down at 13,000 G for five minutes at 4C. To remove potential oxidizers of GSH, 
the supernatants were transferred to 10KDa centrifugal filters (Millipore) and spun down 
at 14,000 G for 15 minutes at 4C. 20µL of ice cold 6N KOH was added to 40µL of each 
sample to precipitate the PCA and then samples were spun down at 13,000 G for 2 
minutes at 4C. 10uL volume of supernatant were transferred to paired 96-well plates in 
duplicate to assay both GSH and GSSG in each sample. To detect GSH, 80µL of 
Glutathione Assay Buffer was added to the 10µL of supernatant. Whereas to detect 
GSSG, 60µL of assay buffer and 10µL of GSH Quencher were added to the well and 
incubated for 10 minutes at room temperature to quench GSH. 10µL of Reducing Agent 
was then added to convert GSSG to GSH.  10uL of OPA probe (o-phthalaldehyde) was 
added to each well and incubated for 40 minutes at room temperature, at which point 
the plate was read by a fluorescence plate reader at an Ex/Em spectrum of 340/420 nm. 
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A.2.9 Analysis of p-AMPK:AMPK  
The activation status of AMPK was assayed using the CytoGlow AMPK 
(Phospho-Thr172) Colorimetric Cell-Based ELISA kit (Assay bioTech). 15,000 VM-M3 
cells were seeded overnight on 96-well plates. Cells were then treated for 4-hours, 
washed twice with TBS, and fixed with 4% paraformaldehyde (w/v) in D-PBS) for 20 
minutes. Cells were then washed 3X in Wash Buffer (0.2% Kathon CG/ICP, 1% Tween 
in TBS) and then incubated in Quenching Buffer (0.05% Sodium Azide, 1% H2O2 in 
TBS) for 20 minutes to inactivate endogenous peroxidase activity. Cells were then 
washed 3X with Wash Buffer and then blocked with Blocking Buffer (0.05% Sodium 
Azide, 0.5% Triton X-100 in TBS) for 1-hour. Cells were then incubated overnight with 
primary antibodies for p-AMPK (Thr172), AMPK or GAPDH, which served as an 
internal positive control. Following three washes with Wash Buffer, the cells were 
incubated in HRP-conjugated secondary antibodies for 90 minutes; Anti-Rabbit IgG for 
p-AMPK (Thr172) and AMPK, and Anti-Mouse IgG for GADPH. Cells were then washed 
3X and incubated in HRP substrate (<0.02% H2O2 and < 0.1% 3,3’,5,5’-
Tetramethylbenzidine [TMB]) for 30 minutes, after which 2N sulfuric acid was added to 
stop the peroxidase reaction. The absorbance at 450nm was then read using a plate 
reader (BioTek ELx800). Cells were then washed 3X and incubated with 0.05% Crystal 
Violet for 30 minutes. After which, the cells were washed and then incubated with SDS 
to solubilize the Crystal Violet for 1-hour. The absorbance was read at 595nm to 
quantify cell number. 
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A.2.10 Survival Studies 
8-10 week old VM/dk were randomly assigned to a treatment group, while 
maintaining age-matching, and subcutaneously implanted with 106 VM-M3/Fluc cells in 
300µL in D-PBS in the left abdominal flank. Treatment began on the day of injection and 
lasted for the entirety of the study. Survival time was denoted as the time in days from 
cancer cell implantation to time of euthanasia. Animals were humanely euthanized by 
CO2 asphyxiation upon presentation of these defined criteria: severe weight loss (>10% 
baseline body weight), reduced appetite, diminished grooming behavior, lethargy, lack 
of response to physical stimuli, loss of mobility, or development of severe ascites. 
 
A.2.11 Drug Administration 
DCA and metformin were administered orally through the animal’s diet. DCA 
(Sigma) and metformin (Sigma) exhibit oral bioavailability and are available in a stable 
powdered dosage form that can be integrated into a powdered form of a standard 
rodent diet (2018 Teklad Global 18% Protein Rodent Diet, Harlan Laboratories).  Each 
agent was pulverized by hand to remove any residual clumping and mixed thoroughly 
with the powdered diet to evenly distribute the drug.  Deionized or reverse osmosis 
(RO) water was added in a 1:1 ratio to generate a firm paste that was fed ad libitum. 
Initial dosing was based on the observation that a 30g VM/Dk mouse will eat 
approximately 6g of food per day. Dietary intake was measured daily and dosing of the 
food was adjusted to reflect the changes in average intake of the animals.  Food was 
replaced every other day to maintain freshness. 
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A.2.12 Blood Metabolite and Weight Measurements 
Blood samples were collected from a perpetual tail lesion of each animal on the 
day prior to cancer cell implantation and every 7 days thereafter at the same time of day 
to control for natural fluctuations in feeding and circadian metabolism. Blood glucose 
was measured with the commercially available Precision Xtra Glucose (Abbot 
Laboratories). Blood lactate was measured with the commercially available LACTATE 
PLUS Lactate Meter (nova biomedical).  Animals were weighed at the same 7-day 
interval for the duration of study with the AWS-1Kg Portable Digital Scale (AWS). 
 
A.2.13 Tumor Burden Analysis.   
The VM-M3/Fluc cells have been transfected with a lentiviral vector containing 
firefly luciferase, which generates a bioluminescent product from the enzymatic 
consumption of its substrate, luciferin. This bioluminescence can be detected and 
quantified by the Xenogen IVIS Lumina System (Caliper LS), permitting non-invasive in 
vivo imaging. Bioluminescent signal (photons/second) intensity is directly correlated with 
tumor burden and is an established measure of tumor growth in luciferase-positive 
tumor models.  Animals will receive a 50 mg/kg intraperitoneal (i.p.) injection of D-
Luciferin 12-15 minutes prior to in vivo imaging. Animals will be placed under light 
isoflurane anesthesia to immobilize the animals for image detection.  The 
bioluminescent signal will be recorded following a 1-10 second exposure with the IVIS 
Lumina CCD camera.  Bioluminescent images of each animal will be taken weekly as a 
measure of tumor burden and a means to track metastatic progression. 
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A.2.14 GC/MS Metabolomics Analysis 
 8-10 week old VM/dk were randomly assigned to a treatment group (Standard 
diet control, 250mg/kg DCA, 250mg/kg metformin, 250mg/kg combination) and treated 
for 21-days. On day 21, animals were euthanized by exanguination, during which 
approximately 250µL of whole blood was collected by cardiac puncture. Serum was 
isolated by centrifugation using Microtainer® Tubes with Serum Separator (Becton 
Dickinson). Serum was transferred and secured in cryovials and flash frozen in liquid 
nitrogen (N2). Subsequently, brain, heart, kidney, liver, skeletal muscle, and spleen 
were harvested and frozen in liquid N2. Frozen samples were sent to the University of 
Utah Health Sciences Metabolomics Core for GC/MS metabolomics. Samples were 
processed and analyzed according to an in-house protocol. A total of 135 unique 
analytes were isolated from these samples and their relative concentrations were 
subsequently determined. Welch’s two-sample t test was used to determine differences 
in the relative abundance of each metabolite for each treatment group compared to 
standard diet control.  
 
A.2.15 Hyperbaric Oxygen Treatment 
Animals assigned to HBOt groups were subjected to hyperbaric oxygen therapy 
(100% O2 at 2.5 ATA) for 90 minutes three times a week (M, W, F) in a hyperbaric 
chamber. Cells were subject to a single 1-hour treatment with hyperbaric oxygen (100% 
O2 at 2.5 ATA). 
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A.2.16 Statistical Analysis 
GraphPad Prism 6 software was used for all statistical analysis. Parametric tests 
were performed for all data sets as all groups were considered normally distributed. 
Paired student’s t tests were performed for the comparison of two groups unless 
specifically noted. One-Way ANOVA with a post hoc Tukey’s multiple comparison test 
was performed for the comparison of more than two groups. Two-Way ANOVA with a 
post hoc Tukey’s multiple comparisons test was performed when two independent 
variables were present. Results were considered significant when p< 0.05.  
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Appendix B: Week 4 Bioluminescent Images 
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B.1 SD Control 
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B.2 125mg/kg DCA 
 
 
  178 
B.3 250mg/kg DCA 
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B.4 125mg/kg Metformin 
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B.5 250mg/kg Metformin 
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Appendix C: Metabolomics Analysis 
 
C.1 Analysis of Brain Metabolites 
Analyte 
DCA/ 
Control p-value 
Metformin/
Control p-value 
Combo/
Control p-value 
fucose 1.07 0.8443 0.97 0.9901 0.77 0.2112 
sedoheptulose-7-P 0.94 0.5062 0.92 0.3074 0.90 0.2590 
glycolic acid 1.09 0.2983 1.02 0.9892 0.85 0.0739 
dopamine 0.99 0.9896 0.98 0.9746 0.95 0.8734 
aminomalonic acid 1.01 0.9732 1.01 0.9975 1.00 0.9980 
phosphoethanolamine 1.02 0.8741 0.99 0.9924 0.93 0.0938 
2-hydroxyglutarate 1.03 0.4834 1.02 0.8118 0.94 0.2150 
ribose 1.00 0.9989 0.96 0.6296 0.96 0.5783 
sarcosine 1.04 0.8521 1.03 0.9100 0.87 0.1339 
diphosphate 1.00 0.9999 0.98 0.9956 0.86 0.4958 
adenine 1.01 0.8693 0.99 0.8617 0.98 0.7294 
uracil 1.00 0.9996 0.98 0.8068 0.96 0.5087 
citric acid 0.97 0.7469 0.97 0.5944 0.93 0.0496 
ornithine 1.11 0.0580 0.99 0.9964 0.90 0.2464 
elaidic acid 0.96 0.3110 0.93 0.0122 1.01 0.7891 
glutamine 1.03 0.3645 1.00 0.9987 0.95 0.2518 
glyceric acid 1.00 0.9999 0.97 0.9713 0.84 0.1590 
cis-Aconitic acid 1.01 0.9763 1.02 0.9427 0.93 0.2652 
tryptophan 1.03 0.4579 0.97 0.3100 0.96 0.2913 
arachidonic acid 0.99 0.9176 0.98 0.4375 0.98 0.7307 
fumaric acid 0.99 0.9909 0.98 0.6908 0.97 0.6859 
proline 1.02 0.8826 1.00 0.9998 0.96 0.7224 
xanthine 0.97 0.4940 0.96 0.2290 0.98 0.6828 
pantothenic acid 1.02 0.6215 1.00 0.9999 0.97 0.4835 
oleic acid 0.96 0.2972 0.93 0.0113 1.01 0.7830 
urea 0.99 0.7912 0.98 0.5934 0.93 0.0034 
phenylalanine 1.00 0.9965 0.98 0.5286 0.97 0.2211 
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Fructose 1.10 0.1218 1.08 0.3081 0.99 0.9999 
glucose-6-phosphate 0.96 0.7925 0.94 0.6275 0.93 0.5393 
fructose-6-phosphate 0.94 0.8986 0.89 0.6527 0.87 0.5627 
glucose-1-phosphate 1.05 0.8935 0.95 0.8932 0.98 0.9998 
homocysteine 1.14 0.8716 0.97 0.9983 0.61 0.7661 
porphobilinogen 1.16 0.7733 0.93 0.9699 0.73 0.7345 
arabinose 1.02 0.9948 1.07 0.7533 0.89 0.6681 
thymine 0.92 0.1517 0.97 0.7529 0.89 0.0221 
Adenosine 1.00 0.9993 0.97 0.5430 0.98 0.9333 
isocitric acid 0.97 0.8757 0.97 0.9312 0.89 0.1573 
lauric acid 1.01 0.9969 1.00 0.9999 0.98 0.9621 
histidine 1.03 0.9550 0.98 0.9822 0.91 0.3330 
Myoinositol 1.00 0.9997 0.98 0.8959 0.94 0.2942 
L-Glutamic acid 1.03 0.5468 1.00 0.9966 0.96 0.5422 
hypoxanthine 0.98 0.4385 0.98 0.3648 0.99 0.9273 
1-monopalmitoylglycerol 1.00 0.9999 0.98 0.7771 0.95 0.3172 
malic acid 0.99 0.9855 0.98 0.7418 0.97 0.5753 
phosphate 1.00 0.9653 1.00 0.9830 0.98 0.5799 
creatinine 1.02 0.8279 1.00 0.9981 0.97 0.6093 
serine 0.98 0.1759 1.00 0.9981 0.95 0.0009 
myristic acid 0.97 0.5176 0.97 0.6247 0.96 0.5908 
3-phosphoglycerate 1.03 0.9300 0.99 0.9974 0.92 0.5606 
myo-inositol 1-
phosphate 1.01 0.9639 0.98 0.7783 0.92 0.0420 
nonadecanoic acid 0.75 0.6827 0.87 0.9395 0.66 0.7265 
succinic acid 1.06 0.3375 1.06 0.3434 0.99 0.9986 
phosphoenolpyruvate 1.17 0.8557 0.85 0.9023 0.90 0.9950 
Stearic acid 0.98 0.9585 0.98 0.9684 0.95 0.8799 
ascorbate 1.03 0.6393 1.01 0.9905 0.95 0.3727 
oleamide 1.02 0.7621 1.00 0.9999 0.98 0.9246 
asparagine 1.02 0.7263 1.02 0.8908 0.96 0.5650 
lysine 1.05 0.0149 1.00 0.9977 0.99 0.9965 
palmitic acid 0.99 0.9320 0.97 0.6316 0.98 0.9776 
pyruvic acid 1.01 0.9874 0.99 0.9884 0.96 0.8486 
1-monostearoylglycerol 1.05 0.6534 1.01 0.9990 0.92 0.5105 
aspartic acid 1.02 0.5328 1.00 0.9999 0.97 0.2757 
5-aminopentanoic acid 1.04 0.9816 0.99 0.9999 1.03 0.9237 
cholesterol 1.05 0.8196 0.99 0.9992 0.93 0.9072 
2,4-dihydroxybutanoic 1.02 0.8814 0.99 0.9423 0.90 0.0034 
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acid 
glycerol 1.00 0.9999 0.99 0.6540 0.98 0.7790 
valine 1.01 0.8553 0.99 0.8709 0.97 0.2146 
1-Linoleoyl-glycerol 1.06 0.8156 1.10 0.5130 0.91 0.7766 
sorbitol 1.07 0.7590 1.07 0.6900 0.95 0.9256 
glutathione 1.03 0.7243 1.00 0.9993 0.93 0.1894 
cysteine 0.95 0.7434 0.88 0.0928 1.03 0.9946 
glycerol 3-phosphate 1.02 0.7051 1.02 0.7161 0.99 0.9948 
2-aminoadipic acid 1.01 0.9961 1.00 0.9994 0.89 0.0977 
glycine 0.99 0.8645 0.98 0.6091 1.02 0.9110 
N-acetylaspartate 1.01 0.8036 1.02 0.7481 0.96 0.4244 
lactic acid 1.02 0.7891 1.00 0.9984 0.97 0.8668 
nicotinamide 1.00 0.9954 0.99 0.8863 0.95 0.2630 
homoserine 0.98 0.8189 0.99 0.9914 0.87 0.0001 
5-aminovaleric acid 0.86 0.9964 1.08 0.6055 0.75 0.8873 
2-hydroxybutyric acid 1.00 0.9996 0.95 0.5193 0.91 0.1659 
isoleucine 1.01 0.7551 0.99 0.9401 0.97 0.3463 
1-oleoyl-glycerol 0.98 0.7304 0.93 0.0140 0.99 0.9826 
leucine 1.00 0.9999 0.98 0.5426 0.98 0.5711 
2-monooleoylglycerol 1.11 0.7692 1.20 0.3393 0.87 0.8712 
threonine 1.01 0.8830 1.00 0.9873 0.94 0.0005 
inosine 0.99 0.9620 0.99 0.9619 0.94 0.0984 
tyrosine 0.99 0.9556 0.99 0.9923 0.93 0.0797 
serotonin 1.03 0.7441 0.91 0.9846 0.86 0.9914 
1,3-bisphosphoglycerate 1.02 0.9891 1.02 0.9844 0.92 0.8074 
L-methionine 0.99 0.8949 0.99 0.9840 0.96 0.3776 
2-ketoglutaric acid 1.12 0.6065 0.91 0.8026 0.77 0.2468 
5'-AMP 1.04 0.5000 1.04 0.4415 0.90 0.0152 
3-hydroxybutyrate 1.08 0.0544 1.01 0.9660 1.00 0.9807 
alanine 0.95 0.4765 0.97 0.8501 0.94 0.2663 
B-alanine 1.01 0.8281 1.00 0.9858 0.96 0.0225 
linoleic acid 1.01 0.9969 1.04 0.8875 1.00 0.9905 
5-hydroxytryptophan 1.19 0.1997 1.00 0.9999 0.61 0.0089 
N-acetylglutamate 1.07 0.1518 1.00 0.9991 0.95 0.6868 
DHAP 0.73 0.0302 0.86 0.4618 1.04 0.9931 
5-hydroxyindoleacetic 
acid 1.15 0.5873 0.99 0.9998 0.68 0.8288 
mannose 1.05 0.5691 1.01 0.9984 0.87 0.0300 
hydroxyproline 1.02 0.3138 1.01 0.6610 1.01 0.6680 
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erythrose 0.98 0.9809 0.93 0.6765 0.81 0.0719 
2-hydroxysebacic acid 0.87 0.2524 0.72 0.5465 0.91 0.7184 
b-Hydroxy-b-
methylglutarate 1.04 0.5812 1.02 0.9028 0.90 0.1298 
 
 
C.2 Analysis of Heart Metabolites 
Analyte 
DCA/ 
Control p-value 
Metformin/
Control p-value 
Combo/
Control p-value 
fucose 1.34 0.7637 0.08 0.6593 1.57 0.4946 
kynurenine 0.89 0.9544 0.42 0.1144 1.16 0.8629 
 galactose 1.32 0.2622 0.79 0.6035 1.41 0.0276 
sedoheptulose-7-P 1.00 0.9999 0.83 0.1121 1.24 0.0305 
glycolic acid 1.08 0.1947 0.91 0.1248 1.04 0.6400 
dopamine 1.11 0.4103 0.93 0.7454 1.07 0.4490 
aminomalonic acid 1.09 0.4835 0.92 0.6252 1.14 0.1324 
phosphoethanolamine 1.09 0.4019 0.96 0.8952 1.16 0.0262 
2-hydroxyglutarate 1.11 0.0004 0.98 0.7632 1.11 0.0001 
ribose 1.01 0.9858 0.89 0.0620 1.09 0.1915 
sarcosine 1.03 0.8868 0.92 0.3303 1.02 0.8742 
diphosphate 1.07 0.6124 0.95 0.8175 1.09 0.2211 
adenine 1.00 0.9993 0.91 0.0017 1.03 0.5232 
uracil 1.05 0.0923 0.95 0.1537 1.07 0.0057 
citric acid 1.10 0.0748 0.99 0.9974 1.01 0.9244 
ornithine 1.05 0.6623 0.95 0.7356 1.04 0.4966 
elaidic acid 1.01 0.9941 0.92 0.0901 1.12 0.0059 
glutamine 1.08 0.0299 0.99 0.9607 1.02 0.7752 
glyceric acid 1.05 0.4990 0.97 0.7988 0.99 0.9999 
ribitol 1.03 0.8663 0.95 0.4303 0.98 0.9992 
cis-Aconitic acid 1.03 0.7633 0.96 0.6265 1.05 0.3474 
tryptophan 1.03 0.1151 0.96 0.0526 1.03 0.1528 
arachidonic acid 0.99 0.9956 0.93 0.0814 1.10 0.0025 
fumaric acid 0.98 0.8335 0.92 0.0075 1.06 0.0382 
proline 1.02 0.9412 0.96 0.4602 1.04 0.3980 
Xanthine 1.01 0.9926 0.95 0.0433 1.04 0.2166 
pantothenic acid 1.04 0.1233 0.99 0.8783 1.05 0.0214 
oleic acid 0.99 0.9409 0.94 0.0688 1.09 0.0048 
urea 0.99 0.9740 0.96 0.1011 0.98 0.8698 
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phenylalanine 1.01 0.9400 0.98 0.3758 1.04 0.0145 
Fructose 0.89 0.0564 1.02 0.9836 0.99 0.9844 
2-phosphoglycerate 1.10 0.7041 1.38 0.0029 1.11 0.5882 
glucose-6-phosphate 1.01 0.9997 1.35 0.0108 1.21 0.1855 
fructose-6-phosphate 1.00 0.9999 1.40 0.0171 1.24 0.2049 
glucose-1-phosphate 0.98 0.9987 1.46 0.0155 1.32 0.1361 
homocysteine 1.15 0.9173 0.81 0.8626 1.32 0.5164 
porphobilinogen 0.93 0.9530 0.70 0.0595 1.09 0.6578 
arabinose 1.11 0.8207 0.85 0.6660 1.36 0.0545 
thymine 1.06 0.9243 0.82 0.2779 1.09 0.6866 
Adenosine 1.03 0.9688 0.86 0.0782 0.96 0.9339 
isocitric acid 1.03 0.9671 0.89 0.2563 1.13 0.0773 
lauric acid 0.97 0.8575 0.87 0.0349 1.07 0.2667 
histidine 1.01 0.9942 0.92 0.5010 1.05 0.6724 
Myoinositol 1.04 0.4960 0.98 0.9502 1.03 0.7296 
L-Glutamic acid 1.05 0.1196 0.99 0.9953 1.02 0.9144 
hypoxanthine 1.00 0.9999 0.95 0.1369 1.07 0.0483 
1-monopalmitoylglycerol 1.02 0.9466 0.97 0.6653 1.08 0.0424 
malic acid 1.00 0.9988 0.96 0.1577 1.07 0.0041 
phosphate 1.00 0.9914 0.98 0.1958 1.02 0.5934 
creatinine 1.00 0.9932 0.97 0.1827 1.00 0.8933 
glucose 0.95 0.6602 1.06 0.5735 1.02 0.9957 
Heptadecanoic acid 1.01 0.9951 0.91 0.4668 1.15 0.0579 
serine 1.02 0.3324 1.01 0.9842 1.03 0.0938 
myristic acid 0.94 0.2141 0.89 0.0080 0.99 0.9999 
2-ethylhexanoic acid 1.02 0.9992 0.71 0.3758 1.15 0.5832 
4-hydroxyproline 1.08 0.4750 0.97 0.9611 1.08 0.3309 
4-aminobutyrate 1.08 0.4830 0.97 0.9596 1.07 0.3412 
3-phosphoglycerate 1.07 0.3478 1.14 0.0081 1.05 0.7141 
gluconic acid 0.93 0.4737 1.03 0.9038 1.02 0.9728 
myo-inositol 1-
phosphate 1.02 0.9876 0.91 0.5454 1.13 0.0999 
sedoheptulose 0.92 0.6189 0.83 0.0803 1.10 0.6287 
Nonadecanoic acid 1.04 0.9679 0.91 0.6797 1.17 0.1122 
succinic acid 0.97 0.8374 1.02 0.9335 0.94 0.4620 
phosphoenolpyruvate 1.03 0.9371 1.12 0.1480 1.13 0.1298 
Stearic acid 1.01 0.9744 0.97 0.7224 1.08 0.0633 
2-monostearylglycerol 0.90 0.4719 0.98 0.9951 0.97 0.9999 
ascorbate 0.98 0.9922 0.87 0.3372 1.08 0.6421 
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oleamide 1.00 0.9982 0.96 0.2943 1.01 0.7848 
asparagine 1.07 0.4660 1.01 0.9972 1.08 0.1938 
lysine 1.04 0.4033 1.02 0.9418 1.07 0.0560 
palmitic acid 1.00 0.9989 0.97 0.7457 1.07 0.0864 
pyruvic acid 0.99 0.9697 1.03 0.8094 0.96 0.8513 
1-monostearoylglycerol 1.02 0.9622 0.97 0.8735 1.09 0.1091 
aspartic acid 1.05 0.1170 1.02 0.7326 0.97 0.6064 
5-aminopentanoic acid 1.00 0.9999 0.92 0.6834 1.05 0.6813 
Cholesterol 1.03 0.8620 0.98 0.9700 1.10 0.0578 
mannitol 0.90 0.0022 0.92 0.0294 0.95 0.3479 
2,4-dihydroxybutanoic 
acid 0.98 0.9414 1.00 0.9994 0.93 0.5803 
Glycerol 0.97 0.2390 0.95 0.0330 1.03 0.4364 
valine 1.00 0.9841 1.00 0.9913 1.00 0.9459 
1-Linoleoyl-glycerol 0.95 0.7759 0.99 0.9939 1.00 0.9988 
sorbitol 0.96 0.9211 0.93 0.7120 1.03 0.8459 
Glutathione 1.02 0.9326 1.00 0.9991 1.03 0.5916 
cysteine 1.06 0.9534 1.01 0.9998 1.24 0.1215 
Glycerol 3-phosphate 1.00 0.9999 0.99 0.9639 1.03 0.2973 
2-aminoadipic acid 1.07 0.4556 1.05 0.7465 1.01 0.9266 
glycine 1.05 0.6219 1.03 0.8779 1.07 0.1441 
N-Acetylaspartate 1.09 0.8626 1.02 0.9988 0.93 0.9784 
lactic acid 0.93 0.4503 0.91 0.2448 0.97 0.9718 
nicotinamide 0.98 0.8499 0.97 0.5712 1.04 0.1705 
uric acid 1.04 0.7938 1.02 0.9610 1.02 0.9955 
homoserine 0.86 0.7230 0.81 0.5029 0.85 0.8492 
5-aminovaleric acid 1.04 0.9949 0.97 0.9971 1.03 0.9906 
2-hydroxybutyric acid 0.92 0.4297 0.94 0.6703 0.94 0.8160 
isoleucine 1.00 0.9999 1.00 0.9820 1.02 0.3617 
1-Oleoyl-glycerol 0.95 0.5489 0.96 0.7969 1.04 0.6100 
leucine 1.02 0.6620 1.03 0.4461 1.04 0.1534 
2-monooleoylglycerol 0.95 0.8930 0.98 0.9873 0.99 0.9994 
Palmitelaidic acid 0.86 0.0151 0.87 0.0281 0.95 0.6465 
threonine 0.99 0.9738 1.00 0.9974 0.99 0.8032 
inosine 0.93 0.1978 0.94 0.3069 0.98 0.9999 
tyrosine 0.99 0.9972 1.00 0.9999 1.02 0.9053 
serotonin 0.99 0.9995 1.01 0.9991 0.97 0.9984 
1,3-bisphosphoglycerate 0.96 0.9806 0.94 0.9377 1.38 0.0077 
L-Methionine 1.00 0.9996 1.00 0.9999 1.01 0.9916 
  187 
2-ketoglutaric acid 1.03 0.9989 1.05 0.9924 0.59 0.2384 
5'-AMP 0.99 0.9970 0.99 0.9892 0.97 0.9574 
3-hydroxybutyrate 1.00 0.9995 1.00 0.9999 1.02 0.7016 
alanine 0.97 0.7302 0.98 0.7959 1.02 0.6071 
B-alanine 1.02 0.8632 1.02 0.9007 1.01 0.8785 
alpha-Lactose 1.13 0.9375 1.12 0.9590 1.21 0.8384 
linoleic acid 0.96 0.7042 0.97 0.7399 1.06 0.3087 
 
C.3 Analysis of Kidney Metabolites 
Analyte 
DCA/ 
Control p-value 
Metformin/
Control p-value 
Combo/
Control p-value 
fucose 0.95 0.7978 0.89 0.1676 0.99 0.9888 
galactose 1.10 0.7962 0.78 0.1798 0.92 0.9569 
sedoheptulose-7-P 0.99 0.9963 1.00 0.9999 1.06 0.3331 
glycolic acid 1.19 0.0017 1.02 0.9710 1.02 0.4983 
aminomalonic acid 1.04 0.5470 0.98 0.9387 0.96 0.8772 
phosphoethanolamine 1.03 0.8563 0.99 0.9976 1.05 0.2976 
2-hydroxyglutarate 1.16 0.0020 1.00 0.9999 1.08 0.1427 
ribose 0.94 0.2741 0.94 0.2983 1.02 0.5995 
sarcosine 1.12 0.0670 0.94 0.5815 1.06 0.2637 
diphosphate 0.98 0.9330 0.97 0.5552 1.03 0.3065 
adenine 1.01 0.9813 0.99 0.9837 0.97 0.8113 
uracil 1.01 0.9525 0.98 0.7678 1.00 0.9353 
citric acid 1.36 0.0025 1.14 0.3846 0.99 0.9922 
ornithine 1.00 0.9999 0.91 0.1549 1.03 0.5472 
elaidic acid 0.96 0.5408 0.96 0.6387 1.02 0.9509 
glutamine 1.02 0.4920 0.99 0.8939 1.00 0.8841 
glyceric acid 0.96 0.7963 0.96 0.8686 0.98 0.9978 
ribitol 0.91 0.2696 0.87 0.0371 0.98 0.9989 
cis-Aconitic acid 1.20 0.5047 1.45 0.0148 1.18 0.3697 
tryptophan 1.01 0.9595 0.99 0.9095 1.02 0.8990 
arachidonic acid 0.99 0.9928 0.98 0.7840 1.01 0.6527 
fumaric acid 0.99 0.9802 0.97 0.6859 1.02 0.7119 
proline 0.96 0.8730 0.95 0.7487 1.04 0.3930 
Xanthine 0.97 0.4412 0.91 0.0028 0.99 0.9985 
pantothenic acid 1.01 0.9569 0.98 0.8630 0.98 0.9882 
oleic acid 0.96 0.5374 0.96 0.6384 1.02 0.9523 
urea 1.00 0.9999 0.98 0.6810 0.99 0.9087 
  188 
phenylalanine 0.97 0.5989 0.97 0.5052 1.01 0.8161 
Fructose 0.99 0.9879 0.94 0.1221 1.00 0.9624 
2-phosphoglycerate 1.03 0.9778 0.95 0.8327 1.12 0.2715 
glucose-6-phosphate 1.02 0.9646 1.01 0.9992 1.05 0.4810 
fructose-6-phosphate 0.99 0.9999 0.93 0.9403 1.21 0.1309 
glucose-1-phosphate 0.51 0.0516 0.90 0.9443 0.95 0.9925 
homocysteine 1.04 0.9920 0.83 0.5717 1.24 0.0938 
thymine 1.11 0.5317 1.01 0.9984 0.92 0.9632 
Adenosine 1.31 0.0121 1.37 0.0016 0.97 0.9188 
isocitric acid 2.16 0.0029 1.53 0.2694 1.28 0.5048 
lauric acid 0.92 0.1229 1.03 0.8387 0.96 0.7708 
histidine 0.90 0.4826 0.85 0.1806 1.04 0.5690 
Myoinositol 0.99 0.9941 0.99 0.9451 1.03 0.6201 
L-Glutamic acid 0.99 0.9775 0.96 0.0943 0.98 0.9376 
hypoxanthine 0.98 0.4431 0.95 0.0066 0.99 0.9999 
1-monopalmitoylglycerol 1.00 0.9998 0.97 0.8214 1.06 0.0700 
malic acid 1.01 0.9832 0.96 0.6488 1.10 0.8560 
phosphate 0.96 0.0025 0.96 0.0004 1.00 0.9576 
creatinine 1.05 0.5080 0.95 0.4185 1.00 0.8553 
glucose 0.97 0.5579 1.04 0.3048 1.02 0.6614 
serine 0.98 0.8571 0.98 0.7070 1.03 0.2482 
myristic acid 0.95 0.3009 0.98 0.8415 0.98 0.9251 
4-hydroxyproline 1.07 0.1365 0.96 0.4275 0.99 0.9960 
4-aminobutyrate 1.07 0.1369 0.96 0.4284 0.99 0.9960 
3-phosphoglycerate 0.94 0.6791 0.97 0.9273 1.04 0.5250 
gluconic acid 0.99 0.9903 1.03 0.6142 1.00 0.9794 
myo-inositol 1-
phosphate 1.00 0.9991 1.01 0.9970 1.06 0.1665 
Nonadecanoic acid 0.93 0.8982 0.96 0.9766 1.14 0.2344 
succinic acid 1.01 0.9861 0.98 0.5000 1.00 0.9867 
phosphoenolpyruvate 0.91 0.6958 0.95 0.9234 1.08 0.4190 
Stearic acid 1.01 0.9546 1.00 0.9990 1.06 0.0113 
oleamide 1.00 0.9985 0.99 0.7803 0.98 0.8143 
asparagine 0.91 0.4030 0.90 0.2267 1.06 0.3354 
lysine 0.96 0.5146 1.00 0.9995 1.04 0.2683 
palmitic acid 0.97 0.5699 0.97 0.3509 1.04 0.1064 
pyruvic acid 1.03 0.5474 1.04 0.2712 1.01 0.9754 
1-monostearoylglycerol 1.00 0.9999 0.99 0.9957 1.07 0.0864 
aspartic acid 0.99 0.8415 1.01 0.9785 1.01 0.6998 
  189 
5-aminopentanoic acid 1.01 0.9977 0.98 0.9235 0.92 0.3603 
Cholesterol 0.98 0.9635 0.91 0.2249 1.04 0.4760 
2,4-dihydroxybutanoic 
acid 0.94 0.5317 0.96 0.7470 0.98 0.9986 
Glycerol 0.94 0.0001 0.92 0.0001 0.98 0.5316 
valine 0.97 0.3378 0.96 0.0834 0.99 0.9998 
1-Linoleoyl-glycerol 0.98 0.9948 1.04 0.9168 1.01 0.9913 
sorbitol 1.02 0.9642 1.00 0.9999 1.00 0.9740 
cysteine 1.13 0.0002 1.01 0.9860 1.12 0.0001 
Glycerol 3-phosphate 0.99 0.9842 0.97 0.6638 1.01 0.7569 
2-aminoadipic acid 0.99 0.9937 0.97 0.8764 0.92 0.4944 
glycine 0.97 0.4369 0.97 0.2081 0.99 0.7659 
N-Acetylaspartate 1.39 0.0501 1.17 0.6228 0.89 0.7529 
lactic acid 0.99 0.8591 0.93 0.0001 0.94 0.0003 
nicotinamide 0.98 0.7527 0.96 0.2799 0.99 0.9994 
uric acid 1.05 0.4441 0.98 0.9312 1.00 0.9999 
homoserine 0.98 0.9434 1.00 0.9999 0.93 0.6657 
5-aminovaleric acid 0.97 0.9638 1.09 0.6067 0.91 0.6976 
2-hydroxybutyric acid 0.97 0.8005 0.98 0.8548 0.93 0.3330 
isoleucine 0.96 0.1825 0.96 0.0843 0.99 0.9999 
1-Oleoyl-glycerol 0.97 0.9675 1.00 0.9999 1.02 0.9853 
leucine 0.96 0.0903 0.96 0.1387 1.00 0.9251 
2-monooleoylglycerol 0.99 0.9983 1.06 0.8435 1.01 0.9925 
threonine 0.96 0.5682 0.98 0.8864 0.99 0.9812 
inosine 1.00 0.9998 1.01 0.9930 1.02 0.9980 
tyrosine 0.96 0.6453 0.98 0.8647 1.01 0.8393 
serotonin 0.98 0.9607 1.00 0.9999 0.98 0.9842 
1,3-bisphosphoglycerate 1.05 0.7643 0.98 0.9888 1.12 0.0509 
L-Methionine 0.96 0.5924 0.98 0.8014 1.02 0.9194 
2-ketoglutaric acid 1.30 0.0143 1.05 0.9476 0.94 0.9852 
5'AMP 1.10 0.1996 1.15 0.0164 1.00 0.9917 
3-hydroxybutyrate 1.08 0.0698 1.01 0.9948 1.04 0.3909 
alanine 0.97 0.6234 0.98 0.8027 1.00 0.9387 
B-alanine 1.03 0.5836 1.06 0.1645 1.04 0.4877 
alpha-Lactose 0.83 0.6031 0.89 0.8316 0.85 0.7773 
linoleic acid 0.95 0.2803 0.98 0.8497 1.01 0.9874 
5-hydroxytryptophan 1.04 0.9918 1.10 0.8615 1.00 0.9849 
N-acetylglutamate 1.54 0.0394 0.96 0.9950 0.89 0.9960 
DHAP 1.19 0.1651 1.21 0.0932 1.06 0.6370 
  190 
mannose 0.99 0.9996 0.89 0.2241 1.01 0.9996 
erythrose 0.97 0.9103 0.88 0.0865 1.00 0.9532 
b-Hydroxy-b-
methylglutarate 1.29 0.0123 1.08 0.7980 1.01 0.8403 
2-phosphoglycerol 1.02 0.9907 1.07 0.6990 0.94 0.9504 
rhamnose 1.09 0.5978 1.04 0.9518 1.06 0.5459 
3,4-dihydroxybutanoic 
acid 1.06 0.9386 1.06 0.9378 1.16 0.2648 
Indoxyl sulfate 1.14 0.2204 1.09 0.5115 1.10 0.2436 
nicotinic acid 0.71 0.1565 0.45 0.0010 0.87 0.9259 
putrescine 1.20 0.2365 1.05 0.9525 1.06 0.7641 
threitol 1.05 0.8523 0.96 0.9271 1.00 0.9842 
 
C.4 Analysis of Liver Metabolites 
Analyte 
DCA/ 
Control p-value 
Metformin/ 
Control p-value 
Combo/ 
Control p-value 
fucose 0.82 0.0584 0.88 0.2714 1.01 0.9999 
kynurenine 0.84 0.6423 0.80 0.4775 0.94 0.9230 
sedoheptulose-7-P 0.96 0.5294 1.01 0.9825 1.02 0.9153 
glycolic acid 1.23 0.0077 0.95 0.8839 0.97 0.9810 
dopamine 0.89 0.0030 0.90 0.0108 0.91 0.0476 
aminomalonic acid 1.02 0.9645 1.00 0.9998 1.01 0.9999 
phosphoethanolamine 0.84 0.0207 1.11 0.1799 0.92 0.4800 
2-hydroxyglutarate 1.17 0.0011 0.96 0.7992 1.05 0.4644 
ribose 0.85 0.0001 0.97 0.7327 0.97 0.7068 
sarcosine 0.91 0.0178 0.90 0.0133 0.89 0.0193 
diphosphate 1.02 0.6626 0.99 0.8741 1.05 0.0844 
adenine 1.02 0.9287 0.97 0.6430 1.00 0.9941 
uracil 0.85 0.0433 0.96 0.9020 1.06 0.5652 
citric acid 0.99 0.9994 1.27 0.0896 0.70 0.2464 
ornithine 1.00 0.9915 0.95 0.0220 0.97 0.3366 
elaidic acid 0.99 0.9940 0.91 0.0291 1.01 0.9999 
glutamine 1.08 0.0001 0.98 0.6665 1.08 0.0002 
glyceric acid 0.79 0.0170 0.95 0.8910 0.91 0.4572 
cis-Aconitic acid 0.75 0.9999 1.41 0.2359 0.62 0.6662 
tryptophan 0.99 0.8196 0.99 0.9899 0.98 0.5664 
arachidonic acid 0.93 0.0003 0.99 0.9590 0.98 0.4811 
fumaric acid 0.84 0.0047 1.05 0.6993 0.94 0.7117 
  191 
proline 0.94 0.1668 0.97 0.6337 0.95 0.3650 
Xanthine 0.94 0.0148 0.98 0.5886 0.99 0.9155 
pantothenic acid 1.01 0.9997 1.03 0.9480 1.17 0.0249 
oleic acid 1.00 0.9962 0.97 0.3646 1.00 0.9996 
urea 0.98 0.7857 0.96 0.4313 0.95 0.2893 
phenylalanine 0.94 0.0125 0.97 0.4284 0.96 0.1150 
Fructose 0.85 0.0003 0.94 0.2973 1.00 0.9954 
2-phosphoglycerate 0.93 0.6528 0.96 0.4175 0.94 0.9476 
glucose-6-phosphate 0.87 0.0060 0.96 0.6461 0.95 0.7127 
fructose-6-phosphate 0.86 0.0438 0.92 0.4222 0.97 0.9453 
glucose-1-phosphate 0.80 0.0043 0.97 0.9307 0.98 0.9993 
Adenosine 1.08 0.3607 1.04 0.8052 1.00 0.8998 
isocitric acid 0.93 0.9797 1.17 0.8179 0.99 0.9876 
lauric acid 0.87 0.2586 0.99 0.9986 0.98 0.8813 
Myoinositol 0.95 0.0343 0.99 0.8927 0.95 0.0980 
L-Glutamic acid 1.06 0.0655 1.03 0.5111 1.00 0.9999 
hypoxanthine 0.90 0.0007 0.97 0.5538 1.01 0.9550 
1-monopalmitoylglycerol 1.02 0.2926 0.99 0.7959 1.03 0.0513 
malic acid 0.85 0.0044 1.05 0.6227 0.91 0.3598 
phosphate 0.98 0.4540 1.00 0.9794 1.01 0.9924 
creatinine 0.93 0.4936 0.91 0.2810 0.94 0.8461 
Heptadecanoic acid 0.90 0.0645 1.07 0.2799 0.98 0.8973 
serine 0.91 0.0168 1.03 0.6512 0.99 0.9427 
myristic acid 0.91 0.0241 0.95 0.3923 0.88 0.0013 
4-hydroxyproline 0.91 0.2162 1.04 0.8230 0.92 0.4095 
4-aminobutyrate 0.91 0.2164 1.04 0.8206 0.92 0.4100 
3-phosphoglycerate 0.94 0.8514 1.06 0.8486 0.94 0.6621 
gluconic acid 0.95 0.0174 0.98 0.4713 0.96 0.2219 
myo-inositol 1-
phosphate 1.00 0.9980 1.05 0.3074 1.06 0.2564 
Nonadecanoic acid 0.86 0.0011 0.96 0.5469 0.90 0.0206 
succinic acid 1.05 0.0495 1.03 0.3543 1.00 0.9985 
phosphoenolpyruvate 0.76 0.1395 1.09 0.8492 0.81 0.1489 
Stearic acid 0.98 0.3117 1.00 0.9996 1.01 0.9180 
2-monostearylglycerol 0.73 0.0001 0.90 0.1811 0.93 0.3082 
ascorbate 0.98 0.9403 0.92 0.2544 0.97 0.9669 
asparagine 0.91 0.0490 0.95 0.3803 0.97 0.7611 
palmitic acid 0.99 0.2988 0.99 0.5934 1.00 0.9456 
pyruvic acid 1.03 0.7517 0.98 0.8756 0.98 0.9895 
  192 
1-monostearoylglycerol 1.01 0.9207 1.01 0.9717 1.04 0.1681 
aspartic acid 0.99 0.9627 1.09 0.0006 0.98 0.5956 
5-aminopentanoic acid 0.86 0.2555 0.89 0.4730 0.82 0.0907 
Cholesterol 0.96 0.3979 1.04 0.4079 1.00 0.9822 
Glycerol 0.98 0.2602 0.99 0.9768 0.98 0.6743 
valine 0.98 0.7830 0.97 0.4465 0.96 0.0845 
1-Linoleoyl-glycerol 1.08 0.4269 1.08 0.4134 1.03 0.8605 
sorbitol 0.78 0.0048 0.91 0.3928 0.96 0.9154 
Glutathione 1.10 0.0078 0.93 0.1006 1.07 0.0804 
cysteine 1.06 0.5107 0.92 0.2872 1.09 0.1879 
Glycerol 3-phosphate 1.05 0.1196 1.06 0.0965 1.02 0.8398 
2-aminoadipic acid 1.01 0.9925 0.95 0.6367 0.91 0.4773 
glycine 0.97 0.3641 0.98 0.7457 1.00 0.9748 
lactic acid 0.97 0.4854 0.98 0.6433 0.96 0.1461 
nicotinamide 0.91 0.0002 0.96 0.1733 0.98 0.8085 
uric acid 0.95 0.2174 1.00 0.9999 0.95 0.2158 
homoserine 0.89 0.0844 1.00 0.9999 0.82 0.0053 
2-hydroxybutyric acid 0.96 0.4085 0.95 0.2634 0.92 0.0302 
isoleucine 0.98 0.7155 0.97 0.4893 0.96 0.1953 
1-Oleoyl-glycerol 1.03 0.8696 0.95 0.6798 1.04 0.9384 
leucine 0.97 0.3381 0.98 0.6566 0.97 0.2443 
2-monooleoylglycerol 1.02 0.9584 1.05 0.6361 0.99 0.9999 
Palmitelaidic acid 0.94 0.2189 0.91 0.0247 0.90 0.0042 
threonine 0.88 0.0013 0.96 0.5700 0.93 0.0310 
tyrosine 1.12 0.5364 1.11 0.6295 1.14 0.4355 
serotonin 0.99 0.9941 1.03 0.8687 1.01 0.9989 
2,3-pyridinedicarboxylic 
acid 1.04 0.9530 1.09 0.7450 0.88 0.5447 
L-Methionine 0.85 0.0001 0.98 0.8630 0.93 0.0959 
2-ketoglutaric acid 1.06 0.9818 1.12 0.8636 1.01 0.9399 
5'-AMP 1.00 0.9881 1.03 0.3199 1.00 0.9994 
alanine 1.00 0.9961 0.98 0.8034 0.99 0.9712 
B-alanine 0.93 0.0615 0.95 0.1735 0.98 0.7565 
linoleic acid 0.94 0.0017 1.02 0.6720 0.97 0.1251 
N-acetylglutamate 0.94 0.4342 1.00 0.9992 0.85 0.0067 
mannose 0.89 0.0001 0.96 0.1294 0.99 0.9499 
b-Hydroxy-b-
methylglutarate 0.78 0.1679 0.97 0.9923 0.84 0.4502 
N-acetylglycine 1.06 0.6698 1.07 0.6005 1.13 0.0918 
  193 
3-indoleproprionic acid 0.58 0.0260 0.77 0.3781 0.25 0.0001 
cytosine 0.96 0.7636 0.92 0.1575 0.98 0.9894 
D-Ribose 5-phosphate 0.96 0.5520 1.03 0.6859 0.97 0.8715 
erythrose-4-phosphate 0.84 0.4706 1.10 0.8011 0.93 0.9781 
nicotinic acid 0.74 0.0052 0.77 0.0138 1.00 0.9998 
 
C.5 Analysis of Skeletal Muscle Metabolites 
Analyte 
DCA/ 
Control p-value 
Metformin/ 
Control p-value 
Combo/ 
Control p-value 
sedoheptulose-7-P 0.57 0.0135 0.77 0.3057 1.14 0.5615 
glycolic acid 1.05 0.6922 0.98 0.9815 1.09 0.0778 
aminomalonic acid 0.91 0.1780 1.03 0.9306 1.05 0.7114 
phosphoethanolamine 0.89 0.7915 1.04 0.9910 1.22 0.1610 
2-hydroxyglutarate 1.10 0.2890 0.95 0.8429 1.09 0.1959 
ribose 0.66 0.0017 0.78 0.0625 1.13 0.3122 
sarcosine 1.01 0.9824 0.98 0.8106 1.07 0.0787 
diphosphate 0.94 0.5044 1.00 0.9999 1.04 0.5898 
adenine 0.89 0.5129 0.96 0.9564 0.94 0.9818 
uracil 1.03 0.9498 1.07 0.7014 1.06 0.6544 
citric acid 1.06 0.7887 1.10 0.4069 1.10 0.2917 
ornithine 0.93 0.6413 0.98 0.9842 1.04 0.8007 
elaidic acid 0.95 0.5915 1.00 0.9995 1.10 0.0493 
glutamine 0.97 0.7903 0.99 0.9701 1.05 0.2040 
glyceric acid 0.73 0.0050 0.70 0.0016 1.00 0.9999 
ribitol 0.95 0.3597 0.93 0.1939 0.99 0.9944 
cis-Aconitic acid 0.95 0.2951 0.98 0.8541 1.01 0.9604 
tryptophan 1.00 0.9978 0.98 0.8786 1.02 0.5647 
arachidonic acid 0.82 0.0851 0.84 0.1498 1.15 0.1417 
fumaric acid 0.95 0.5728 0.96 0.7130 1.03 0.6493 
proline 0.96 0.6729 0.98 0.9574 1.02 0.9871 
Xanthine 0.94 0.4134 0.92 0.2853 1.07 0.2773 
pantothenic acid 1.00 0.9998 1.00 0.9990 1.04 0.1055 
oleic acid 0.98 0.9055 1.03 0.7717 1.10 0.0034 
urea 0.98 0.6578 0.98 0.8213 0.99 0.9177 
phenylalanine 0.96 0.1888 0.98 0.6327 1.03 0.4118 
Fructose 0.78 0.0663 0.84 
2745.00
00 1.01 0.9682 
2-phosphoglycerate 1.06 0.8348 1.14 0.2513 0.71 0.0064 
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glucose-6-phosphate 1.01 0.9991 1.06 0.4755 0.84 0.0250 
fructose-6-phosphate 1.00 0.9999 1.10 0.7019 0.78 0.2426 
glucose-1-phosphate 0.98 0.9963 1.05 0.8929 0.82 0.2025 
homocysteine 0.89 0.9078 1.03 0.9976 0.84 0.6498 
Adenosine 1.13 0.9189 1.01 0.9999 0.75 0.6723 
lauric acid 0.94 0.8939 1.16 0.3019 1.09 0.6830 
histidine 0.96 0.8977 1.04 0.9247 1.03 0.8487 
Myoinositol 0.94 0.3718 0.95 0.4914 1.04 0.3794 
L-Glutamic acid 1.06 0.0929 0.98 0.8863 1.16 0.0001 
hypoxanthine 0.90 0.0820 0.92 0.2150 1.09 0.0997 
1-monopalmitoylglycerol 0.95 0.1372 0.97 0.6744 0.99 0.9998 
malic acid 0.95 0.6397 0.98 0.9461 1.05 0.3474 
phosphate 0.95 0.1770 0.97 0.6487 1.02 0.6470 
creatinine 0.95 0.2403 0.97 0.7109 1.02 0.6981 
glucose 0.90 0.1928 0.93 0.4549 1.10 0.2471 
Heptadecanoic acid 0.88 0.2097 0.97 0.9439 1.09 0.3155 
serine 0.98 0.7009 1.02 0.7465 1.05 0.0331 
myristic acid 0.90 0.0219 1.02 0.9428 1.02 0.8872 
4-hydroxyproline 1.04 0.9533 0.99 0.9995 1.05 0.7800 
4-aminobutyrate 1.04 0.9521 0.99 0.9996 1.06 0.7783 
3-phosphoglycerate 1.03 0.9150 1.08 0.3427 0.82 0.0061 
gluconic acid 0.90 0.1214 0.96 0.7744 1.08 0.2944 
myo-inositol 1-
phosphate 0.87 0.3592 0.93 0.8032 1.17 0.1277 
Nonadecanoic acid 0.84 0.5164 0.94 0.9560 1.17 0.2739 
succinic acid 1.06 0.6510 0.96 0.8484 0.90 0.0956 
phosphoenolpyruvate 0.97 0.9056 1.05 0.7069 0.85 0.0423 
Stearic acid 0.94 0.2880 0.97 0.8279 1.04 0.5196 
asparagine 0.94 0.5398 1.01 0.9994 1.07   
lysine 0.91 0.1346 0.98 0.9616 1.04 0.5031 
palmitic acid 0.95 0.1188 0.98 0.7364 1.02 0.6500 
pyruvic acid 0.91 0.4112 0.97 0.9265 1.10 0.2335 
1-monostearoylglycerol 0.92 0.3464 0.93 0.5039 0.99 0.9982 
aspartic acid 0.98 0.9325 1.06 0.3726 1.07 0.1050 
5-aminopentanoic acid 0.69 0.0254 0.91 0.8115 1.13 0.6714 
Cholesterol 0.89 0.1308 0.92 0.3928 1.05 0.4636 
mannitol 0.95 0.3842 0.97 0.8415 0.99 0.9956 
Glycerol 0.97 0.3583 0.97 0.3813 1.04 0.0753 
valine 0.99 0.8894 1.00 0.9998 1.03 0.2282 
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1-Linoleoyl-glycerol 0.96 0.9499 1.06 0.8140 1.13 0.1636 
sorbitol 0.96 0.5080 1.04 0.5624 0.99 0.9860 
Glutathione 1.01 0.9956 1.00 0.9999 1.08 0.0263 
cysteine 0.87 0.6437 0.92 0.8689 1.10 0.8305 
Glycerol 3-phosphate 1.02 0.9681 0.99 0.9982 0.90 0.0577 
2-aminoadipic acid 0.95 0.6789 0.97 0.9085 1.12 0.0230 
glycine 0.93 0.1605 1.03 0.8010 1.02 0.8622 
N-Acetylaspartate 0.93 0.9815 0.87 0.8805 1.05 0.8976 
lactic acid 0.96 0.5215 0.94 0.2263 1.04 0.3183 
nicotinamide 0.98 0.7045 0.99 0.9216 1.03 0.2389 
uric acid 1.07 0.4135 1.08 0.2238 1.00 0.9968 
homoserine 1.02 0.8835 1.17 0.9145 1.18 0.8157 
5-aminovaleric acid 0.58 0.0002 0.78 0.0752 0.78 0.1621 
2-hydroxybutyric acid 0.99 0.9957 0.97 0.9679 1.07 0.6402 
isoleucine 0.99 0.9816 1.00 0.9975 1.04 0.0677 
1-Oleoyl-glycerol 0.99 0.9940 1.05 0.7725 1.14 0.0346 
leucine 0.99 0.9243 1.00 0.9998 1.04 0.0533 
2-monooleoylglycerol 0.95 0.9047 1.06 0.8321 1.16 0.1532 
Palmitelaidic acid 0.95 0.7154 1.03 0.9238 1.04 0.7823 
threonine 0.93 0.0149 1.00 0.9977 0.99 0.9902 
tyrosine 0.94 0.1026 0.99 0.9912 0.99 0.9999 
2,3-pyridinedicarboxylic 
acid 0.68 0.3687 0.81 0.7518 1.04 0.9474 
L-Methionine 0.95 0.1221 0.99 0.9675 1.01 0.9303 
2-ketoglutaric acid 1.77 0.3030 0.96 0.9996 2.20 0.0451 
5'-Adenosine 
monophosphate 1.06 0.6208 1.07 0.4762 0.97 0.9995 
alanine 0.91 0.0298 1.01 0.9751 1.00 0.9958 
B-alanine 1.04 0.4351 1.04 0.5037 1.06 0.2611 
linoleic acid 0.97 0.7041 1.02 0.8129 1.09 0.0057 
3-indoleproprionic acid 0.34 0.4136 0.62 0.9884 1.33 0.3875 
D-Ribose 5-phosphate 0.88 0.5408 1.00 0.9999 1.12 0.2516 
 
 
 
 
 
  196 
C.6 Analysis of Serum Metabolites 
Analyte 
DCA/ 
Control p-value 
Metformin/ 
Control p-value 
Combo/ 
Control p-value 
fucose 0.93 0.7870 0.93 0.3021 1.04 0.9440 
kynurenine 1.25 0.1921 0.96 0.9864 0.96 0.9810 
glycolic acid 0.82 0.0004 1.23 0.9984 1.08 0.4053 
2-hydroxyglutarate 0.71 0.2583 1.13 0.0468 1.05 0.8672 
ribose 0.79 0.2290 1.13 0.3796 1.04 0.9236 
sarcosine 0.96 0.8387 1.05 0.9998 1.04 0.8901 
diphosphate 0.97 0.0417 1.08 0.2852 1.05 0.2617 
adenine 0.80 0.7420 0.85 0.8541 0.88 0.9304 
uracil 1.00 0.9999 0.93 0.6334 0.92 0.5310 
citric acid 0.94 0.2807 1.03 0.1565 0.99 0.9545 
ornithine 0.96 0.2028 1.08 0.6910 1.03 0.8216 
elaidic acid 0.87 0.9716 0.86 0.0005 0.98 0.8436 
glutamine 0.99 0.4369 1.04 0.7656 1.02 0.8716 
glyceric acid 0.93 0.0157 1.20 0.2187 1.00 0.9999 
ribitol 0.88 0.3969 1.13 0.9999 0.96 0.9430 
cis-Aconitic acid 0.85 0.6509 1.07 0.3253 0.94 0.7273 
tryptophan 0.96 0.4343 1.02 0.1301 1.00 0.9964 
arachidonic acid 0.93 0.0516 0.93 0.1449 0.99 0.9943 
fumaric acid 0.97 0.9881 1.01 0.9767 0.98 0.9607 
proline 1.02 0.9999 1.00 0.8848 0.99 0.9802 
Xanthine 0.96 0.7494 1.12 0.9215 0.98 0.8418 
pantothenic acid 0.97 0.9291 1.01 0.9256 0.99 0.9635 
oleic acid 0.96 0.8109 0.94 0.1072 0.98 0.8386 
urea 1.10 0.2633 1.01 0.9987 1.02 0.9688 
phenylalanine 1.01 0.0589 0.97 0.3379 0.98 0.2221 
Fructose 1.05 0.7486 0.95 0.9999 0.95 0.6362 
glucose-6-phosphate 1.04 0.7807 0.96 0.9999 1.00 0.9999 
homocysteine 0.97 0.9965 0.79 0.8195 0.73 0.7297 
arabinose 1.01 0.9923 0.98 0.9972 1.08 0.6825 
Adenosine 0.90 0.8873 1.14 0.9995 0.22 0.0119 
lauric acid 0.99 0.3028 0.89 0.2265 0.87 0.1486 
histidine 0.92 0.1679 1.14 0.8654 1.00 0.9999 
Myoinositol 0.93 0.1029 1.09 0.9503 0.99 0.9987 
L-Glutamic acid 0.85 0.0106 1.29 0.6493 0.96 0.9543 
hypoxanthine 1.35 0.3892 1.35 0.8924 1.11 0.9508 
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1-monopalmitoylglycerol 0.96 0.8763 1.02 0.6424 0.98 0.8486 
malic acid 0.98 0.9999 1.00 0.9426 0.99 0.9973 
phosphate 1.01 0.6371 1.02 0.3308 0.95 0.0111 
creatinine 1.33 0.0818 1.11 0.8551 0.99 0.9999 
glucose 0.99 0.5499 0.98 0.2260 0.99 0.8909 
Heptadecanoic acid 0.96 0.4017 0.95 0.0442 0.92 0.0579 
serine 1.01 0.1483 1.03 0.0610 1.02 0.6699 
myristic acid 1.03 0.0704 0.87 0.1568 0.87 0.0765 
4-hydroxyproline 1.03 0.0598 1.14 0.0112 1.07 0.4634 
4-aminobutyrate 1.03 0.0584 1.14 0.0111 1.07 0.4633 
gluconic acid 1.05 0.0034 0.92 0.4925 0.97 0.3722 
myo-inositol 1-phosphate 0.98 0.6201 1.06 0.8282 1.04 0.8074 
Nonadecanoic acid 0.97 0.6885 0.94 0.2985 0.85 0.0314 
succinic acid 1.02 0.0964 0.93 0.2136 0.99 0.9946 
Stearic acid 0.98 0.9929 0.97 0.1996 0.99 0.7677 
2-monostearylglycerol 1.15 0.6291 1.60 0.3201 1.39 0.8444 
asparagine 1.00 0.5019 1.07 0.4884 1.02 0.9566 
lysine 0.86 0.0636 1.24 0.8984 1.04 0.9758 
palmitic acid 0.97 0.9692 0.97 0.0984 0.98 0.5474 
pyruvic acid 0.91 0.6778 1.06 0.9202 0.98 0.9666 
1-monostearoylglycerol 0.96 0.7142 1.04 0.9999 1.01 0.9837 
aspartic acid 1.01 0.4279 1.08 0.3076 0.92 0.3266 
5-aminopentanoic acid 0.90 0.1466 0.88 0.0571 0.84 0.0102 
Cholesterol 0.97 0.9186 0.96 0.0146 1.01 0.9090 
Glycerol 0.96 0.0702 0.96 0.0004 0.96 0.0727 
valine 1.00 0.8461 0.99 0.7985 0.99 0.4700 
1-Linoleoyl-glycerol 0.95 0.0077 0.91 0.0001 0.86 0.0001 
cysteine 0.98 0.3829 0.88 0.2215 1.08 0.7031 
Glycerol 3-phosphate 1.00 0.9806 1.02 0.9677 0.97 0.8534 
2-aminoadipic acid 1.01 0.9435 0.98 0.9915 0.88 0.0269 
glycine 1.02 0.5690 1.04 0.1814 0.99 0.9952 
lactic acid 1.00 0.9954 0.99 0.9815 1.02 0.8312 
uric acid 0.90 0.0573 0.95 0.4801 1.02 0.9621 
homoserine 1.11 0.6006 0.94 0.7353 0.81 0.0008 
2-hydroxybutyric acid 0.90 0.0918 0.92 0.1499 0.95 0.5847 
isoleucine 1.01 0.6660 0.98 0.8369 0.99 0.8063 
1-Oleoyl-glycerol 1.02 0.9704 0.81 0.0002 0.97 0.8192 
leucine 1.00 0.6904 0.99 0.8884 0.99 0.6604 
2-monooleoylglycerol 0.88 0.0120 0.83 0.0002 0.83 0.0001 
  198 
Palmitelaidic acid 1.07 0.0372 0.83 0.2075 0.85 0.0808 
threonine 1.04 0.8740 0.99 0.5550 0.95 0.0266 
inosine 1.02 0.9982 0.93 0.9270 0.98 0.9964 
tyrosine 1.10 0.0392 0.92 0.9224 0.93 0.0385 
1,3-bisphosphoglycerate 0.99 0.9765 0.96 0.1551 0.99 0.9009 
2,3-pyridinedicarboxylic 
acid 1.14 0.6327 1.00 0.9999 0.88 0.7103 
L-Methionine 1.04 0.9347 0.99 0.4923 0.96 0.1042 
2-ketoglutaric acid 0.66 0.2471 1.15 0.0147 1.02 0.9906 
alanine 1.03 0.0360 0.96 0.9741 0.98 0.2972 
B-alanine 0.98 0.2961 1.15 0.4254 0.94 0.8593 
linoleic acid 0.98 0.4677 0.95 0.0823 0.97 0.3642 
erythrose 0.93 0.9993 0.98 0.9160 0.97 0.9971 
N-acetylglycine 1.01 0.1540 2.06 0.1080 1.84 0.6261 
3,4-dihydroxybutanoic 
acid 0.97 0.5609 1.06 0.8800 1.12 0.0899 
isocitrate 0.92 0.3130 1.21 0.9331 1.14 0.9998 
lactate 0.96 0.7042 0.97 0.1046 0.98 0.8569 
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C.7 Analysis of Spleen Metabolites 
Analyte 
DCA/ 
Control p-value 
Metformin/ 
Control p-value 
Combo/ 
Control p-value 
fucose 1.10 0.7144 0.80 0.2318 1.10 0.6816 
kynurenine 1.09 0.9775 0.50 0.1707 1.33 0.4298 
sedoheptulose-7-P 0.96 0.5403 1.01 0.9640 1.00 0.9767 
glycolic acid 1.05 0.5037 0.96 0.7242 1.00 0.9996 
dopamine 1.06 0.9227 0.91 0.8091 1.13 0.5215 
aminomalonic acid 0.99 0.9632 0.98 0.9305 1.01 0.9894 
phosphoethanolamine 1.00 0.9976 0.94 0.0464 0.98 0.5770 
2-hydroxyglutarate 1.13 0.0051 0.93 0.1786 0.96 0.4649 
ribose 0.91 0.4706 0.87 0.2361 1.01 0.9999 
sarcosine 1.11 0.0013 0.95 0.2663 1.00 0.9651 
diphosphate 1.06 0.1980 1.04 0.6296 1.04 0.5131 
adenine 1.05 0.3672 0.99 0.9747 1.00 0.9990 
uracil 0.97 0.0656 0.94 0.0003 0.99 0.8987 
citric acid 0.96 0.7789 0.94 0.4944 0.97 0.9271 
ornithine 0.96 0.6370 0.91 0.0825 1.20 0.7870 
glutamine 0.99 0.9750 0.97 0.2397 1.01 0.9959 
glyceric acid 1.02 0.9518 1.01 0.9809 1.05 0.6100 
ribitol 1.00 0.9999 0.89 0.4184 1.07 0.8295 
cis-Aconitic acid 0.88 0.9042 0.75 0.5793 0.97 0.9988 
tryptophan 0.99 0.9975 0.97 0.9204 1.04 0.6094 
arachidonic acid 0.97 0.7647 0.91 0.0871 0.99 0.8265 
fumaric acid 0.97 0.2407 0.96 0.0199 0.99 0.7731 
proline 0.93 0.0329 0.94 0.1805 1.02 0.5086 
Xanthine 0.96 0.0255 0.97 0.0632 1.00 0.9927 
pantothenic acid 1.03 0.4738 0.97 0.6217 1.02 0.8473 
oleic acid 0.96 0.8277 0.93 0.4828 1.01 0.9999 
urea 0.99 0.9707 0.97 0.1402 0.95 0.0255 
phenylalanine 0.95 0.0211 0.97 0.2853 1.01 0.8722 
Fructose 0.80 0.0019 0.89 0.1401 1.09 0.1476 
glucose-6-phosphate 0.86 0.0237 0.96 0.7717 1.00 0.9923 
fructose-6-phosphate 0.87 0.0305 0.97 0.8772 1.01 0.9847 
glucose-1-phosphate 0.82 0.0153 0.93 0.5779 0.99 0.9999 
homocysteine 0.69 0.0332 0.83 0.4271 1.04 0.9013 
porphobilinogen 0.94 0.8997 0.76 0.0495 0.96 0.9587 
arabinose 0.89 0.5025 0.91 0.6558 1.04 0.9922 
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thymine 1.03 0.7807 1.03 0.7929 1.02 0.8883 
Adenosine 1.46 0.0037 1.25 0.2155 1.02 0.9988 
isocitric acid 0.94 0.9058 0.90 0.6472 0.98 0.9060 
lauric acid 0.95 0.9574 0.92 0.8371 0.91 0.7309 
histidine 0.90 0.0996 0.96 0.8494 1.04 0.5767 
Myoinositol 1.03 0.3193 1.00 0.9920 1.02 0.4896 
L-Glutamic acid 1.04 0.0148 0.98 0.4921 1.00 0.9971 
hypoxanthine 0.95 0.0101 0.98 0.4112 1.01 0.7227 
1-monopalmitoylglycerol 0.99 0.8448 0.99 0.5824 1.01 0.6649 
malic acid 0.97 0.1534 0.96 0.0318 0.98 0.3227 
phosphate 0.99 0.5997 0.98 0.0420 1.00 0.8927 
creatinine 1.03 0.7126 0.90 0.0072 0.95 0.2903 
glucose 0.96 0.7857 0.95 0.5411 1.00 0.9924 
Heptadecanoic acid 0.91 0.1057 0.91 0.1539 0.97 0.8741 
serine 0.94 0.0090 0.96 0.1797 1.01 0.8056 
myristic acid 0.92 0.3855 0.89 0.1457 0.96 0.7163 
4-hydroxyproline 0.98 0.6612 0.95 0.0261 0.96 0.3092 
4-aminobutyrate 0.98 0.6645 0.95 0.0265 0.96 0.3095 
3-phosphoglycerate 0.79 0.0094 0.78 0.0118 1.02 0.9380 
gluconic acid 0.96 0.7898 0.93 0.4178 1.01 0.9891 
myo-inositol 1-phosphate 1.00 0.9999 1.00 0.9997 1.04 0.5077 
sedoheptulose 0.78 0.0002 0.94 0.5748 1.06 0.5490 
Nonadecanoic acid 0.89 0.0286 0.90 0.0541 0.91 0.1035 
succinic acid 1.32 0.0229 0.99 0.9995 1.00 0.9956 
phosphoenolpyruvate 0.68 0.0119 0.67 0.0147 1.03 0.9530 
Stearic acid 0.98 0.3925 0.96 0.0585 0.99 0.9383 
ascorbate 1.07 0.5664 0.93 0.6205 1.01 0.9977 
oleamide 0.99 0.9767 0.96 0.0471 0.99 0.9446 
asparagine 0.92 0.2282 0.97 0.8451 1.04 0.5414 
lysine 0.95 0.0869 0.97 0.5726 1.02 0.5853 
palmitic acid 0.97 0.5168 0.96 0.2849 0.99 0.9042 
pyruvic acid 1.03 0.9253 0.96 0.8395 0.99 0.8770 
1-monostearoylglycerol 0.99 0.9048 0.98 0.5433 1.03 0.1509 
aspartic acid 1.00 0.9855 0.98 0.2784 0.99 0.9345 
5-aminopentanoic acid 0.90 0.1606 0.90 0.2008 0.98 0.9820 
Cholesterol 1.01 0.7466 1.00 0.9953 1.02 0.3400 
mannitol 0.89 0.1459 0.87 0.0621 0.83 0.0066 
2,4-dihydroxybutanoic 
acid 0.90 0.0182 0.96 0.5348 0.98 0.9893 
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Glycerol 0.97 0.1936 0.97 0.1646 1.01 0.9757 
valine 0.97 0.1022 0.98 0.4106 1.00 0.8916 
1-Linoleoyl-glycerol 0.91 0.6205 0.85 0.2256 1.01 0.9941 
sorbitol 1.03 0.9368 0.93 0.4966 1.01 0.9999 
Glutathione 1.01 0.9937 1.00 0.9999 1.01 0.9999 
cysteine 1.01 0.9483 0.91 0.0087 1.01 0.9982 
Glycerol 3-phosphate 1.04 0.9039 0.96 0.9218 0.95 0.6756 
2-aminoadipic acid 0.99 0.9347 0.96 0.1894 0.93 0.0094 
glycine 0.96 0.0084 0.99 0.7956 1.00 0.9541 
N-Acetylaspartate 1.03 0.8519 0.97 0.9303 0.99 0.9304 
lactic acid 1.02 0.5628 0.99 0.9497 0.97 0.2837 
nicotinamide 1.03 0.0764 1.01 0.8573 1.01 0.9077 
uric acid 1.01 0.9564 0.97 0.6759 0.98 0.5842 
homoserine 0.94 0.1698 0.94 0.2401 0.89 0.0134 
5-aminovaleric acid 0.83 0.4887 0.85 0.6276 0.85 0.7276 
2-hydroxybutyric acid 0.96 0.6273 0.93 0.1178 0.90 0.0184 
isoleucine 0.97 0.1582 0.98 0.2910 1.01 0.8550 
1-Oleoyl-glycerol 0.94 0.7551 0.88 0.2200 1.01 0.9996 
leucine 0.97 0.0790 0.98 0.3264 1.00 0.9792 
2-monooleoylglycerol 0.88 0.5454 0.82 0.2208 1.04 0.9999 
Palmitelaidic acid 0.89 0.4594 0.87 0.3559 0.96 0.8343 
threonine 0.94 0.0119 0.97 0.3657 0.99 0.9994 
inosine 1.03 0.4942 1.01 0.9296 1.02 0.9583 
tyrosine 0.92 0.0275 0.96 0.5909 1.01 0.7659 
serotonin 1.03 0.3692 0.98 0.7143 1.01 0.9986 
1,3-bisphosphoglycerate 1.06 0.1772 0.98 0.8078 1.03 0.9578 
L-Methionine 0.94 0.0182 0.97 0.4094 1.01 0.9187 
2-ketoglutaric acid 0.99 0.9999 0.78 0.6432 1.11 0.9365 
5'-AMP 1.35 0.0009 1.19 0.1272 0.92 0.5256 
3-hydroxybutyrate 1.08 0.1846 1.03 0.8713 1.04 0.9042 
alanine 0.90 0.0030 0.97 0.7374 0.99 0.9992 
B-alanine 1.00 0.9924 1.01 0.9014 0.97 0.1967 
N-acetylglutamate 1.45 0.3600 1.27 0.7664 0.83 0.9225 
b-Hydroxy-b-
methylglutarate 1.03 0.8967 0.93 0.4795 0.96 0.7487 
rhamnose 0.87 0.7392 0.85 0.5975 1.14 0.6789 
Galactitol 1.02 0.9804 0.92 0.2973 0.99 0.9791 
phenylpyruvate 0.86 0.8543 0.55 0.2737 0.78 0.5934 
 
